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General introduCtion
Polycystic liver disease (PCLD) is a devastating disease to many patients as there is 
no effective or curative treatment available. So far, clinicians rely on palliative treat-
ment options such as surgery. In order to develop a suitable and tailored treatment 
for PCLD patients, an in-depth knowledge of the pathogenesis of the disease is 
required. In PCLD, numerous cysts arise in the liver due to mutations in PRKCSH 
and SEC63, which encode the proteins hepatocystin and Sec63p respectively. The 
putative functions of hepatocystin and Sec63p suggest that both proteins play a role 
in protein processing to achieve proper topology and folding of glycoproteins. De-
spite our knowledge on the presumed biological roles of hepatocystin and Sec63p, 
this fails to provide immediate insight in the cystogenesis of PCLD. 
The main aim of this thesis was to gain knowledge of the pathogenesis of PCLD 
using a combined genetic and cell biological approach. The studies described in this 
thesis focus on our attempts to unravel PCLD using various approaches and tech-
niques. 
First, chapter 2 presents an overview of the literature on the subject of PCLD, he-
patocystin, Sec63p, and glycosylation. Chapters 3 and 4 investigate the phenotype-
genotype correlation and the effect of mutations on the protein structure. Chapter 
5 focuses on a novel serum biomarker to monitor disease progress and chapter 6 
presents the results of an extensive study on the fate of hepatocystin in vivo together 
with an exploration of the contents of cyst fluid. Subsequently, chapter 7 identi-
fies common molecular pathways involved in PCLD cystogenesis. In chapter 8, we 
study the cellular and subcellular localization of hepatocystin and Sec63p during 
fetal liver development, adult life and in PCLD tissue. Finally, chapter 9 discusses 
a pilot study on the second hit model in PCLD and chapters 10 and 11 encompass 
the summary and recommendations on future work. 
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Polycystic liver disease (PCLD) is a rare disorder of which the pathogenesis is 
not yet completely elucidated. The disease is characterized by the development 
of cysts in the liver and it is caused by mutations in PRKCSH and SEC63. The 
encoded proteins, hepatocystin and Sec63p, are involved in glycoprotein pro-
cessing and translocation. The mechanism by which the mutated genes lead to 
cystogenesis limited to the liver is unknown. In recent years, research on the 
pathogenesis of PCLD has revealed novel insights in disease pathology such 
as ER localization of both implicated proteins and the absence of hepatocystin 
in PCLD cyst epithelia, indicating a two-hit model for PCLD cystogenesis. In 
this review, we describe the molecular functions of hepatocystin and Sec63p in 
PCLD with a specific focus on protein glycosylation and we will discuss the po-
sitioning of PCLD in relation to the congenital disorders of glycosylation.  
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IntroductIon
Today, more and more inherited diseases are recognized, described and thanks to the 
availability of state-of-the-art techniques associated with genes. One of these disor-
ders is polycystic liver disease (PCLD, MIM# 174050). With an estimated incidence 
of 0.05 to 0.13% in the Western population, it is regarded as a rare disease 1-3. How-
ever, the incidence rate is deduced from autopsy studies and may be an underesti-
mate. The disease shows a great variability in phenotype and is often not recognized 
or asymptomatic. 
PCLD is diagnosed when more than 20 cysts are found in the liver using ultrasound 
or computed tomography and no other organs seem to be affected. Patients develop 
problems mainly due to the mass effect of the liver and symptoms of abdominal pain, 
early satiety and shortness of breath are common 4. Liver volumes can reach up to 10 
liters with cyst diameters of 30 cm. PCLD exhibits a more apparent and more severe 
phenotype in women, especially in women who had a number of pregnancies 5.
The cysts in PCLD arise from malformations of the ductal plate during embryonic 
liver development. Normal bile ducts arise from this ductal plate through growth 
and apoptosis. However, in PCLD dense complexes of intralobular bile ductules 
remain intact 6. These Von Meyenburg complexes develop throughout life into cysts 
by disconnection from the biliary tree, fluid secretion and growth 5, 7. PCLD is a 
progressive and autosomal dominant inherited disorder, but it is unknown exactly 
what drives cyst growth.
prKcsh – hepatocystIn
After Reynolds et al. associated a locus on chromosome 19 with PCLD in 2000, it 
took until 2003 to identify the first causative gene, PRKCSH 8-10. PRKCSH codes for 
the 527 amino acid protein hepatocystin, which is expressed in a wide variety of or-
gans including liver, kidney, pancreas, brain and muscle 9, 10. This directly pinpoints 
the paradox in PCLD: despite the systemic expression of the gene involved, the 
phenotype of PCLD is restricted to the liver.
Hepatocystin appears to be a versatile protein with many different functions in dif-
ferent cellular compartments. First, it is proposed to be the β-subunit of glucosidase 
IIα involved in glycoprotein processing in the endoplasmic reticulum (ER). Second, 
located at the plasma membrane, hepatocystin is proposed to function as an AGE 
receptor mediating cell activation, chemotaxis and cell secretion 11. At the cell sur-
face of HEK293 cells, hepatocystin is found to interact with TRPV5, an epithelial 
Ca2+ channel 12. The two EF-hand domains of hepatocystin are proposed to be the 
Ca2+ sensor controlling the channel. Third, hepatocystin is suggested to play a role 
in vesicle trafficking. Bovine VASAP-60, an orthologue of hepatocystin, is found in 
the ER, endosomes, and in intracellular vesicles of luteal cells 13, 14. Further, hepato-
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cystin was found to interact with proteins from the GLUT4 trafficking complex in 
CHO cells 15. Recently, a fifth possible function was added to the list of hepatocystin 
functions. It was found that fibroblast growth factor signaling in rat myoblast cells 
involves a complex of fibroblast growth factor receptor 3 (FGFR-3), GRB2-Sos and 
hepatocystin 16. In addition, hepatocystin expression in human breast cancer speci-
mens correlated with FGF-1 expression and FGF-1 stimulation resulted in translo-
cation of hepatocystin to the nucleus of MCF-7 cells, which could indicate a role in 
gene transcription 17. 
Nevertheless, ER localization and associated function in glycosylation hold the most 
promise in PCLD pathogenesis. Using immunofluorescence confocal laser scanning 
microscopy and cell fractionation, we have shown that hepatocystin is indeed local-
ized in the ER of human bile duct cells, the cells from which PCLD originates 18. 
Further, hepatocystin contains an HDEL endoplasmic reticulum retention signal 
at the C-terminus and several domains are shared with luminal ER proteins, such 
as the negatively charged glutamic acid repeat and two calcium binding EF-hand 
domains (Figure 2.1). The glutamic acid repeat can form a zipper structure linking 
ER proteins in a loose matrix 19. Next to these ER-associated domains, hepatocystin 
contains an N-terminal signaling sequence, a low-density lipoprotein receptor do-
main, and a mannose 6-phosphate receptor domain.
F i g u r e   2 .1   Schematic representation of PRKCSH and hepatocystin. 
The genetic structure is represented by black boxes depicting non-coding exons and blue boxes depicting 
coding exons. The superimposed protein structure consists of an N-terminal signaling sequence (yellow), 
low-density lipoprotein receptor domain (LDLa) (orange), 2 putative calcium binding EF-hand domains 
(blue), a glutamic acid repeat (pink), a variable protein domain (green), a mannose-6-phosphate receptor 
domain (purple) and the C-terminal HDEL ER-retention signal sequence (yellow).
hepatocystIn functIons In glycosylatIon
In the ER, hepatocystin functions as the β-subunit of glucosidase IIα 20. It binds 
glucosidase IIα in a non-covalent manner and retains the protein in the ER through 
its HDEL signal sequence. Mutation of this HDEL sequence leads to secretion of 
glucosidase IIα 21. In mice, hepatocystin binds glucosidase IIα with two domains; 
interacting domain 1 (ID1) spans 118 amino acids at the N-terminus and ID2 spans 
amino acids 273 to 400 at the C-terminus 22. It is proposed however that due to for-
mation of di-sulphide bonds, these two domains become one domain in the tertiary 
protein structure 22.
The heterodimer glucosidase complex is involved in glycoprotein processing (Figure 
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2.2) 20. In the ER, oligosaccharide structures are attached to nascent glycoproteins to 
assist in their solubility, folding, and quality control. These structures or N-glycans 
are constructed on the lipid dolichol, anchored in the ER membrane, and consist 
of 3 glucoses, 9 mannoses, and 2 N-acetyl-glucosamines (Glc
3
Man9GlcNAc2). The 
preformed glycan is then transferred en bloc to Asn-Xaa-Ser or Asn-Xaa-Thr se-
quences (Xaa being any amino acid except proline) of nascent proteins emerging 
into the ER lumen during co- or post-translational translocation 23. Subsequently, 
the attached glycans are modified. Almost immediately after attachment, the first 
glucose is cleaved by glucosidase I 24. The innermost two glucoses are cleaved by the 
glucosidase II complex in a more controlled manner. After the first of two cleavages, 
a Glc1Man9GlcNAc2 structure remains, which is bound by the luminal ER chaper-
ones calnexin and calreticulin. ERp57 associated with calnexin/calreticulin medi-
ates disulfide bond formation and folding of the nascent glycoprotein. The cleavage 
of the final glucose residue by the glucosidase II complex subsequently releases the 
nascent protein from the calnexin/calreticulin 25. Properly folded proteins are then 
transferred to the Golgi for further post-translational modification. When the pro-
tein is not folded properly, it is reglucosylated by UDP-glucose glycoprotein:glucosyl 
transferase in order to enter the cycle again 26. Terminally misfolded proteins are 
recognized by mannosidase I, which targets the protein for degradation by cleaving 
a terminal mannose 27. 
Even though glucosidase IIα holds the enzymatic activity in the complex, hepatocys-
tin is essential for the activation and proper function. Yeast cell mutants, deficient 
for either glucosidase IIα or hepatocystin were both devoid of any glucosidase II ac-
tivity, but viable under non-stress conditions. More precisely, hepatocystin mutants 
did show products of the first glucosidase II cleavage but not of the second cleavage, 
indicating that hepatocystin is essential for the cleavage of the glucose-mannose 
linkage 29, 30. In addition, transfection of human glucosidase IIα without its β-subunit 
resulted in an inactive protein 31 and Pelletier and coworkers showed that hepato-
cystin is necessary for the solubility, retainment in the ER and activation of human 
glucosidase IIα 21.
Recently, it has been confirmed that glucosidase IIα has a low cleavage activity on its 
own, but it is activated by hepatocystin 24. Hepatocystin binds the mannose branch 
of the glycan with its mannose-6-phosphate receptor domain and causes a conforma-
tional change allowing effective cleavage of the last glucose. This hypothesis seems 
confirmed by the finding that the glucosidase II complex has one active site but two 
binding affinities 21, 32. 
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F i g u r e   2 .2   Schematic overview of N-glycosylation and glycoprotein processing in the 
endoplasmic reticulum. 
The position of hepatocystin and Sec63p in the glycosylation pathway is marked in blue. The steps in the 
pathway at which glycosylation disorders CDG-Ih, CDG-IIb and PCLD occur are indicated in red. Abbrevia-
tions: CNX, calnexin; CRT, calreticulin; EDEM, ER degradation-enhancing α-mannosidase-like protein; 
ERAD, ER-associated degradation. Adapted from 28.
The glycoprotein quality control system depends on proper functioning of the glu-
cosidase II complex. Incomplete glucose cleavage results in reduced rates of protein 
folding, accelerated protein degradation, reduced expression of cell-surface proteins 
and defects in protein secretion. Paradoxically, cell viability is not always affected 
and the above-mentioned effects are not observed for all glycoproteins (33 and refer-
ences therein). This indicates that alternative pathways exist for oligosaccharide pro-
cessing in the ER. In addition, alternative isoforms of glucosidase IIα and hepato-
cystin with specific affinity for different glycoproteins have been described. Baldwin 
and coworkers found that only alternatively spliced hepatocystin can associate with 
CD45 in hematopoietic cells 34. This is interesting, as the explicit liver pathogenesis 
of PCLD indicates a liver specific process. We hypothesize that mutant hepatocystin 
causes problems in processing of liver specific client proteins. 
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sec63 - sec63p
In 2004, Davila et al. linked a second gene to PCLD 35. This gene, called SEC63, is 
located on chromosome 6q21 and consists of 21 exons distributed over an 88 kb 
interval 36. SEC63 is mainly expressed in liver but expression was also found in heart, 
brain, spleen, lung, skeletal muscle, kidney and testis 35. 
The corresponding protein, Sec63p, is an 83 kD integral ER-membrane protein with 
three trans-membrane spanning domains and a DnaJ-like domain between trans-
membrane segments 2 and 3 37. The DnaJ domain and probably also the N-terminus 
are pointed towards the ER lumen 37, 38. The C-terminus, in contrast, is oriented 
toward the cytosol and is unusually negatively charged 38. This charged region might 
serve to force the insertion of the N-terminus and the DnaJ domain into the ER lu-
men. An overview of the genetic structure and the corresponding protein domains 
is given in figure 2.3. 
F i g u r e   2 .3   Schematic representation of SEC63 and Sec63p. 
The genetic structure is represented by black boxes depicting non-coding exons and blue boxes depicting 
coding exons. The superimposed protein structure consists of three transmembrane domains (green tubes), 
a DnaJ domain (red) and a negatively charged C-terminus (light blue).
molecular functIons of sec63p
Sec63p is a functionally complex protein. It is involved in the translocation of secre-
tory and integral membrane proteins into the ER. The main player in ER transloca-
tion is the Sec61 complex. This heterotrimeric complex, consisting of Sec61α, Sec61β 
and Sec61γ, forms a transmembrane channel which translocates nascent proteins as 
they are formed by ribosomes bound on the ER membrane (co-translational) and 
fully translated proteins from the cytosol (post-translational). 
Extensive research in yeast showed that Sec63p is involved in both co-translational 
and post-translational pathways, however the latter pathway requires a higher level 
of Sec63p and depends on different domains of the protein 39, 40. The C-terminal 
domain of Sec63p is important for the formation and stability of the Sec62p/Sec63p/
Sec71p/Sec72p complex that binds the Sec61 channel in the post-translational path-
way 40-43. In the absence of protein forming ribosomes in this pathway, the complex 
is responsible for the recruiting of precursor proteins to the cytosolic face of the 
ER membrane and Sec63p and the chaperone BiP provide the driving force for the 
translocation 44, 45. After ATP regulated interaction with the DnaJ domain of Sec63p, 
multiple BiP molecules bind the nascent protein and prevent retrograde movement 
Chapter 2
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through the Sec61 channel 46-48. In addition, BiP blocks ion transport through the 
Sec61 channel when the channel is not in use for protein translocation 49. The co-
translational pathway also requires functional Sec63p, but here the ribosomes pro-
vide the nascent proteins and the C-terminal domain required for the stabilization 
of Sec62p in the post-translational pathway is not imperative in the co-translational 
pathway 40, 50. 
In mammalian cells, it is still unclear whether Sec63p plays a role in post- and/or 
co-translational processing. Meyer et al. showed that Sec63p does not bind the co-
translational ribosome-Sec61 complex, but ribosome free Sec61 complex only (post-
translational) 51. They and others also found that only a small portion of Sec63p 
was bound to Sec61p 51, 52. This might implicate additional and still to be identified 
molecular functions for Sec63p in mammalian cells. Accordingly, in yeast, Sec63p is 
also implicated in nuclear fusion processes and ER associated degradation (ERAD) 
53, 54. The latter system translocates misfolded proteins out of the ER to be degraded 
by the ubiquitin-proteasome system 54, 55.
glycosylatIon dIsorders
Considering the function of hepatocystin in glycoprotein processing and of Sec63p 
in glycoprotein translocation, a comparison with the group of congenital disorders 
of glycosylation (CDG) is valid.
CDG is a collective term for genetic disorders that affect the correct assembly of 
the glycoprotein glycans. There are many CDG subtypes, classified according to 
the specific enzymes involved in glycan processing. Two variants of CDG concern-
ing N-glycosylation are recognized. Type I CDG relates to disorders that affect the 
assembly of the oligosaccharide in the ER membrane and the initial transfer to gly-
coproteins. Type II CDG includes disorders that affect the processing of glycans 
attached to the glycoprotein. Therefore, we propose to classify PCLD as a novel 
variant of type II CDG. 
However, PCLD is an odd duck amongst the CDGs. All CDG subtypes identified 
so far show autosomal recessive inheritance. In contrast, PCLD is inherited in an 
autosomal dominant fashion. As a consequence, cells maintain a healthy allele and 
show residual protein function. For this reason, no hypo- or hyper-glycosylated gly-
coproteins are detected in the serum and urine of PCLD patients. To our knowledge, 
no disorder has been described which involves complete and systemic knockout of 
hepatocystin. Even though yeast cells without functional hepatocystin are viable, it 
is questionable whether this is also true for more complex organisms. 
As a consequence, PCLD is not a systemic disease. The phenotype is limited to 
the liver. A model that could explain this local phenotype is the two-hit model. It 
hypothesizes that the disease is recessive at the cellular level and that hepatocystin 
is inactivated by a somatic mutation in addition to the germline mutation. This can 
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provide growth advantages for the epithelial cell to proliferate clonally into a cyst. 
Evidence is growing for this model. Our research has recently shown a lack of he-
patocystin expression in cyst epithelia and the absence of hepatocystin secretory 
products in cyst fluid indicating that hepatocystin is either not produced or degraded 
intracellularly 18, 56. Research is now focusing on the identification of somatic muta-
tions in PCLD cyst epithelia.
Interestingly, in addition to neurological, muscular and dysmorphic features, many 
CDGs show hepatomegaly, hepatic fibrosis or related liver problems as key symp-
toms 57. Two closely related CDGs in the glycosylation pathway are CDG-Ih and 
CDG-IIb, both associated with steps just prior to glucosidase II (Figure 2.2). In 
CDG-Ih, the ALG8 gene, encoding dolichyl-P-glucose:Glc1Man9GlcNAc 2-PP-
dolichyl α3 glucosyltransferase, is affected 58. This enzyme adds glucose to the man-
nose tree before it is transferred to the nascent glycoprotein resulting in a glycan 
resembling the Glc1Man9GlcNAc2 structure after the first glucosidase II cleavage. 
The five patients described presented mainly with gastrointestinal symptoms, includ-
ing hypoalbuminaemia, oedema, ascites, diarrhea, and hepatomegaly. Pathological 
studies in one patient revealed cystic intra- and extrahepatic bile ducts, cholestasis, 
and diffuse renal microcysts 59. Second, mutations in GLS1 encoding glucosidase 
I lead to CDG-IIb. This CDG is described in one neonate patient, who showed 
symptoms of generalized hypotonia and hypomotility, dysmorphic features, hepato-
megaly, hypoventilation, feeding problems and seizures 60. The patient died at 74 
days and pathological studies showed proliferation and dilatation of bile ducts in the 
liver. Both CDG-Ih and CDG-IIb show a more severe and systemic phenotype than 
PCLD, but strikingly bile duct abnormalities, a pathological hallmark of PCLD, are 
found in both diseases. This indicates that glycosylation processes are important in 
the normal development of bile ducts.  
Further studies on glucosidase I showed that the mutated protein was unable to 
cleave the first glucose of the glycan on nascent glycoproteins, arresting protein fold-
ing and processing. However, the lack of glucosidase I was partly compensated by in-
crease in endo-α1,2-mannosidase activity, which cleaved the terminal three glucose 
residues together with one mannose residue all at once 61. This bypass mechanism 
resulted in the normal processing of >80% of the glycoproteins. Multiple bypass 
mechanisms and alternative routes are now described in glycan processing, implying 
interesting treatment options 57. 
concludIng remarKs and future perspectIves
Much has been learned about PCLD over the last few years, but still many issues are 
unclear. By classifying PCLD as a CDG we hope to open a whole new discussion in 
the pathogenesis research. By aligning the disease next to related disorders we might 
gain insight in the pathogenesis and obtain inspiration for future treatments. Future 
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studies should first confirm the two-hit model. Subsequently, it will be important 
to investigate the cell type specific effects of hepatocystin knockout and identify 
possible glycan and protein accumulations. It would be interesting to find whether 
a liver specific client protein of hepatocystin exists. These studies could also lead to 
the identification of other genes involved in PCLD pathogenesis, which is implied 
by the low mutation frequency found in patients. 
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Autosomal dominant polycystic liver disease (PCLD) is characterized by pro-
gressive development of multiple (>20) liver cysts. Two separate genes, PRKCSH 
and SEC63, have been identified to cause familial PCLD. We designed this study 
with two goals: (1) to  assess the relative contribution of PRKCSH and SEC63 
mutations in a cohort of unrelated patients with a variable number of liver cysts 
and (2) to assess the effect of these mutations on the severity of the PCLD phe-
notype. We selected patients with 2 or more liver cysts on radiological studies 
and excluded those with renal cysts. A total of 51 patients entered the study and 3 
groups were distinguished: group A, 2-10 cysts (18 patients); group B, 11-20 cysts 
(9 patients); and group C, more than 20 cysts (24 patients). In total we found that 
8 patients with multiple liver cysts (16%) had PRKCSH (5) or SEC63 (3) muta-
tions. Two patients (11%) from group A had missense mutations (1 PRKCSH 
and 1 SEC63). Six patients (25%) with more than 20 liver cysts had mutations 
(4 PRKCSH and 2 SEC63), of which five mutations were chain-terminating. In 
conclusion, both PRKCSH and SEC63 mutations are associated with polycystic 
liver disease. Frequency and severity of mutations is higher among patients with 
more than 20 liver cysts, but also patients with as few as 8 liver cysts can be mu-
tation carriers. 
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IntroductIon
Single and multiple hepatic cysts have a relatively high prevalence of 2.5 to 10% 
among the general population 1, 2. By contrast, polycystic livers, arbitrarily diagnosed 
once more than 20 liver cysts are present, are infrequent. Polycystic livers can occur 
as an autosomal dominant inherited condition designated as polycystic liver disease 
(PCLD, MIM# 174050), which has been described in less than 20 families 3.
In PCLD, multiple cysts arise from progressive dilatation of abnormal ducts in bil-
iary hamartomas 4. Hamartomas are the result of a ductal plate malformation at the 
level of the small intrahepatic bile ducts. These small bile ducts have lost continuity 
with the remaining biliary tree, which explains the non-communicating nature of 
the cysts in polycystic liver disease 5.
PCLD is inherited in an autosomal dominant fashion, and so far two genes, PRKCSH 
(MIM# 177060) and SEC63 (MIM# 608648), have been implicated to cause the 
disease 6, 7. PRKCSH is located on chromosome 19p13.2 and encodes hepatocystin 6. 
The exact function of hepatocystin remains to be elucidated, but it is thought to act 
as the regulatory subunit of glucosidase IIα, and to be involved in the folding and 
quality control of newly synthesized glycoproteins 8-12. The second gene, SEC63, is 
located on chromosome 6q21 and encodes Sec63p, which is probably involved in the 
protein translocation machinery in the endoplasmic reticulum 7, 13-16. 
Another disease in which liver cysts can be predominant is autosomal dominant 
polycystic kidney disease (ADPKD). PCLD is different from ADPKD at the phe-
notypical as well as genotypical level. Patients with PCLD do not have polycystic 
kidneys, whereas up to 60% of patients suffering from ADPKD may have polycystic 
livers in addition to polycystic kidneys 17, 18. Further, PCLD is unlinked to the two 
ADPKD genetic loci, PKD1 and PKD2 19-21.
The discovery of the genes was facilitated by the input of well-characterized families 
with a clear polycystic phenotype and an autosomal dominant inheritance pattern. It 
is unclear however, whether patients who possess less than the 20 cysts required for 
the diagnosis of PCLD may also have mutations in either PCLD gene and whether 
their mutation rate is different from patients with PCLD 3, 22. Lastly, it is unknown if 
there are phenotypical differences between patients with a PRKCSH and those with 
a SEC63 mutation. 
To resolve these issues, we designed this study with the primary goal to assess the 
mutation frequency of the PCLD genes in a cohort of unrelated patients with the 
full phenotypical spectrum of liver cysts. Our second goal was to assess the effect of 
these mutations on the severity of the PCLD phenotype.
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materIals and methods
Patients
A series of 43 unrelated patients were retrieved from the Radiology database at the 
Radboud University Nijmegen Medical Center. We performed an automated search 
for the period between January 2000 and August 2004 and searched for records that 
contained the combination of the terms multiple, liver, and cyst(s). The retrieved 
records were scrutinized and we selected patients who had 2 or more liver cysts on 
abdominal ultrasonography and/or abdominal computer tomography. We also ob-
tained samples from 8 patients, who were on the waiting list for liver transplant or 
had underwent a liver transplant at the Erasmus MC University Medical Center (Rot-
terdam, the Netherlands), as a consequence of severe polycystic livers. Patients with 
a clinical diagnosis of ADPKD and/or who fulfilled the formal ultrasonographic 
criteria for ADPKD were excluded from the study 23. Patients had to be at least 18 
years-of-age to participate and all gave a written informed consent. The study was 
approved by the local Medical Ethical Committee (CMO Regio Arnhem-Nijmegen).
Genotyping
Genomic DNA was purified from peripheral blood by standardized methods (Gen-
tra Systems, Minneapolis, MN, USA). Mutation screening was performed for the 
17 exons enclosing the open reading frame of PRKCSH and 20 exons comprising 
SEC63. Genomic DNA was amplified by PCR using standard protocols with oligo-
nucleotide primers complementary to flanking intronic sequences (available upon re-
quest). The PCR reaction mix (50 μl) consisted of 200 ng genomic DNA, 0.25 mmol 
of each dNTP, 5.0 U Taq-DNA-polymerase, 200 nM of each primer, 10 mmol Tris-
HCl (pH 9.0), 50 mmol KCl, 0.1% TRITON and 1.5-2.5 mM MgCl2. The PCR pro-
gram started with 5 minutes preheating at 95°C, followed by 35 cycles of 30 seconds 
at 95°C, 30 seconds at 55-65°C and 1 minute at 72°C. The program terminated with 
5 minutes elongation at 72°C. PCR products were purified after gel electrophoresis 
with the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) and sequenced 
using the BigDye terminator kit and an ABI3730 capillary sequencer (Perkin Elmer 
Applied Biosystems, Boston, MA, USA) according to the manufacturer’s manual.
Mutation verification
Missense variants were verified in a set of healthy controls with a similar ethnic back-
ground (European) using the Restriction Fragment Length Polymorphism technique 
(RFLP). For the three PRKCSH variants we first used site directed mutagenesis to 
accomplish a restriction site that included the variant site (primer sequences available 
upon request). The PCR reaction mix and program were used as described above. 
Subsequently, amplicons were digested with NdeI (c.416G>A), AluI (c.464A>G) or 
MwoI (c.871G>A), separated on a 3% agarose gel and stained with ethidium bromide. 
The missense variant in SEC63 (c.502G>C) disrupted a restriction site. Verification 
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of this variant in the control population was accomplished by PCR amplification of 
SEC63 exon 5 as indicated above and digestion with the enzyme NlaIII. Digested 
samples were electrophoresed on a 3% agarose gel and stained with ethidium bro-
mide. Conservation of the mutation regions was verified using the MultAlin align-
ment program (http://prodes.toulouse.inra.fr/multalin/multalin.html). Hepatocys-
tin and Sec63p were aligned with homologs from mouse, rat, dog, chimpanzee, cow, 
and chicken.
Pyrosequencing
Missense variants c.1666G>A and c.2027C>T in SEC63 were verified by pyrose-
quencing. A nested PCR was performed to amplify and biotinylate the PCR products. 
The PCR reaction was performed in a 50 µl reaction volume and with a thermal 
cycling program as described above. The pyrosequencing procedure was performed 
according to manufacturer’s instructions on a PSQ 96MA system (Biotage, Uppsala, 
Sweden). 
GenBank accession numbers
GenBank nucleic acid reference numbers used for PRKCSH DNA: NC_000019.8 
and for mRNA: NM_002743.2. Accession numbers for hepatocystin: Homo sa-
piens P14314; Mus musculus O08795; Rattus norvegicus XP_238534.3; Canis familiaris 
XP_542057.2; Pan troglodytes XP_512394.1; Bos Taurus AAI04525.1. Nucleic acid refer-
ence numbers for SEC63 DNA: NC_000006.9 and mRNA: NM_007214.3. Acces-
sion numbers for Sec63p: Homo sapiens CAB46275.1; Mus musculus Q8VHE0; Rattus 
norvegicus XP_228305.2; Canis familiaris XP_532252.2; Pan troglodytes XP_518668.1; 
Gallus gallus XP_419802.1.
results
Mutational screening
We identified a total of five PRKCSH mutations and three SEC63 mutations among 
our sample, five of which have not been previously reported (Table 3.1). We also de-
tected three polymorphisms, one in PRKCSH and two in SEC63. All detected vari-
ants were found in a heterozygous state. Figure 3.1 depicts the detected mutations 
superimposed on a schematic structure of the genes. As can be concluded from this 
figure, the mutations do not segregate to mutational hotspots.    
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ta b l e   3 .1   PRKCSH and SEC63 gene mutations.
Gene Location Variant ORF change No. alleles Phenotype (no. cysts)
PRKCSH
IVS 2 c.76_79+4dup8 p.N27SfsX117 1* >20
IVS 4 c.292+1G>C p.D98AfsX3 1 >20
Exon 6 c.416G>A p.R139H 1 >20
Exon 6 c.464A>G p.K155R 1** 8
IVS 15 c.1338-2A>G p.T448X 1 >20
SEC63
Exon 5 c.502G>C p.D168H 1 9
Exon 16 c.1577C>A p.S526X 1 >20
Exon 19 c.2006_2007delAT p.H669RfsX41 1 >20
Location reflects the genomic location of the mutation. Nomenclature of mutations refers to the cDNA 
sequence with the A of the translation initiation codon designated as +1 (GenBank reference numbers 
NM_002743.2 (PRKCSH) and NM_007214.3 (SEC63)). ORF denotes open reading frame, No. alleles in-
dicates alleles found in this study and Phenotype indicates the number of liver cysts as detected with ra-
diological techniques. * Cousin of index patient also affected. ** Two siblings of index patient also affected. 
Mutations identified in this study are depicted in bold face
F i g u r e   3 .1   Schematic representation of PRKCSH (top) and SEC63 (bottom). 
The mutations found in this study are depicted superimposed on the gene structures. Note that, for both 
genes, mutations are not distributed in mutational hot spots. Black boxes represent non-coding exons, 
blue boxes show coding exons and the introns are indicated by a black line. Yellow boxes exemplify the 
corresponding protein domains. Abbreviations: LDLa: low-density lipoprotein receptor domain A; EF: EF-
hand calcium binding domain; ee: glutamic acid rich region; M6P: mannose 6-phosphate receptor domain; 
HDEL: ER retention signal domain; DnaJ: heat shock protein DnaJ; SEC63: SEC63 domain. Nomenclature 
of mutations refers to the cDNA sequence with the A of the translation initiation codon designated as +1 
(GenBank reference numbers NM_002743.2 (PRKCSH) and NM_007214.3 (SEC63)).
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PRKCSH mutations
Sequence analyses yielded five PRKCSH mutations (Table 3.1). Two were missense 
mutations: c.416G>A and c.464A>G. The first leads to an amino acid change of 
arginine to histidine at position 139, while the c.464A>G mutation results in the 
substitution of lysine to arginine at position 155. Both mutations were verified using 
PCR and RFLP and were not found among a panel of control alleles (164 and 90 
respectively). Both mutations affect nucleotides that are highly conserved among a 
wide range of species (Table 3.2). This suggests that these mutations affect structur-
ally and/or mechanic important residues in the sequence. Consequently, they are 
considered pathogenic mutations. The patient with the c.464A>G mutation (II6) 
had 8 small liver cysts at 58 years-of-age. She had an extensive family with 9 siblings. 
We collected DNA from all siblings and discovered that 2 brothers also carried the 
c.464A>G mutation. One brother (II8), 60 years-of-age, had 6 liver cysts on ultra-
sonography, the largest being 1 cm. The other brother (II7), 63 years-of-age, did not 
have liver cysts, but two small (< 1 cm) cysts limited to the right kidney. The other 
siblings were genetically unaffected (Figure 3.2). 
ta b l e   3 .2   Sequence alignment of the mutation sites in hepatocystin and Sec63p.
Organism
Mutation
PRKCSH c.416G>A PRKCSH c.464A>G SEC63 c.502G>C
Homo sapiens REGFRLKKIL AREEKQKKLI FGNPDGPQAT
Mus musculus REGFRLKKIL AREEKQSKLL FGNPDGPQAT
Rattus norvegicus REGFRLKKIL AREEKQSKLL FGNPDGPQAT
Canis familiaris REGFRLKKIL AREEKQEKLT FGNPDGPQAT
Pan troglodytes REGFRLKKIL AREEKQ • • • • FGNPDGPQAT
Gallus gallus FGNPDGPQAT
Bos Taurus REGFRLKKIL AREEKQKKLI
Consensus REGFRLKKIL AREEKQ • k l • FGNPDGPQAT
Amino acids affected by the mutations are indicated in bold red. Capitals in the consensus sequence repre-
sent identical residues in all sequences; lower-case letters represents low consensus and neutral consensus 
is indicated by a dot. Accession numbers for hepatocystin are as follows: Homo sapiens P14314; Mus musculus 
O08795; Rattus norvegicus XP_238534.3; Canis familiaris XP_542057.2; Pan troglodytes XP_512394.1; Bos 
Taurus AAI04525.1. Accession numbers for Sec63p are as follows: Homo sapiens CAB46275.1; Mus musculus 
Q8VHE0; Rattus norvegicus XP_228305.2; Canis familiaris XP_532252.2; Pan troglodytes XP_518668.1; Gal-
lus gallus XP_419802.1.
Chapter 3
 32 
F i g u r e   3 .2   Segregation of the PRKCSH c.464A>G mutation in a single family. 
The squares indicate males; the circles reflect females and the filled symbols indicate the PCLD genotype. 
All siblings were screened genetically for the c.464A>G mutation and affected siblings were subjected to 
ultrasonography. The lower panel indicates a representative image of the ultrasound studies of index patient 
II6 and siblings II7 and II8. Patient II6 and II8 had multiple liver cysts, while patient II7 had 2 renal but no 
liver cysts. Cysts are indicated with white arrows. 
In a patient with more than 20 cysts, we identified an 8 base pair insertion in 
PRKCSH (c.76_79+4dup8), which results in the duplication of the splice site located 
4 base pairs into intervening sequence 2 (IVS 2) (Figure 3.3a). We analyzed this vari-
ant for potential splice site effects using the splice site prediction by neural network 
(SSPNN; http://www.fruitfly.org/seq_tools/splice.html). Splice site scores predicted 
the theoretical impact upon the strength of donor and acceptor sites and the prob-
ability that sequence variants created novel splice sites. With the duplication of 8 
base pairs, the original splice site is not recognized and the newly formed splice site 
acquires a probability score of 0.97. Without the duplication the original splice site 
scores a probability of 0.95. In order to test which splice site is actually transcribed, 
we performed an RT-PCR experiment. The PCR products were separated on acryl 
amide gel electrophoresis, which yielded two fragments, with lengths corresponding 
to wild type and mutant alleles (approximately 8 base pairs difference) (Figure 3.3b). 
Sequence analysis indicated that the insertion activates the cryptic splice-acceptor 
site motif so that it is used preferentially over the upstream authentic splice site (Fig-
ure 3.3c). Utilization of the novel splice donor site results in a frameshift and intro-
duces a stop codon in exon 6 of the gene. Apart from being shortened, the predicted 
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amino acid composition of this mutant protein is very different from the original 
protein. The index patient had a cousin affected with severe PCLD (>20 liver cysts) 
and DNA screening revealed this patient to be a mutation carrier. Figure 3.3d shows 
the segregation of the c.76_79+4dup8 mutation in this family. 
Finally, we detected two PRKCSH splice variants c.292+1G>C and c.1338-2A>G 
in this cohort. These variants both result in retention of the intron, frameshift and 
premature termination of translation and were reported earlier in familial PCLD 6.
F i g u r e   3 .3   Analysis of the 8 base pair duplication in intervening sequence 2 of PRKCSH 
(c.76_79+4dup8). 
a| Schematic overview of the duplication and the novel introduced splice site. One indicates the wild type 
splice site and 2 the mutant splice site. Usage of the mutant splice site results in an insertion of 8 base pairs, 
frameshift and premature termination. b| Ethidium bromide stained agarose gel of RT-PCR products. 
Product source is indicated above the lanes. Numbers specify the base pairs of the 100 base pair-spaced 
molecular-size marker. C| Sequence electropherogram showing high mutant allele sequence and low wild 
type sequence. d| Overview of the segregation of the PRKCSH c.76_79+4dup8 mutation in a single family. 
Squares indicate males; circles reflect females; the filled symbols indicate the PCLD phenotype and the 
shaded symbols indicate obligate carriers.
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SEC63 mutations
We detected three SEC63 mutations: one missense mutation, one nonsense muta-
tion and a 2 base pair deletion (Table 3.1). The novel missense mutation, c.502G>C, 
substitutes aspartic acid for histidine at position 168 and was absent upon testing 
in a control panel of 98 alleles. MultAlin analysis demonstrated that the nucleotide 
affected by the mutation site is highly conserved among different species (Table 
3.2). The c.1577C>A nonsense mutation results in the inclusion of an in frame stop 
codon and subsequently premature termination of the translation. Lastly, deletion 
c.2006_2007delAT (exon 19 of SEC63) results in frameshift and premature termina-
tion of translation and has been associated previously with familial PCLD 7.
Polymorphisms
One missense variant in PRKCSH, c.871G>A, was found in a similar frequency in 
patients as well as in controls (26% in 186 control alleles), suggesting that it repre-
sents a true polymorphism. The two SEC63 variants c.1666G>A and c.2027C>T 
were verified by pyrosequencing. We found no statistically significant differences 
in prevalence in patients compared to 190 (c.1666G>A) or 166 (c.2027C>T) healthy 
control alleles (10% vs. 7% and 12% vs. 16% respectively).
Phenotype-mutation relation
We arbitrarily divided the patients into three patient groups according to the number 
of liver cysts on diagnosis (Figure 3.4). Group A contained 18 patients (6 males, 12 
females), who had 2 to 10 liver cysts. The median age of the patients was 60 years 
(range 30 to 79 years). Group B consisted of 9 patients (5 males, 4 females) with 10 
to 21 liver cysts. The median age was 57 years (range 45 to 73). Group C contained 
24 patients (13 males, 11 females) with most severe PCLD, who possessed at least 21 
liver cysts. The median age was 52 years (range 30 to 79).
F i g u r e   3 .4   Computer tomography images of patients from the three groups of disease 
severity. 
Group A contained patients with 2-10 liver cysts, group B enclosed patients with 11-20 liver cysts and group 
C comprised patients with more than 20 liver cysts.
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Only 2/18 patients with the mildest phenotype (group A) carried a PCLD mutation 
(frequency 11%), and there were no patients with a PCLD gene mutation among pa-
tients with an intermediate phenotype (11 to 20 cysts). A total of 6 out of 24 patients 
with most severe PCLD carried mutations (25%). All 5 chain-terminating mutations 
and one missense mutation were found in the severe disease group, group C. The 
two remaining missense variants were found in group A. An overview of our find-
ings is described in Table 3.1. Collectively, the mutation frequency was 16% with 
PRKCSH being the most frequently implicated gene (10% vs. 6% for SEC63). 
dIscussIon
This is the first study on the mutation frequency of PRKCSH and SEC63 in a large 
cohort of patients with a wide phenotypical range of multiple liver cysts. Sequencing 
of the entire coding sequence and splice sites in a group of 51 patients with multiple 
liver cysts resulted in the identification of 8 mutations, 5 of which have not been pre-
viously reported. On the whole, the mutation frequency in our study group was 16% 
(10% for PRKCSH and 6% for SEC63). We also assessed the relation between the 
presence of mutations and disease severity. Most mutations were found among those 
with more than 20 liver cysts. Likewise, the mutations tended to be more disrupting 
in patients with severe disease. We found that all but one mutation in the patients 
with severe disease were chain-terminating, while patients with mild disease (group 
A) carried only missense mutations. 
We detected 3 missense mutations in our patient group. None of these mutations 
were found in healthy control alleles and nucleotides affected were all highly con-
served among sub mammalian vertebrates underscoring the functional importance 
of the change. The c.464A>G PRKCSH gene mutation results in a substitution of 
lysine into arginine and c.502G>C in SEC63 results in a change of aspartic acid into 
histidine. These two mutations were found in the mild disease group. In contrast, 
the c.416G>A PRKCSH mutation, which results in the change of arginine into his-
tidine, was found in a patient with a severe disease phenotype. Lysine and arginine 
are two similar amino acids, which could account for the mild disease phenotype. 
Aspartic acid and histidine, however, are not similar albeit the change in pKa of the 
side chains is small compared to the change in pKa of the substitution of arginine 
into histidine. This could explain the difference in phenotypes, but also mechanical 
and structural changes in the protein resulting from the amino acid change should 
be taken into account.
All chain-terminating mutations described in this study were found in the severe 
disease group. When translated, the protein products of these altered genes would all 
be truncated due to frameshifts and/or early translation termination events. These 
proteins are potentially as short as 100 amino acids and miss important domains 
like the endoplasmic reticulum retention signal in case of hepatocystin. However, in 
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this context we should also consider nonsense-mediated decay (reviewed in 24). This 
process degrades mRNA transcripts that contain premature stop codons before they 
are translated into truncated proteins. As a consequence, it can be hypothesized that 
in PCLD, chain-terminating mutations are associated with lower levels of functional 
protein, rather than production of mutated protein.
We found a rather low mutation frequency of 16% in our cohort, and even in patients 
with severe disease (patients with >20 cysts), 18 patients (75%) did not have a muta-
tion in either PCLD gene. This indicates that PCLD is a genetic heterogeneous dis-
ease and even more genes are implicated. This corroborates with the findings from 
other studies in PCLD families. There, researchers analyzed 66 individuals with 
PCLD and detected 9 patients (14%) with PRKCSH 25 and 8 patients (12%) carried 
SEC63 mutations 7. It is to be expected that novel PCLD genes will be discovered in 
the future by genome wide linkage analysis in mutation negative families. Given the 
role of hepatocystin and Sec63p, it is likely that these novel PCLD genes encode for 
proteins involved in protein processing in the endoplasmic reticulum 16.
In conclusion, this study describes comprehensive molecular analysis of PRKCSH 
and SEC63 genes in a large cohort of unrelated patients with multiple liver cysts. The 
results indicate that 16% of this cohort has either PRKCSH or SEC63 mutations. The 
frequency and severity of mutations is higher among patients with more than 20 liver 
cysts, but also patients with as few as 8 liver cysts can be mutation carriers.
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Polycystic liver disease (PCLD) is characterized by intralobular bile duct cysts 
in the liver. It is caused by mutations in PRKCSH, encoding hepatocystin, and 
SEC63, encoding Sec63p. The main goals of this study were to screen for novel 
mutations in both genes and to analyze all known mutations for effects on pro-
tein structure and function. We screened 445 subjects including 76 probands 
by direct sequencing or conformation-sensitive capillary electrophoresis. We 
analyzed the effects of all known and novel mutations using a combination of 
splice site recognition, evolutionary conservation, Grantham score differences, 
PolyPhen scores, and secondary and tertiary structure predictions. We identi-
fied a total of 24 novel mutations in PRKCSH (n=14) and SEC63 (n=10), includ-
ing 4 splice site mutations, 7 insertions/deletions, 5 nonsense mutations and 8 
missense mutations. All mutations located at splice sites influenced splicing. 
Further, all missense mutations were rare mutations, showed a high Grantham 
score difference or were located in conserved locations or CpG islands. Homol-
ogy modeling for two domains of Sec63p showed severe effects of the residue 
substitutions. Mutations n PRKCSH were concentrated in exons 6 and 16, but 
mutations in SEC63 were distributed evenly over the gene. Finally, we found 
substantially more truncating mutations in PRKCSH, whereas in SEC63 mostly 
missense mutations were found. In conclusion, 78% of the patients screened in 
this study did not reveal a mutation in either gene indicating involvement of a 
third locus. In addition, mutation analysis is important in the correct diagnosis 
of PCLD and in identifying important protein domains. 
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IntroductIon
Polycystic liver disease (PCLD, MIM# 174050) is a rare but potentially disabling 
disease characterized by overgrowth of fluid-filled cysts limited to the liver. The 
cysts arise from the intralobular bile ducts and are lined with a single layer of biliary 
epithelial cells 1, 2. The number and size of the cysts may cause severe hepatomegaly 
with concomitant symptoms such as severe dyspnoea and wasting 3, 4.
PCLD is a congenital disease and inherited in an autosomal dominant fashion 5. 
Using positional cloning, two groups independently identified PRKCSH (MIM# 
177060) in 2003 as the molecular culprit causing PCLD. Drenth and colleagues iden-
tified 2 founder mutations among 4 families, while Li and coworkers discovered 
6 mutations in 6 families 6, 7. The discovery of PRKCSH came as a surprise, as the 
function of the encoded protein, the non-catalytic β-subunit of glucosidase IIα or 
hepatocystin, is apparently unrelated to known pathways of cystogenesis. Glucosi-
dase IIα is located in the endoplasmic reticulum (ER) and is involved in carbohydrate 
processing and quality control of glycoproteins 2, 8. A second locus was mapped to 
6q21 after the identification of a family with autosomal dominant PCLD not linked 
to the PRKCSH gene 9. The linkage interval contained an attractive candidate SEC63 
(MIM# 608648). Indeed, 7 mutations were found in 5 families and 3 singleton cases 
9. SEC63 encodes Sec63p, which like the protein product of PRKCSH is an ER resi-
dent protein 2. Sec63p functions in the protein translocation into and out of the ER 
10, 11. In all, mutations of either PRKCSH or SEC63 gene account for approximately 
25% of PCLD cases, indicating the existence of at least one more locus for PCLD 6, 
7, 9, 12. 
Mutation analysis of both the PRKCSH and the SEC63 genes may become increas-
ingly important for establishing a diagnosis of PCLD in affected patients. It can 
be helpful in the differential diagnosis with autosomal dominant polycystic kidney 
disease (ADPKD) where patients can also have polycystic livers sometimes as the 
predominant feature. This is important as renal function is preserved in PCLD, but 
not in ADPKD. In an effort to provide a full overview of all known mutations in 
PRKCSH and SEC63, we collated results of mutation analyses from institutions cur-
rently involved in genetic research in PCLD. 
We expected to shed light on the molecular pathology of PCLD and to aid the devel-
opment of an effective molecular testing strategy for diagnostic testing. Therefore, 
we established two objectives: (1) to find novel mutations by screening the entire cod-
ing region of PRKCSH and SEC63 in patients presented for polycystic liver disease 
DNA diagnostics; and (2) to estimate, by bioinformatic methods, the possible effect 
of new and described mutations on the structure and function of the proteins.
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materIals and methods
Patients
For this study we used data from two diagnostic centers; the Radboud University 
Nijmegen Medical Center and the Mayo Clinic-Yale University collaborative group. 
In these centers, molecular diagnostics is carried out on patient samples from all 
over Europe and North America. Blood samples presented on suspicion of PCLD 
between 2004 and 2008 were screened for mutations in PRKCSH and SEC63. In 
Nijmegen, we analyzed 205 singleton cases and 9 unrelated probands from a total of 
26 samples. In the United States, mutation analysis was carried out in 67 unrelated 
affected probands from a total of 214 samples. A proband was defined as a patient 
with at least one more affected family member. None of the individuals in whom we 
report mutations here have been previously reported.
Genomic DNA extracted from peripheral blood (Gentra Systems, Minneapolis, 
USA) was used for mutation screening through direct sequencing or conformation-
sensitive capillary electrophoresis (CSCE). 
Direct sequencing
Direct sequencing was performed as described earlier 12. Briefly, exons and adjoining 
intronic segments including splice donor and acceptor sites of PRKCSH and SEC63 
were amplified using standard PCR (primer sequences available upon request). The 
PCR products were verified on gel electrophoresis and subsequently purified using 
QIAEXII Gel Extraction Kit (Qiagen, Hilden, Germany). Finally, the samples were 
sequenced using the BigDye terminator kit and an ABI3730 capillary sequencer (Ap-
plied Biosystems, Foster City, CA, USA).
Conformation-sensitive capillary electrophoresis (CSCE) 
The heteroduplex-based mutation detection consisted of two standard PCR reac-
tions with primers complementary to flanking intronic sequences (available upon re-
quest). The first forward primer contained a 5’ M13 primer sequence and the second 
forward primer was a M13 forward primer labeled with Fam, Ned, Vic or Rox. After 
PCR, the products were pooled (one of each color) and diluted in MQ containing a 
GeneScan 500 LIZ size standard (Applied Biosystems, Foster City, CA, USA). After 
purification, the samples were run on an ABI 3730 with a 48-capillary array (Applied 
Biosystems, Foster City, CA, USA). Finally, the acquired data was analyzed using the 
GeneMapper software (Applied Biosystems, Foster City, CA, USA). Deviant samples 
were sequenced to determine the exact mutation. 
Mutation nomenclature
To determine primer and mutation positions, we used PRKCSH genomic DNA 
(Genbank accession number NC_000019.8), cDNA (Genbank accession number 
NM_002743.2), and protein sequences (Genbank accession number NP_002734.2) 
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as well as SEC63 genomic DNA (Genbank accession number NC_000006.10), 
cDNA (Genbank accession number NM_007214.3), and protein sequences (Gen-
bank accession number NP_009145.1). Mutation nucleotide numbering was based on 
the cDNA sequences with the A of the ATG translation initiation codon designated 
as nucleotide +1. All mutations are described according to mutation nomenclature 
standards (www.hgvs.org/mutnomen) 13. 
In silico analysis
First, whenever samples were available, the segregation of a novel mutation with the 
disease within the family was tested. Next, all mutations were tested for influence 
on (cryptic) splice sites using the web based splice site prediction by neural network 
(SSPNN; http://www.fruitfly.org/seq_tools/splice.html). This online program pre-
dicts the theoretical strength of donor and acceptor splice sites.
Subsequently, the effect of amino acid substitutions resulting from missense muta-
tions was analyzed using different approaches. (1) We examined the conservation of 
the proteins using multiple protein sequence alignments constructed with the EN-
SEMBL Genome browser (www.ensembl.org), Clustal-W (www.ebi.ac.uk/clustalw) 
and Jalview (www.jalview.org). Hepatocystin was aligned with 19 orthologues and 
Sec63p with 17 orthologues (Supplementary Table T4.1). We classified the muta-
tion location as highly conserved when no other residues were found at that loca-
tion. When similar residues were present we considered the location conserved, but 
when various residues were found in the different organisms the location was not 
conserved. (2) Grantham scores were assigned to substitutions to evaluate chemi-
cal differences like side chain volume, composition, and polarity 14. A Grantham 
score larger than 100 shows a strongly dissimilar residue and a score smaller than 60 
represents a similar and therefore probably benign substitution. We calculated the 
ratio of the Grantham score and the highest cross species difference. A ratio larger 
than 3 was considered pathogenic. (3) We analyzed the effects of substitutions us-
ing PolyPhen (http://genetics.bwh.harvard.edu/pph/). (4) The mutations were also 
examined in relation to functional protein domains and CpG island disruption.
We were able to perform homology modeling for two domains of Sec63p; the lu-
minal DnaJ domain and a yet unassigned part of the protein in the SEC63 domain 
(amino acids 626-719). For the model of the J-domain, we used the structure of a 
J-domain from mouse DnaJ subfamiliy C (Protein Data Bank code 2CTW, 45% 
identity over 75 amino acids). The model for the second domain was based on PDB-
file 2Q0Z (38% identity over 93 amino acids). Homology modeling was performed 
using the WHAT IF-server for modeling and Yasara for energy minimization and 
analysis (http://swift.cmbi.ru.nl and www.yasara.org) 15, 16. To assess the effect of the 
mutations in the remaining part of the proteins, we used a secondary structure pre-
diction using the PsiPred-server (PSIPRED v2.6, www.bioinf.cs.ucl.ac.uk/psipred/) 
17, 18. The PRKCSH gene contains a large helix structure and we analyzed mutations 
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in this region using a helical wheel predictor at http://www.cti.itc.virginia.edu/cmg/
Demo/wheel/wheelApp.html.
results
We conducted an extensive screen for mutations in both PRKCSH and SEC63 of 
up to 445 samples including 76 unrelated probands. In addition to the 13 previously 
reported PRKCSH and 9 previously reported SEC63 mutations, we found 14 hith-
erto unreported mutations in PRKCSH and 10 in SEC63 (Tables 4.1 and 4.2). The 
novel PRKCSH mutations included 2 splice site mutations, 5 deletion/insertions, 4 
nonsense mutations and 3 missense mutations. In SEC63, we found 2 splice site 
mutations, 2 deletion/insertions, 1 nonsense mutation and 5 missense mutations. All 
mutations were found in a heterozygous state. One patient was transheterozygous 
for both a PRKCSH mutation and a SEC63 mutation, but showed no exceptional 
phenotype. 
Next, we performed extended in silico analyses to examine the effect of the mutations 
on the structure and function of both hepatocystin and Sec63p. We analyzed all mu-
tations; novel mutations described in this paper and mutations previously described 
in the literature. The mutations are published on www.livercyst.org and detailed 
information about the in silico analyses can be found at www.cmbi.ru.nl/~hvensela/
PRKCSH.
Splice sites
First, we analyzed the mutations for effect on (cryptic) splice sites using the splice 
site prediction from neural network. All splice site mutations in our study resulted in 
abolishment of the existing splice site (Supplementary Table T4.2). In addition, the 
nonsense mutation c.487C>T in PRKCSH also abolished the neighboring acceptor 
splice site, even though the mutation is situated 20 base pairs into the exon. None of 
the other mutations found in this study influenced the strength of the neighboring 
splice site or resulted in the formation of a new splice site. 
Missense mutations in PRKCSH
All missense mutations found in PRKCSH are rare variants. They were found < 1% 
of the tested population (>1000 alleles), and are therefore regarded as pathogenic 
mutations 19. Table 4.3 shows an overview of the mutations and the results of our in 
silico analyses. 
Both the mutations p.R139H and p.K155R in hepatocystin (PRKCSH) were previ-
ously described 12. The mutations are located in a conserved region, which indicates 
an important role for the concerning side chains. Moreover, the p.R139H mutation 
is located at a CpG island, disruption of which might have influence on the gene 
translation control.
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ta b l e   4 .1   PRKCSH mutations identified in PCLD patients.
Posi-
tion Nucleotide change
Amino acid 
change Alleles
* Origin Reference
Splice site
IVS 2 c.76-79+4dup8 p.N27SfsX117 0 12
IVS 4 c.292+1G>C p.D98AfsX100 8 Dutch 6
IVS 8 c.598-4delGCAG p.V229X 2 USA This study
IVS 9 c.762+2T>C p.L292PfsX330 0 7
IVS 15 c.1341-2A>G p.T448X 11 Dutch 6
IVS 15 c.1341-1G>A p.T448X 1 USA This study
IVS 16 c.1440+1delGT p.T448CfsX457 1 Finnish 7
Insertion/Deletion
Exon 4 c.215_216insA p.N72KfsX81 0 7
Exon 6 c.353_354insA p.K119EfsX122 1 USA This study
Exon 6 c.368delA p.E123GfsX130 1 USA This study
Exon 6 c.374_375delAG p.E125VfsX145 4 Dutch 32
Exon 6 c.430_432delCTTins7bp p.L144NfsX147 3 Dutch This study
Exon 8 c.668delA p.D223VfsX231 1 USA This study
Exon 13 c.1168_1169insC p.I391HfsX401 0 7
Exon 15 c.1336delC p.G447AfsX463 2 USA This study
Nonsense
Exon 6 c.466C>T p. Q156X 1 USA This study
Exon 7 c.487C>T p.Q163X 2 UK This study
Exon 7 c.593G>A p.W198X 1 USA This study
Exon 14 c.1240C>T p.Q414X 0 7
Exon 15 c.1269C>G p.Y423X 0 7
Exon 16 c.1395T>G p.Y465X 2 Dutch This study
Missense
Exon 6 c.416G>A p.R139H 1 Dutch 12
Exon 6 c.464A>G p.K155R 0 12
Exon 7 c.523A>G p.M175V 1 USA This study
Exon 10 c.781A>T p.T261S 1 French Canadian This study
Exon 10 c.841C>T p.R281W 0 20
Exon 13 c.1141G>A p.E381K 1 USA This study
 Total number of  mutations found in this study 45
* Number of alleles found in this study excluding family members. Mutations identified in this study are 
depicted in bold face.
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ta b l e   4 .2   SEC63 mutations identified in PCLD patients.
Position Nucleotide change Amino acid change Alleles
* Origin Reference
Splice site
IVS 1 c.125-2A>G p.E42GfsX156 0 9
IVS 8 c.733+1G>A p.L246KfsX247 0 9
IVS 8 c.733+1G>T p.L246KfsX247 1 French This study
IVS 11 c.1053_1054+4delAGgtga p.R353EfsX355 1 Turkish This study
Insertion/Deletion
Exon 4 c.441_442insA p.A148SfsX155 0 9
Exon 12 c.1118_1126del 9bp p.A373Gdel 3aa 1 Dutch This study
Exon 17 c.1702_1704delGAA p.E568del 4 Dutch 9
Exon 17 c.1813_1817delCAAAA p.N606RfsX607 1 Dutch This study
Exon 19 c.2006_2007delAT p.H669RfsX689 0 9
Nonsense
Exon 2 c.173G>A p.W58X 0 9
Exon 8 c.715C>T p.R239X 1 Dutch This study
Exon 10 c.891T>A p.Y297X 0 9
Exon 16 c.1577C>A p.S526X 0 12
Missense
Exon 4 c.359T>C§ p.I120T§ 1§ Dutch This study
Exon 5 c.502G>C p.D168H 0  12
Exon 8 c.649C>T p.R217C 1 Dutch This study
Exon 9 c.801A>C p.R267S 2 USA This study
Exon 12 c.1124A>C p.Q375P 1 Dutch This study
Exon 19 c.1951T>G p.W651G 1 Dutch This study
Total number of  mutations found in this study 15
* Number of alleles found in this study excluding family members. § Mutation found transheterozygously 
with PRKCSH c.1341-2A>G. Mutations identified in this study are depicted in bold face.
We identified two new missense mutations in PRKCSH, c.523A>G (p.M175V) and 
c.781A>T (p.T261S). Both mutations are located in a non-conserved area of the gene 
and both are predicted benign by the PolyPhen program. On the other hand, the 
p.T261S mutation was found to segregate with the disease in a family. Secondary 
structure analysis showed that the p.T261S mutation is located in between two heli-
ces. The small but effective difference between threonine and serine and the location 
between two helices is reminiscent of a ligand-binding domain. Furthermore, this 
mutation is located in the EF-hand domain of hepatocystin. The p.M175V is pre-
dicted to be in a helix. Because helices often interact with each other by hydrophobic
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side chains, this residue might be important for the packing of two helices. Both 
methionine and valine are hydrophobic but a change from a large side chain to a 
smaller one might lead to less hydrophobic interactions and destabilization of the 
domain. The secondary structure prediction of hepatocystin is available as Supple-
mentary Figure F4.1.
The p.R281W mutation was also previously reported 20. Again, it affects a conserved 
residue. Moreover, the Grantham score is larger than 100 and compared to the high-
est cross species difference the ratio is larger than 3. In addition, this mutation is 
located at a CpG island in the second EF-hand protein domain. The residue changes 
into the biggest possible residue, tryptophan. The positive charge of arginine is lost, 
and the side chain of tryptophan is possibly too big to fit in the location of arginine.
Finally, we identified the novel c.1141G>A (p.E381K) mutation. This last mutation is 
located in a helix and changes glutamic acid into a lysine. With a helical wheel predic-
tor we were able to see that this helix is amphipathic with a hydrophobic and hydro-
philic side (Figure 4.1a). The hydrophobic side can interact with other domains of 
the protein, leaving the hydrophilic side free for complex formation with other pro-
teins or maybe another part of the protein. A mutation from the negatively charged 
glutamic acid into a positively charged lysine might disturb these interactions.
Missense mutations in SEC63
In SEC63 we analyzed 6 missense mutations and two in-frame deletions (Table 4.3). 
Sec63p is a highly conserved protein with hardly any variability in amino acids at the 
mutation sites. The Grantham scores assigned to the substitutions were almost all 
highly disturbing and the Grantham ratio’s where applicable, were all higher than 3. 
Both p.I120T and p.D168H are located in the luminal DnaJ domain for which we 
have constructed a homology model of the tertiary structure (Figure 4.1b). The DnaJ 
domain mainly consists of alpha-helices. The side chain of isoleucine (p.I120T) is 
located in the hydrophobic space between two helices. Isoleucine is hydrophobic 
and is important for the stability of the two helices. Threonine is smaller and less 
hydrophobic, which might result in loss of the interactions in the core between the 
helices and consequently loss of stability.
The second mutation in the DnaJ domain is an aspartic acid that changes into the 
bigger histidine (p.D168H) 12. The bigger side chain of histidine does not exactly fit 
in the space between the helices. Secondly, it is possible that the negative charge of 
aspartic acid is needed for the turn between the two helices. Therefore, a mutation 
into histidine is likely to disturb the local conformation.
Just downstream of the DnaJ domain, the arginine of p.R217C was predicted to be in 
a helix in the cytoplasmic domain of Sec63p. As arginine is negatively charged and 
can make hydrogen bonds, it is likely that a mutation to a hydrophobic and smaller 
cysteine disrupts the interaction with other residues. Moreover, this mutation is lo-
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cated at a CpG island in the gene. The secondary structure prediction of Sec63p is 
available as Supplementary Figure F4.2.
The arginine of p.R267S was not predicted to be in a certain secondary structure 
or domain. We can only say that a mutation to serine results in a much smaller and 
uncharged residue.
Next, both p.A373Gdel3aa and p.Q375P are located in the same region of the pro-
tein. The alanine at position 373 is not very conserved. However, the three amino 
acids that follow and that are deleted in the p.A373Gdel3aa mutation are highly 
conserved. The residues are predicted to be in a helix. A substitution of glutamine 
with a proline (p.Q375P) will have severe impact on the structure of this helix as the 
torsion of proline will introduce a turn. The fact that an in frame deletion of three 
amino acids at this location results in PCLD indicates an important functional role 
for this region of the protein. 
The p.E568del mutation was previously described by Davila and coworkers 9. This 
mutation is located in the middle of an alpha-helix. A deletion of a Glutamic acid will 
result in a shift of all following residues of approximately 100 degrees in the turn of 
the helix. As a result, all properties of the remaining residues in the helix will move 
to a different place, which can disturb the structure severely.
Finally, the mutation p.W651G is located in the second domain in Sec63p that we 
modeled (amino acids 626-719, Figure 4.1c). The large tryptophan at position 651 is 
located in the core between two beta-sheets. Mutation into a glycine, which has no 
side chain at all, results in a big hole in the middle of the domain. This alters the 
structure profoundly and may influence the protein function. 
Mutation hotspots
Analysis of the mutation locations revealed a concentration of mutations in exon 6 of 
PRKCSH (Figure 4.2a). We found a total of 7 mutations in this exon including mis-
sense mutations, insertions, deletions and nonsense mutations. Exon 16 is also well 
represented with 3 different splice site mutations and 1 nonsense mutation. Even 
though exons 6 and 16 comprise only 13.7% of the PRKCSH coding sequence, we 
found 41% of the different mutations in these two exons. In SEC63, the mutations 
were distributed more evenly over the entire open reading frame (Figure 4.2d). 
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F i g u r e   4 .1   Structure analyses of hepatocystin and Sec63p.
a| Helical wheel prediction of hepatocystin. The p.E381K mutation changing glutamic acid into a lysine is 
located in a helix. The helix has a hydrophobic and hydrophilic side. A mutation from the negatively charged 
glutamic acid (position 10) into a positively charged lysine may disturb interactions of the helix with other 
domains. The helical plot was constructed using amino acids 369-395 of the hepatocystin protein sequence. 
b-C| Tertiary structure models of Sec63p. The models are shown in gray with the side chain of the residues 
exposed. The mutation sites are visible with wild type residues in green and mutations in red. b| Model for 
the DnaJ domain. The p.D168H mutation is depicted on the left. Notice the large mutant side chain that 
does not fit in the space between the helices. On the right is depicted the p.I120T mutation. The smaller 
side chain of the mutation may result in the loss of stability between the two adjacent helices. C| Model for 
the C-terminal 626-719 amino acids of Sec63p. The p.W651G mutation  location is visible in green for the 
wild type situation. The mutant glycine has no side chain and therefore leaves a hole in the structure. 
Mutation type
Most mutations found in PRKCSH are truncating mutations, but in SEC63 a large 
percentage are missense mutations (22% vs 43%). Truncating mutations accounted 
for 78% of the PRKCSH mutations and 57% of the mutations found in SEC63 (Fig-
ure 4.2b and e). Truncating mutations were defined as deletions, insertions, splice site 
mutations and nonsense mutations that cause a frameshift and/or early termination 
of protein translation.  
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F i g u r e   4 .2   Mutation analyses of PRKCSH-hepatocystin and SEC63-Sec63p.
a| Mutation location in PRKCSH. Notice the large number of mutations in exons 6 and 16. b| Types of mu-
tations found in hepatocystin. Missense mutations are found in a small fraction (22%, light blue). Truncating 
mutations (78%, dark blue) are predominant in hepatocystin and consist of deletions (15%, green), insertions 
(15%, yellow), nonsense mutations (22%, purple) and splice site mutations (26%, red). C| The location of 
the different mutations depicted on the schematic structure of hepatocystin. The structure consists of an 
N-terminal signaling sequence (yellow), low-density lipoprotein receptor domain (LDLa, orange), 2 putative 
calcium binding EF-hand domains (blue), a glutamic acid repeat (pink), a variable protein domain (green), a 
mannose-6-phosphate receptor domain (purple) and the C-terminal HDEL ER-retention signal sequence 
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(yellow). Mutations found in this study are highlighted with a red asterisk. d|  Mutation location in SEC63. 
The mutations are equally divided over the exons. e| Mutation types found in Sec63p. Missense mutations 
and in frame deletions are found in almost half of the cases (43%, light blue and orange). Truncating muta-
tions (57%, dark blue) consist of deletions (11%, green), insertions (5%, yellow), nonsense mutations (21%, 
purple) and splice site mutations (21%, red). F| The location of the different mutations depicted on the 
schematic structure of Sec63p. The integral ER-membrane protein contains three trans-membrane span-
ning domains (green tubes), a luminal DnaJ-like domain between trans-membrane segments 2 and 3 (red) 
and a large cytoplasmic domain with a negatively charged C-terminus (-). Mutations found in this study are 
highlighted with a red asterisk.
dIscussIon
Here, we describe 24 hitherto unreported mutations together with an extensive struc-
tural analysis of all 46 mutations described in PRKCSH and SEC63. We found that 
all splice site mutations and one nonsense mutation influenced splice site recognition. 
Furthermore, most missense mutations are located in conserved regions and have a 
severe impact on secondary or tertiary protein structure. Finally, PRKCSH harbors 
considerably more truncating mutations than SEC63 and contains two hotspots; ex-
ons 6 and 16.
Excluding family members of the probands, we found 60 mutations in a total of 281 
samples. This results in a mutation frequency of 21.3% (16% in PRKCSH and 5.3% 
in SEC63) indicating that a third locus is involved in PCLD pathogenesis. However, 
in PCLD research, estimation of mutation frequencies has some limitations. Firstly, 
the diagnostic criteria of PCLD are not unambiguous. In general the lower limit of 
20 liver cysts is used for PCLD diagnosis, but in this study we found an established 
mutation in two patients who had <20 liver cysts. In addition, in 2006 we have shown 
that even patients with as few as 8 liver cysts have mutations in PRKCSH and SEC63 
12. Secondly, because the disease is often asymptomatic or non-penetrant, family his-
tory is frequently negative. This might explain the large number of singleton cases in 
our cohort. In our study, we found the PRKCSH mutations c.292+1G>C and c.1341-
2A>G in respectively 8 and 10 unrelated singleton cases. However, Drenth and col-
leagues have previously shown that both mutations occur in the Netherlands due 
to a founder effect 6. Therefore, when calculating mutation frequencies haplotype 
analyses should always be used to exclude family ties and founder effects. Thirdly, 
we see numerous patients with a large polycystic liver in combination with a few or 
multiple kidney cysts, but without renal failure. These patients are excluded from 
muation frequency studies. However, an overlapping phenotype between ADPKD 
and PLCD is not inconceivable. 
All missense mutations were found in less than 1% of the studied population (>1000 
alleles). Cotton and coworkers stated that a mutation that occurs in less than 1% of 
the population is by definition rare and probably pathogenic 19. In contrast, neutral 
variants are likely to escape negative evolutionary selection and are thus more preva-
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lent. In concordance, even though some of the new mutations described here showed 
a low level of conservation or lacked a severe difference in amino acid characteristics, 
they are expected to be disease-causing mutations. As it is unclear how mutations in 
hepatocystin and Sec63p lead to cystogenesis in PCLD, the identification of impor-
tant protein domains by mutational analysis might reveal the mechanism of molecu-
lar functions, protein-protein interactions or protein-glycan interactions.
We identified one patient who was transheterozygous for the common PRKCSH 
c.1341-2A>G mutation and the novel SEC63 c.359T>C (p.I120T) mutation. To our 
knowledge, this is the only patient described with mutations in both PCLD genes. 
Unfortunately, family information was not available and we could not investigate 
whether the SEC63 c.359T>C mutation alone can result in PCLD. However, the 
mutation was very rare, located in the highly conserved DnaJ domain of the protein 
and both PolyPhen and secondary structure analysis showed effects on the protein 
structure. Therefore, we feel it is valid to conclude that this mutation is indeed patho-
genic.
The in-frame deletion of glutamic acid (p.E568del) in SEC63 was identified in four 
unrelated female patients. Interestingly, even though analyses showed that the mu-
tation is very deleterious, we found a marked variation in disease phenotype in our 
patients. Two of the patients displayed a severe phenotype, with more than 20 liver 
cysts and massive hepatomegaly at the age of 39 and 43 (liver volumes of 6.3 liters). 
However, the other two patients presented with a few small cysts on radiological 
studies at ages 63 and 82 (two cysts of 2.5 cm and one cyst of 3 cm respectively). This 
indicates that the penetrance of the disease is indeed less than 100%. On the other 
hand, these results can also indicate that other genetic or environmental factors play 
a role in disease initiation.
Further, we found 6 missense mutations located at CpG dinucleotides, three of which 
were C>T transitions. Cytosine to thymidine mutations are most common at CpG is-
lands, as a methylated cytosine is receptive to spontaneous deamination resulting in a 
thymidine 29. Recently, it was described that not only promoter methylation regulates 
transcription of a gene, but intragenic methylation also has influence 30, 31. Therefore, 
disruption or creation of CpG dinucleotides by mutations may alter the transcription 
regulation of a gene. 
Finally, we found relatively high mutation rates in exons 6 and 16 of PRKCSH. Even 
though these exons comprise 13.7% of the coding sequence, we found 41% of the dif-
ferent mutations in these two exons. An explanation for these hotspots in PRKCSH 
is not apparent. We did not find large repetitive sequences that might hamper DNA 
replication facilitating the introduction of mutations. Also, it is remarkable that exon 
6 harbors many different types of mutations (Figure 4.2). An explanation might be 
that the secondary structure of this region is predicted to be a helix, on which small 
structural changes have a severe effect.
Notwithstanding, we would not advise just to screen exons 6 and 16 for PCLD diag-
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nosis. In the Netherlands, the c.292+1G>C is a common mutation due to a founder 
effect 32. This mutation is located at the splice site of exon 4, which would exclude it 
from a hotspot analysis. The other common splice site mutation in the Netherlands, 
c.1341-2A>G, would be detected, as this mutation is located at the splice site of 
exon 16. Therefore, family history and migration patterns are a valuable tool for fast 
identification of mutations in PCLD. In cases where family history is absent or no 
mutations are previously described, we recommend to screen the patient with direct 
sequencing. Although this method is time consuming, it is highly sensitive and has 
a low false negative result rate. 
In conclusion, 46 mutations have now been identified to be involved in PCLD patho-
genesis, and their effect on protein structure was evident. Still 78% of the patients 
screened did not show a mutation in either PRKCSH or SEC63 indicating involve-
ment of at least one more locus. 
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Su p p l e m e n ta ry  ta b l e   t4.1   Ensembl peptide IDs of orthologues aligned with 
hepatocystin and Sec63p.
Species
Hepatocystin Sec63p
Ensembl peptide ID Ensembl peptide ID
Homo sapiens ENSP00000252455 ENSP00000357998
Pan troglodytes ENSPTRP00000017915 ENSPTRP00000031547
Pongo pygmaeus ENSPPYP00000010745 ENSPPYP00000018910
Macaca mulatta ENSMMUP00000003116 ENSMMUP00000033296 
Otolemur garnettii ENSOGAP00000014318
Bos taurus ENSBTAP00000010787 ENSBTAP00000022030
Equus caballus ENSECAP00000021407 ENSECAP00000005298
Canis familiaris ENSCAFP00000025632 ENSCAFP00000005595
Felis cattus ENSFCAP00000004549
Mus musculus ENSMUSP00000110987 ENSMUSP00000019937
Rattus norvegicus ENSRNOP00000018009 ENSRNOP00000000345
Monodelphis domestica ENSMODP00000008236 ENSMODP00000022461 
Ornithorhynchus anatinus ENSOANP00000028282
Gallus gallus ENSGALP00000024664
Myotis lucifugus ENSMLUP00000014869
Danio rerio ENSDARP00000025069 ENSDARP00000006629
Gasterosteus aculeatus ENSGACP00000018269 ENSGACP00000014702
Tetraodon nigroviridis GSTENP00034392001 GSTENP00030258001
Takifugu rubripes ENSTRUP00000026365 ENSTRUP00000040694
Oryzias latipes ENSORLP00000006799 ENSORLP00000020823
Xenopus tropicalis ENSXETP00000036514
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Su p p l e m e n ta ry  ta b l e   t4.2   SSPNN Splice site scores for the splice site muta-
tions.
Gene Position Nucleotide change Original splice site score
Mutated splice 
site score
PRKCSH
IVS 2 c.76-79+4dup8 0.95 0.97*
IVS 4 c.292+1G>C 0.99 Not recognized
Exon 7 c.487C>T 0.45 Not recognized
IVS 8 c.598-4delGCAG 0.80 Not recognized
IVS 9 c.762+2T>C 0.92 Not recognized
IVS 15 c.1341-2A>G 0.66 Not recognized
IVS 15 c.1341-1G>A 0.66 Not recognized
IVS 16 c.1440+1delGT 0.97 Not recognized
SEC63
IVS 1 c.125-2A>G 0.98 Not recognized
IVS 8 c.733+1G>A 0.98 Not recognized
IVS 8 c.733+1G>T 0.98 Not recognized
IVS 11 c.1053_1054+4delAGgtga 0.98 Not recognized
*Mutated splice site is preferred over the original splice site; reported in 12. Mutations identified in this study 
are depicted in bold face.
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Su p p l e m e n ta ry  F i g u r e   F4.1   Secondary structure prediction of hepatocystin.
Helices are depicted as green tubes, strands are yellow arrows and coiled domains are presented by a black 
line. 
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speCtrum of prKCsh and seC63 mutations
Su p p l e m e n ta ry  F i g u r e   F4.2   Secondary structure prediction of Sec63p.
Helices are depicted as green tubes, strands are yellow arrows and coiled domains are presented by a black 
line. 
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We evaluated tumor marker CA19-9 measurement in polycystic liver patients af-
ter observing high CA19-9 cyst fluid levels in a benign polycystic liver case. We 
determined CA19-9 levels in serum (n=120) and hepatic cyst fluid (n=81), from 
patients with polycystic livers (n=109) and simple hepatic cysts (n=24). Further, 
we analyzed CA19-9 expression in normal and polycystic liver tissue (n=17). Cyst 
fluid CA19-9 levels from both polycystic livers and simple hepatic cysts were 
extremely elevated (median 91,000 U/mL, range 14-15,870,000 U/mL; median 
85,000 U/mL, range 332-1,744,000 U/mL respectively). Serum CA19-9 levels 
were significantly higher in polycystic liver patients (median 30 U/mL, range 
0-1200 U/mL) compared to patients with simple hepatic cysts (median 10 U/mL, 
range 3-200 U/mL, P=0.0011). Serum CA19-9 levels correlated with those in cyst 
fluid (r=0.3979, P=0.0399), polycystic liver volume (r=0.3870, P=0.0025) and the 
size of the largest cyst (simple cysts group; r=0.5319, P=0.0280). Cyst epithelia 
showed strong CA19-9 expression. Evacuation of cyst fluid resulted in dramatic 
decrease of serum CA19-9 levels (60-95%). In conclusion, CA19-9 is elevated in 
cyst fluid and serum of polycystic liver disease patients due to production and 
secretion by cyst epithelia. It does not reflect malignancy in these patients and 
may be of value as a biomarker for intervention efficiency assessment.
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IntroductIon
Carbohydrate antigen 19-9 (CA19-9) is a tumor-associated antigen originally isolated 
from a human colorectal cancer cell line. The assays for CA19-9 use the monoclo-
nal antibody 1116NS-19-9, which interacts with the sialyl Lewis-a structure lacto-N-
fucopentaose II. This carbohydrate epitope can be linked to glycoproteins as well as 
glycolipids. In serum and bile, it associates with mucin 1. 
Elevated serum levels of CA19-9 can be detected in many patients with colorectal, 
gastric, biliary tract, and pancreatic carcinoma 2. In fact, CA19-9 is used as a tumor 
marker, as it correlates with tumor progression and prognosis of various types of 
gastrointestinal cancers 3-5. Clinically, CA19-9 is used to differentiate benign gas-
trointestinal disorders from pancreatic, colorectal, gastric and hepatic carcinomas, 
and a serum level of at least 37 U/mL is often considered to indicate the presence of 
malignancy. On the other hand, markedly elevated CA 19-9 levels can also be seen in 
benign disease, especially in patients with extrahepatic biliary obstruction 6-8. This is 
probably due to damage of the bile duct epithelium, as CA19-9 is synthesized in the 
epithelia of bile ductules and interlobular bile ducts 9.
Liver cysts result from progressive dilation of the abnormal ducts in biliary hamar-
tomas or as part of a ductal plate malformation at the level of the small intrahepatic 
bile ducts 10, 11. These small bile ducts have lost continuity with the remaining biliary 
tree. As such, liver cysts can be regarded as a disorder of the biliary epithelium. 
Isolated liver cysts are common in the population, but polycystic livers are rare 12, 13. 
Polycystic liver disease occurs secondary to autosomal dominant polycystic kidney 
disease (ADPKD) or results from isolated autosomal dominant polycystic liver dis-
ease (PCLD) 14-16.
Recently, we observed very high levels of CA19-9 in aspirated cyst fluid obtained 
from a single ADPKD case. In order to further investigate this finding, we system-
atically evaluated the role of CA19-9 in serum, cyst fluid and cyst tissue in a cohort 
of patients with simple hepatic cysts and polycystic liver disease.
materIals and methods
Patients and samples
Patients with either polycystic livers or simple hepatic cysts from the Radboud Uni-
versity Nijmegen Medical Center and University Hospital Leuven were eligible for 
inclusion in our analysis. We selected patients for whom biological specimen (serum 
or cyst fluid) was available.
Cyst fluid was obtained between 2002 and 2008 by percutaneous cyst aspiration 
or laparoscopic cyst fenestration. Samples were stored in aliquots at –20 °C until 
analysis. PCLD liver tissue samples (n=10) were collected during laparoscopic cyst 
fenestration procedures, fixed in buffered formalin and embedded in paraffin 17. 
Non-pathological liver samples for control purposes were collected from 7 autopsy 
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livers following the guidelines for adequate use of secondary tissue (Version 2002, 
Federation of Medical Scientific Societies, www.fmwv.nl).
We divided the patients into 2 groups. The polycystic liver group consists of patients 
with ≥ 20 liver cysts. The second group contains patients with less than 5 liver cysts 
on radiological studies and who did not fulfill the Ravine criteria for ADPKD 18. We 
have defined this group as simple hepatic cysts. None of the patients had a previous 
diagnosis of carcinoma with the exception of a single patient, who had a history of 
basal cell carcinoma of the skin.
Assays
CA19-9 levels were determined in serum and cyst fluid using an automated immu-
nochemical analyzer. The upper level of normal was defined as 37 U/mL. Serum 
bilirubin, γ-glutamyl transferase (γGT), alkaline phosphatase (AP), alanine amin-
otransferase (ALAT) and aspartate aminotransferase (ASAT) were measured using 
standard automated techniques. The laboratory reference values were used for the 
purpose of this study.
Liver volume
Liver volumes of polycystic livers were determined from CT-scan using Pinnacle3 
(version 8.0d, Philips, Eindhoven, The Netherlands) according to previously pub-
lished methods 17. Briefly, the liver margins were outlined on CT-scan every 9 mm 
and the software interpolated and calculated the volume within the margins. The 
diameter of the largest cyst in patients with simple hepatic cysts was assessed from 
abdominal ultrasonography or abdominal computer tomography.
Immunohistochemistry
We analyzed CA19-9 expression in tissue using immunohistochemistry according to 
previously published methods 19. Briefly, paraffin sections (4 µm) were pre-incubated 
with hydrogen peroxide (3%) and antigen retrieval was performed by 10 min micro-
wave exposure in 10 mM citrate buffer. After a 90 min cool down, avidin and biotin 
were blocked (Vector Laboratories Inc., Burlingame, CA, USA). Subsequently, slides 
were pre-incubated with 20% normal horse serum (10 min) and incubated overnight 
with primary antibody against CA19-9 (clone 1116NS-19-9, Covance, Princeton NJ, 
USA). Finally, incubation with biotinylated horse-anti-mouse secondary antibody 
and avidin-biotin-peroxidase complex (Vector Laboratories Inc, Burlingame, CA, 
USA) was followed by visualization with 3,3’-diaminobenzidene and counterstaining 
with hematoxylin. Negative controls were constructed by omitting the primary anti-
body. Staining results were classified according to a scale from negative (-) to weakly 
positive (+/-), positive (+) and strongly positive (++).
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Statistical Analyses
Differences between general characteristics of the polycystic liver and simple hepatic 
cyst groups were analyzed using student t-test and Fisher’s exact test. Between-group 
comparisons to compare CA19-9 levels were analyzed using two-sided Mann–Whit-
ney U test. We used Spearman’s rank correlation for analysis of the relation between 
CA19-9 serum and fluid levels and both total liver volume and the volume of the 
largest cyst. All statistical analyses were performed using GraphPad Prism 4 (Ver-
sion 4.02, GraphPad Software Inc., San Diego, CA, USA). A P-value of ≤ 0.05 was 
considered significant.  
results
General characteristics
We entered a total of 133 patients in our study. The cohort was then divided into two 
groups (Table 5.1). The polycystic liver group comprised 109 patients (95 females, 
14 males), with a polycystic liver associated with either ADPKD (n=61) or PCLD 
(n=48). The simple hepatic cysts group consisted of 24 patients (16 females, 8 males). 
Patients with simple hepatic cysts were older than polycystic liver patients (mean 
age 64 and 53 years respectively, P<0.0001). In addition, the polycystic liver group 
contained more female patients (P=0.0289), in line with the notion that females with 
ADPKD or PCLD have more extensive polycystic liver disease compared to males 
10, 20.
ta b l e   5 .1   General characteristics of the study population.
Polycystic liver Simple hepatic cysts
Patients, n 109 24
Age, mean (SD) 53 (± 11.5) 64 (± 14.9)*
Gender, female/male 95/14 16/8**
Liver parameters, n elevated / n normal
γGT 37/18 3/4
AP 9/45 0/7
ALAT 4/50 0/7
ASAT 3/52 0/7
Total Bilirubin 24/29 0/7
*Tested with t-test P<0.0001, ** tested with Fisher’s exact test P=0.0289. Serum liver parameters did not 
differ significantly between groups. Note that laboratory tests were not performed in all patients.
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CA19-9 is severely elevated in cyst fluid
We analyzed a total of 81 cyst fluid samples; 68 samples from the polycystic liver 
group (31 patients) and 13 samples from the simple hepatic cyst group (12 patients). 
The mean number of cyst samples per patient was 1 (range 1-7). We then compared 
CA19-9 levels in cyst fluid from polycystic livers with cyst fluid from simple hepatic 
cysts and found that CA19-9 was grossly elevated in cyst fluid from both groups: 
median CA19-9 level in polycystic liver cyst samples was 91,000 U/mL (range 14-
15,870,000 U/mL) compared to 85,000 U/mL (range 332-1,744,000 U/mL) in simple 
hepatic cysts (P=0.8369, Figure 5.1a). There was no difference of CA19-9 cyst fluid 
levels between ADPKD and PCLD.
F i g u r e   5 .1   Box and whisker plot displaying CA19-9 levels in cyst fluid (a) and serum 
(b) from polycystic livers compared to simple hepatic cysts.
The box shows the range between the 25th and 75th percentiles with a horizontal line at the median value. 
The whiskers extend from the edge of the box to the 5th and 95th percentile of the data. Colored back-
ground represents the reference value for CA19-9 (37 U/mL). Serum CA19-9 levels differed significantly 
between polycystic liver patients and simple hepatic cysts patients (*P=0.0011).  
CA19-9 in serum
Next, we determined serum CA19-9 levels in 120 patients (105 polycystic liver pa-
tients and 19 simple hepatic cyst patients) (Table 5.2, Figure 5.1b). Although serum 
CA19-9 levels were not of the magnitude of the cyst fluid levels, serum CA19-9 was 
elevated above reference level in 45% of the polycystic liver patients and in 11% of 
the simple hepatic cyst patients (P=0.0048, Figure 5.1b). Serum levels were higher 
in polycystic liver patients (median 30 U/mL, range 0-1200 U/mL) compared to 
patients with simple hepatic cysts (median 10 U/mL, range 3-200 U/mL, P=0.0011) 
(Figure 5.1b). Again, we found no significant differences between ADPKD and 
PCLD serum levels. Elevated serum CA19-9 was not influenced by age, gender, or 
elevated liver test parameters (Table 5.2).
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ta b l e   5 .2   General characteristics of serum samples analyzed.
CA19-9 ≤ 37 U/mL CA19-9 > 37 U/mL
Patients, n 73 47
Age, mean (SD) 56 (± 12.8) 53 (± 11.8)
Gender, female/male 59/14 41/6
Liver parameters, n elevated / n normal
γGT 20/10 16/7
AP 3/26 4/19
ALAT 0/29 3/20
ASAT 0/30 2/21
Total Bilirubin 11/18 9/14
Values and serum liver parameters did not differ among groups (tested with t-test and Fisher’s exact test). 
Note that laboratory tests were not performed in all patients.
Correlations
We hypothesized that high serum CA19-9 levels are the result of CA19-9 leakage 
from the cysts into the circulation. As a consequence, a larger number of cysts, or 
larger size of cysts would contribute to high serum CA19-9 levels. We therefore cal-
culated whether there was a correlation between serum and fluid CA19-9 levels and 
analyzed paired serum and fluid levels. Serum and cyst fluid CA19-9 levels correlated 
well in the entire group (r = 0.3979, P=0.0399) and in the polycystic liver group (r 
=0.5310, P=0.0160), but not in the simple hepatic cyst group (r =0.0714, P=0.9063) 
(Figure 5.2a and b). The latter result can be attributed to a type II error as this group 
contained only 7 paired serum and fluid values. Next, we determined the correlation 
between serum CA19-9 levels and liver volume in polycystic liver patients. There 
was significant correlation (r =0.3870, P=0.0025) (Figure 5.2c). Finally, we found a 
significant correlation between serum CA19-9 levels and the size of the largest cyst 
in simple hepatic cyst patients (r =0.5319, P=0.0280) (Figure 5.2d).
Immunohistochemistry
To confirm that CA19-9 is produced in the cysts, we analyzed CA19-9 expression in 
cyst epithelia of polycystic livers. We immunohistochemically stained CA19-9 in 10 
polycystic liver and 7 control liver specimen. We found that all bile ducts in control 
liver were positive for CA19-9 expression (+). Polycystic liver cyst epithelia showed 
variable staining intensities, but most were strongly positive (++) for CA19-9 expres-
sion (Figure 5.3). This corroborates with the notion that CA19-9 is locally produced 
and released.
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F i g u r e   5 .2   Correlations of serum CA19-9 levels.
a-b| Serum CA19-9 shows a good correlation with fluid CA19-9 levels in polycystic liver patients (a, 
r=0.5310, P=0.0160), but not in simple hepatic cyst patients (b, r=0.0714, P=0.9063). Only paired serum 
and fluid samples were used. C-d| In polycystic liver patients, serum CA19-9 correlated with liver volume 
(C, r=0.3870, P=0.0025), and serum CA19-9 correlated with the size of the largest cyst in simple hepatic 
cyst patients (d, r=0.5319, P=0.0280).
F i g u r e   5 .3   Immunohistochemical analysis of CA19-9 expression in normal and poly-
cystic liver.
CA19-9 is highly expressed in bile ducts in normal liver (a) and in non-neoplastic cyst epithelia (b) indicated 
by arrowheads. Scale bars correspond to 100 µm.
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Follow-up
The findings that serum CA19-9 levels are associated with cyst fluid CA19-9 levels 
and that CA19-9 is produced in the cyst epithelia, lead to the hypothesis that serum 
CA19-9 levels drop when the source (cyst epithelia and fluid) is removed. Our study 
population contained 4 patients for whom post treatment CA19-9 serum levels were 
available. Two patients underwent a fenestration procedure, one patient had a liver 
transplant, and one patient suffered from a spontaneous cyst rupture followed by 
drainage. Serum CA19-9 in the latter patient decreased from 335 U/mL to 18 U/
mL (95%) in the course of 1 month. Serum CA19-9 levels of the other 3 patients de-
creased from 68 to18 U/mL (74%), 96 to 38 U/mL (60%), and 32 to 15 U/mL (53%). 
This reflects an average decrease of 71% (range 60-95%), and CA19-9 normalized 
(<37 U/mL) in 3 out of 4 patients.
dIscussIon
In this study, we demonstrated that CA19-9 levels are elevated in hepatic cyst fluid as 
well as in serum of patients with benign liver cysts. Serum CA19-9 was significantly 
elevated in patients with a larger polycystic liver or with larger simple hepatic cysts. 
Furthermore, immunohistochemistry showed high CA19-9 expression in epithelial 
cyst lining. As a consequence, elevation of serum CA19-9 levels in patients with liver 
cysts is probably due to production and secretion of this compound by local cyst 
epithelia and leakage into the circulation.
An elevated serum CA19-9 level does not always imply malignant disease, but may 
point to a benign cause. Some examples of benign gastrointestinal causes of CA19-9 
elevation include acute liver failure, chronic hepatitis, chronic liver disease, alcoholic 
and non-alcoholic liver disease, and acute and chronic pancreatitis 7, 8. Even heavy 
tea consumption can lead to elevated serum CA19-9 levels 21. The cause for CA19-9 
elevation in benign gastrointestinal disease is most often due to cholestasis. In those 
cases, there is a strong correlation between serum CA19-9 levels and standard pa-
rameters of cholestasis; alkaline phosphatase and bilirubin. In the present study, we 
did not find such a correlation. This is consistent with our suggestion that high 
serum CA19-9 level is derived from liver cyst epithelium and not from biliary epithe-
lium of the large bile ducts.
Bile duct epithelium secretes CA19-9 into bile. In case of obstruction and elevated 
pressure in biliary ducts, clearance of CA19-9 from biliary ducts might be stalled. 
Moreover, junctional complexes of biliary epithelia might be destroyed due to high 
pressure. Several studies are consistent with this hypothesis, as in ADPKD both 
adherens junctions and desmosomes are disrupted 22-24. In addition, we previously 
found that PCLD cyst epithelia show loss of several cell adhesion molecules, among 
which E-cadherin, a central component of adherens junctions 25. Thus, in polycystic 
livers CA19-9 may leak into lymphatic or capillary vessels through the lateral mem-
Chapter 5
 70 
branes of the cyst epithelium. This was supported in our study by the significant 
correlation between serum and cyst fluid CA19-9 levels.
Another cause for high serum CA19-9 levels may be inflammation. It has been sug-
gested that inflammation contributes to CA19-9 secretion in epithelial cells 26. How-
ever, we have analyzed polycystic fluid contents and failed to detect acute phase 
parameters 27. Thus, it is unlikely that inflammation is responsible for the excessive 
CA19-9 release in liver cyst fluid.
Several arguments suggest that CA19-9 can serve as a biomarker to monitor for poly-
cystic liver disease. First, it correlates well with the severity of the disease, as patients 
with polycystic liver disease have higher serum values compared to simple hepatic 
cyst patients. Furthermore, serum CA19-9 levels appear to be dependent on cyst 
fluid CA19-9 levels and on the size and volume of the cysts. Finally, we found that 
serum CA19-9 levels decrease dramatically (up to 95%) after treatment of hepatic 
cysts. Therefore, CA19-9 serum levels might be useful to assess the effect of medical 
intervention trials in the future.
The use of CA19-9 as a biomarker has at least two disadvantages. Some patients will 
not have increased CA19-9 serum levels despite the presence of a bonafide cause 
for elevation. These Lewis blood group negative (Lea-b-) individuals lack α1-4 fuco-
syltransferase (Lewis locus) and are unable to synthesize Lewis a (Lea) antigen (re-
viewed in 28). Biosynthesis of CA19-9, or sialyl Lewis-a epitope, depends on the abil-
ity to form Lea. As a consequence, CA19-9 levels in Lea-b- individuals are extremely 
low. On the other hand, only a small proportion of the Caucasian population (6%) 
harbors the Lea-b- genotype. Further, we noted that the variability of Ca19-9 levels in 
polycystic patients is very large, and that a substantial proportion (55%) of patients 
will have normal CA19-9 levels.
In conclusion: CA19-9 is elevated in cyst fluid and serum of patients with benign 
polycystic liver disease. This is probably due to production and secretion by local 
cyst epithelia. It does not reflect malignant degeneration of polycystic liver disease. 
CA19-9 might be of value as a novel biomarker to monitor disease progression and 
treatment efficiency. 
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Autosomal dominant polycystic liver disease (PCLD) is characterized by multiple 
liver cysts and is caused by mutations in PRKCSH (hepatocystin). Mechanisms 
of cystogenesis are unknown, but previous studies have shown that hepatocystin 
is secreted in vitro. The goal of this study was to determine the fate of hepatocys-
tin in vivo. Using immunoprecipitation, we determined that mutant hepatocys-
tin is secreted from both the apical and basolateral cell surface of MDCK cells 
stably transfected with mutant hepatocystin. Analysis of 60 cyst fluid samples 
from polycystic livers using Western blot, MALDI-TOF MS or nLC-MS/MS did 
not detect hepatocystin in liver cyst fluid. We did identify 163 ubiquitous serum 
proteins. No paracrine or autocrine factors were recognized. Although cyst flu-
ids vary greatly in protein concentration, a PCLD specific protein pattern was 
not established. In conclusion, hepatocystin is not secreted in PCLD liver cyst 
fluid suggesting that mutant hepatocystin is either not produced or degraded 
intracellularly. PCLD cysts develop from the intralobular bile ductules, and cyst 
fluid mainly contains common serum proteins comparable to that of other poly-
cystic diseases.
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IntroductIon
Polycystic liver disease (PCLD) is an autosomal dominant inherited condition char-
acterized by numerous fluid filled cysts in the liver, without renal involvement 1. The 
main differential diagnosis is autosomal dominant polycystic kidney disease (AD-
PKD). Here, the predominant feature is the presence of polycystic kidneys, though 
up to 80% of the patients develop hepatic cysts as the primary extrarenal manifesta-
tion 2. 
PCLD is associated with mutations in PRKCSH 3, 4. This gene encodes hepatocys-
tin, a protein that is involved in the folding of glycoproteins in the endoplasmic 
reticulum. It serves as the non-catalytic β-subunit of glucosidase IIα, an enzyme 
that cleaves the two innermost glucoses from the mannose tree of glycoproteins 5. 
This releases the glycoprotein from calnexin/calreticulin and makes it available for 
translocation to the Golgi. This mechanism represents the quality control for correct 
folding of glycoproteins in the ER (reviewed in 6).
Most hepatocystin mutations associated with PCLD lead to premature termination 
of translation producing a truncated protein. Transfection studies in HeLa cells have 
shown that mutant, but not wild-type PRKCSH, results in a protein that does not 
assemble with the α-subunit, loses retainment in the ER and is secreted into the me-
dium 7. It is unclear whether these in vitro findings reflect the situation in PCLD, and 
whether hepatocystin is secreted in vivo.
Recent developments in mass spectrometry technologies have enabled analysis of 
differential proteomics, such as the comparison between normal and disease status. 
This allows identification of protein markers that may serve to identify a specific 
physiological or pathological state. We used single-dimension SDS-PAGE for pro-
tein separation in combination with high-throughput techniques for protein identifi-
cation in liver cyst fluids. We performed proteomic analysis on a platform of matrix-
assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF 
MS) and nano scale liquid chromatography tandem mass spectrometry (nLC-MS/
MS). 
This study was designed with the main aim to determine whether hepatocystin is 
secreted in cyst fluid in vivo. We hypothesized that similar to in vitro experiments, 
(mutant) hepatocystin is secreted into hepatic cysts of patients carrying a mutant 
PRKCSH allele. Second, we set out to identify substantially abundant proteins in cyst 
fluid from PCLD patients in order to obtain a unique protein signature. In addition, 
we hoped to identify autocrine and parcrine factors that stimulate cyst formation 
and growth. The results may help to clarify the mechanism that drives the hepatic 
cystogenesis and may aid in the identification of biomarkers for the disease.
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materIals and methods
Development of cell lines 
Madin-Darby canine kidney (MDCK) cells were cultured in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, penicillin 100 
U/mL and streptomycin 100 U/mL. We transfected the cells with eukaryote ex-
pression vectors containing wild-type and mutated PRKCSH 7 using Fugene reagent 
(Roche, Indianapolis, IN, USA). Transfected clones expressing the introduced genes 
were selected using G418 resistance. Stably transfected MDCK cells were grown on 
an Anopore filter with a pore size of 0.02 µm (Nalge Nunc International, Rochester, 
NY, USA). Medium was collected on the apical and basolateral side of the membrane 
after 3, 6, 9, and 12 hours and subsequently used for immunoprecipitation experi-
ments.
Immunoprecipitation
Aliquots with equal protein concentration were precipitated with 30 µL of anti-HA 
monoclonal antibody (clone HA.11, Covance, Richmond, CA, USA) bound to pro-
tein G/agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 16 h at 
4°C. Next, samples were centrifuged (3 min, 2000×g, 4°C), washed twice with 1 mL 
lysis buffer containing 0.1% Triton X-100 and subsequently washed once with 0.5 
mL of PBS. Samples were then analyzed on Western blot using anti-HA antibody. 
Western blot 
Proteins resolved by SDS-PAGE were transferred onto a Protran nitrocellulose mem-
brane (Whatman Inc., Florham Park, NJ, USA). Membranes were blocked with 5% 
low-fat milk and incubated overnight with primary antibodies, directed against He-
magglutinin (HA)-tag (clone HA.11, Covance, Richmond, CA, USA) or hepatocystin 
(BD Transduction Laboratories, San Jose, CA, USA), followed by incubation with 
appropriate secondary antibodies labeled with horseradish peroxidase (HRP). Sec-
ondary antibodies were visualized using ECL Western blotting detection reagents 
(GE Healthcare Limited, Buckinghamshire, UK) and Hyperfilm MP (Amersham 
Biosciences UK Ltd., Buckinghamshire, UK).  
Patients and samples 
PCLD was diagnosed when (1) more than 20 liver cysts were seen on abdominal 
computer tomography and the formal ultrasonographic criteria for ADPKD were 
not applicable 8 or (2) mutations were found in PRKCSH. We collected 60 cyst fluid 
samples from 25 patients who underwent percutaneous cyst aspiration or laparo-
scopic cyst fenestration. The patient group consisted of 16 PCLD patients (50 sam-
ples, all female), 3 ADPKD patients (3 samples, 2 female/1 male) and 6 patients with 
isolated liver cysts who did not meet the PCLD or ADPKD criteria (7 samples, 4 
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female/2 male). Samples were frozen in aliquots to prevent recurrent thawing and 
stored at –20°C. 
Genotyping 
Patients included in this study were screened for PCLD mutations by extracting ge-
nomic DNA from peripheral blood leukocytes (Gentra Systems, Minneapolis, USA) 
and genotyping for PRKCSH as described earlier 9. From the 16 PCLD patients, 7 
patients showed a mutation in PRKCSH. The patients with isolated liver cysts were 
all wild-type for PRKCSH.
Routine chemistry
Total protein concentration and albumin concentration was determined in all flu-
ids using an Aeroset 2.0 automated analyzer (Abbott Laboratories, Abbott Park, IL, 
USA).
Protein profiling
All cyst fluid samples were subjected to SDS-PAGE analysis. The samples were 
albumin-depleted and subsequently concentrated to prevent disruption of experi-
ments by high albumin concentrations. Albumin was removed from cyst fluids us-
ing ProteoExtract Albumin removal kit (Calbiochem, Darmstadt, Germany) and the 
samples were concentrated using YM3 Microcon centrifugal filter devices (Millipore, 
Billerica, MA, USA) according to manufacturer’s instructions. After separation on a 
12% polyacrylamide gel electrophoresis, samples were either processed for Western 
blot analysis or proteins were in-gel digested with trypsin followed by matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for 
identification of proteins. 
In-gel trypsin digestion 
SDS-PAGE gels were fixed in 12% TCA, stained with Coomassie Brilliant Blue 
G250 and destained in 20% methanol-7% acetic acid. Gels were then carefully sealed 
in 23% ammonium sulfate and stored at 4°C until further use. Each of the pro-
tein bands visible on SDS-PAGE gels was analyzed in 10 different samples. Spots 
of interest were cut from the gels (approximately 1.5 mm3) using a scalpel or a pi-
pet. Gel pieces were washed with 25 mM ammonium bicarbonate and dehydrat-
ed with increasing concentrations of acetonitrile. Next, gel pieces were rehydrated 
on ice with ~15 ng/µL Trypsin Gold (Promega, Madison, WI, USA) in 25 mM 
ammoniumbicarbonate/5 mM n-octyl-β-D-glucopyranoside. Excess trypsin solu-
tion was removed, pieces were covered with 25 mM ammoniumbicarbonate/5 mM 
n-octyl-β-D-glucopyranoside and incubated overnight at 37°C. Peptides were ex-
tracted using 50% acetonitrile/0.5% trifluoroacetic acid (TFA)/5 mM n-octyl-β-D-
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glucopyranoside. After 1 h incubation and 2 min sonification the liquid was trans-
ferred to a new tube, and extracts were dried using a vacuum centrifuge.
MALDI-TOF MS 
Samples were dissolved in 0.1% TFA, spotted on an MTP ground steel plate, cov-
ered with a matrix solution containing 20 mg/ml 4-hydroxy-a-cyanocinnamic acid 
in 50% acetonitrile/ 0.05% TFA, and allowed to air-dry. Series of eight samples were 
spotted around one external calibration mixture. This calibration mix contained 1.26 
mM bradikinin, 1.26 mM P14R, 0.19 mM angiotensin and 0.95 mM ACTH in ma-
trix solution. After protein spotting, the sample plate was transferred into the mass 
spectrometer (Bruker Biflex III MALDI-TOF MS, Bruker Daltonics Inc., Billerica, 
MA, USA) and spectra were obtained in the reflectron mode. All relevant peaks 
seen on the MALDI-TOF MS spectrum were manually annotated as their monoiso-
topic peptide peaks and the respective m/z values were stored in a peak search list 
using the X-TOF program (Version 5.1.0, Bruker Daltonics, Billerica, MA, USA). 
The search list representing the protein peptide mass fingerprint was compared to 
the Swiss-Prot database (version 20040730) using BioTools (Version 2.01, Bruker 
Daltonics, Billerica, MA, USA) and the MASCOT search algorithm (Version 1.6, 
Matrix Science Inc, Boston, MA, USA). Search parameters were set to look for pro-
teins from Homo sapiens only, with methionine oxidation as a possible modification 
and allowing 1 trypsin misscleavage. Protein identifications were assigned a Mowse 
score calculated by -10Log(P), were P is the probability that the observed match is 
a random event 10. A Mowse score greater than 53 with a protein mass tolerance ≤ 
0.2 Da was considered significant (p<0.05). Resulting hits were scrutinized based on 
their Mowse score, sequence coverage, and the similarity between theoretical and 
experimental molecular weight obtained from gel electrophoresis. Keratin identifi-
cations were excluded since they are likely to be contaminants in MALDI-TOF MS 
experiments 11.
nLC MS/MS
A pool of 5 cyst fluid samples from different patients was analyzed using nanoflow 
liquid chromatography linear ion trap Fourier transform-ion cyclotron resonance 
mass spectrometry (nLC-LIT FT-ICR MS). The proteins were separated on a 12% 
SDS-PAGE gel. The gel was divided into 5 pieces (front-23 kDa, 23-30 kDa, 30-50 
kDa, 50-70 kDa, 70 kDa-high end), which were subsequently in-gel-reduced with 10 
mM dithiotreitol, alkylated with 50 mM iodoacetamide and digested with trypsin. 
Prior to nLC-MS/MS analysis, samples were purified and desalted using Stage tips 
12. Peptides were analyzed using the nLC LTQ FTMS (Thermo Scientific, Waltham, 
MA, USA) equipment of the Nijmegen Proteomics Facility (NPF, www.proteomic-
snijmegen.nl) and RAW spectrum files were converted with the aid of DTAsuper-
 79 
hepatoCystin is not seCreted in pCld Cyst fluid
charge (http://msquant.sourceforge.net/) into a Mascot generic peak list. Peptides 
and proteins were identified using the Mascot search program (Version 2.1.03, Ma-
trix Science Inc, Boston, MA, USA) and the NCBInr database (version 20070212, 
www.ncbi.nlm.nih.gov) using Homo sapiens taxonomy. The search algorithm was set 
to perform a tryptic search allowing 2 miscleavages and searched for carbamidom-
ethyl modifications on cysteine residues and possible oxidation of methionine and 
deamidation of glutamine and asparagine, with a mass accuracy of 20 ppm for the 
ICR cell and 0.8 Da for the LIT of the instrument. False-discovery rates (FDR) were 
estimated by Mascot searches performed against the reversed protein database using 
the criteria mentioned above. To validate the protein hits resulting from Mascot, the 
files were reanalyzed using PROVALT 13. This automated program takes large MS 
data sets and reorganizes them by grouping together peptides according to their pre-
dicted matching protein. FDR calculations by PROVALT provide a reasonable bal-
ance between the number of correct and incorrect protein assignments. In this study, 
the FDR was set at 1%. PROVALT clusters proteins together in homologous groups. 
From each group, only the protein identified with the most peptides per protein was 
taken into account for further analyses. 
The annotation of protein cellular localization and biological function was per-
formed using gene ontology (GO) biological process and the GO cellular component 
terms 14. GO analysis was performed using ProteinCenter (Proxeon Biosystems A/S, 
Odense Denmark, www.proxeon.com). 
results 
Mutated hepatocystin is secreted by MDCK cells
To determine whether hepatocystin can be secreted in cyst fluid, we first analyzed on 
which side of the polarized epithelial cell hepatocystin is secreted. To this end, we 
stably transfected MDCK cells with epitope-tagged wild-type and mutant PRKCSH. 
Immunoprecipitation and Western blot analysis confirmed expression of full-length 
(wild-type) and truncated (mutant) hepatocystin by these cell lines (Figure 6.1a). Next, 
we cultured the cells on a membrane and analyzed medium on the apical and baso-
lateral side of the cells. We found that truncated hepatocystin is secreted into both 
the apical and basolateral medium. Secretion was both substantial and rapid, already 
detectable only 3 h after changing the medium. In contrast, full-length hepatocystin 
was retained in the cells. The presence of the HA-tag after 12 h probably represents 
loss through cell lysis. 
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F i g u r e   6 .1   Immunoblot analysis of hepatocystin secretion by MDCK cells.
a| HA-tagged wild-type (full-length) and mutant (truncated) hepatocystin is expressed in stably trans-
fected MDCK cells. Introduced hepatocystin was detected on immunoblot using anti-HA tag antibody. b| 
Mutated hepatocystin is secreted form the apical and the basolateral side of MDCK cells. Stably transfected 
MDCK cells were grown on an Anopore membrane. After 3, 6, 9 or 12 h, medium was collected from 
the apical and the basolateral side and immunoprecipitated using an antibody against HA-tag. Protein was 
visualized on immunoblot with an anti-HA-tag antibody. Notice that full-length (wild-type) hepatocystin 
is not secreted by the MDCK cells.
General chemistry of human cyst fluids
A total of 60 liver cyst fluids were included in this study (16 PCLD patients, 50 sam-
ples; 3 ADPKD patients, 3 samples; 6 patients with isolated liver cysts, 7 samples). 
We detected 7 heterozygous PRKCSH mutation carriers among 16 tested PCLD pa-
tients, while the remaining patients were wild-type for PRKCSH. Total protein and 
albumin concentrations were determined in all fluid samples. Both parameters were 
within the range of normal values in serum, but showed great variability. The mean 
total protein content of hepatic cysts was 25.2 g/L (range 0.2-84.4 g/L), while mean 
albumin value was 12.9 g/L (range 0-44g/L). There were large differences between 
patients, but also between individual cyst fluids obtained from the same patient. We 
observed no differences between PCLD, ADPKD and isolated liver cyst content. 
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Hepatocystin is absent in PCLD liver cyst fluid
To study the presence of hepatocystin in liver cyst fluid, we subjected 17 PCLD cyst 
fluid samples (6 PRKCSH wild-type, 11 PRKCSH mutants) to Western blot analysis 
followed by immunostaining for hepatocystin. We failed to detect mutant hepatocys-
tin in fluids from PRKCSH mutation carriers. Likewise, none of the cyst fluids dem-
onstrated wild-type hepatocystin staining, indicating the absence of hepatocystin in 
these samples (Figure 6.2). 
F i g u r e   6 .2   Western blot analysis of hepatocystin in cyst fluids.
A representative image is shown of four PCLD cyst fluids (numbered lanes) and a positive control (+). 
Albumin-depleted and concentrated samples were subjected to Western blot analysis followed by immu-
nostaining of hepatocystin. No hepatocystin was detected in the cyst fluids. We used cholangiocyte whole 
cell lysate for positive control. Molecular mass is indicated on the left (kDa).
MALDI-TOF MS analysis 
Next, we determined the protein profile of 60 cyst fluids (50 PCLD, 3 ADPKD and 
7 isolated liver cysts) by one-dimensional SDS-PAGE gel electrophoresis and pro-
tein staining with Coomassie Brilliant Blue (Figure 6.3). We compared the protein 
profiles with profiles from three healthy control sera. The cyst fluid profiles revealed 
highly similar images consistent with a serum-like pattern. We observed no staining 
pattern unique to fluids derived from either group. 
Electrophoresis of cyst fluids revealed 25 unique protein bands. To limit variation, we 
handpicked each band 10 times from the gels. Samples were subsequently analyzed 
using in-gel trypsin digestion and MALDI-TOF MS. We identified a total of 10 pro-
teins (Table 6.1). We detected transferrin and ferritin, both involved in iron transport, 
and apolipoprotein A-1 and transthyretin, which participate in cholesterol and thy-
roxine transport, respectively. Furthermore, we identified albumin, α-1-antitrypsin, 
and complement C3 in addition to fibronectin and fibrinogen. One sample contained 
hemoglobin indicating that the cyst had bled. All proteins identified are commonly 
present in serum. All identifications were confirmed with nLC-MS/MS analysis (see 
below), although α-1-antitrypsin was not a first hit in its protein group. Hepatocystin 
was not detected in our samples. 
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F i g u r e   6 .3   Protein profile of PCLD cyst fluid.
A representative image of six PCLD cyst fluids (numbered lanes) is shown. Cyst fluid samples were albu-
min-depleted and subsequently concentrated to prevent disruption by high albumin concentrations. After 
SDS PAGE electrophoresis, proteins were visualized using Coomassie Brilliant Blue. Notice highly similar 
and serum-like protein profiles for all patients. Molecular mass is indicated on the left (kDa).
ta b l e   6 .1   Overview of proteins identified by MALDI-TOF MS analysis.
Protein Swiss-Prot Accession No.
Average 
Mowse score
No. 
Hits
Peptides 
matched
Sequence 
coverage (%)
Fibronectin P02751 95 3/10 22/42 19
Serotransferrin P02787 109 2/10 18/29 28
Complement C3 P01024 142 2/3 21/35 22
Serum albumin P02768 121 8/10 16/21 34
α-1-antitrypsin P01009 117 10/10 15/40 56
Fibrinogen β chain P02675 90 6/10 21/34 41
Apolipoprotein A-I P02647 119 7/10 13/24 53
Ferritin light chain P02792 88 1/10 8/24 37
Transthyretin P02766 65 2/10 5/22 74
Hemoglobin β chain P68871 74 1/10 6/24 51
No. Hits represents the number of identifications of the particular protein in relation to the number of 
samples analyzed. Peptides matched are based on the annotation in the hit with the highest Mowse score. 
Total sequence coverage is calculated from the peptides matched in all hits for a specific protein. 
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nLC-MS/MS
Finally, we analyzed a pool of 5 PCLD liver cyst fluids with one-dimensional SDS-
PAGE gel electrophoresis followed by nLC MS/MS. In addition to the 10 proteins 
already detected by MALDI-TOF MS, nLC-MS/MS demonstrated the presence of 
153 unique proteins, when likely contaminants such as keratins were omitted (Sup-
plementary Table T6.1, available online at http://pubs.acs.org. The first hit in each 
group is highlighted in red, likely contaminants are listed in gray). Again, hepatocys-
tin was not present. 
Classification of the identified proteins according to their Gene Ontology (GO) 
terms showed that of the 163 identified proteins 119 proteins are involved in me-
tabolism (73%), 67 proteins are involved in regulation of biological processes (41%), 
and 63 proteins are involved in defense response (39%) (Figure 6.4a). Next, we clas-
sified proteins according to their cellular component GO annotation. This revealed 
that most identified proteins were extra-cellular (127 proteins, 78%), or associated 
with membranes (52 proteins, 32%). Also, 36 proteins were associated with protein 
complexes (22%) (Figure 6.4b). 
dIscussIon
Here, we show that (1) mutant hepatocystin is secreted from MDCK cells on the 
apical as well as on the basolateral side; (2) liver cyst fluids from PCLD, ADPKD 
and isolated liver cysts vary greatly in total protein and albumin concentration, but 
show similarity in protein profile when visualized on SDS-PAGE gel electrophoresis; 
(3) none of the fluids analyzed contain hepatocystin; and (4) the 163 proteins identi-
fied by MALDI/TOF MS and nLC-MS/MS are mainly extra-cellular or membrane 
bound and involved in metabolism and regulation of biological processes.
Previous research has shown that mutant hepatocystin can be secreted from HeLa 
cells 7. In this study, we confirm this finding and we show in addition that mutant he-
patocystin is secreted on the apical as well as on the basolateral side of MDCK cells. 
This suggests that cysts from patients harboring a PRKCSH mutation theoretically 
might contain mutant hepatocystin. 
We used 3 different techniques to analyze hepatocystin presence in human liver cyst 
fluid, but failed to identify hepatocystin in our samples. This discrepancy can be 
explained two-fold. First, the in vitro experiments comprise artificial introduction 
and overexpression of protein, and might not have been the correct reflection of the 
in vivo setting. Second, high-abundance proteins such as albumin, which constitutes 
50% of protein content in cyst fluids, are a disturbing factor in either of the used 
techniques. We depleted all samples from albumin, but samples were not completely 
de-albuminized as shown by both MALDI-TOF MS and nLC-MS/MS analysis.
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F i g u r e   6 .4   Classification of the proteins identified in PCLD cyst fluid. 
A total of 163 proteins was identified from a pool of 5 PCLD cyst fluids using one-dimensional SDS-PAGE 
gel electrophoresis followed by nLC-MS/MS. Proteins were categorized according to their Gene Ontology 
terms for (a) involvement in biological processes and (b) predicted cellular localization. 
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Therefore, would hepatocystin be bound to albumin, it would have been detected as 
well by these techniques. Finally, we performed a Western blot analysis
with immunostaining for hepatocystin on non-albumin-depleted samples (n=6, data 
not shown). Once again hepatocystin was not detected. All in all, these data suggest 
that hepatocystin is not secreted in liver cyst fluid. This indicates that hepatocystin 
is either contained in the cells lining the cysts or is not produced at all. Recently, we 
have shown that hepatocystin is absent in cyst epithelia of patients harboring a trun-
cating mutation in hepatocystin 15. Thus, it seems that despite the dominant inheri-
tance pattern of the disease, hepatocystin is not produced in cyst epithelia. Further 
research is needed to clarify the mechanisms involved. One of the possibilities is that 
mutated PRKCSH mRNA from cyst lining is subjected to nonsense mediated RNA 
decay (reviewed in 16).
In 1982, Patterson and coworkers described the biochemical characteristics of two 
liver cyst fluid samples from a single PCLD patient 17. In line with our results, they 
found a serum like protein pattern and identified α-1-antitrypsin, α-2-macroglobulins, 
hepatoglobin, albumin, transferrin and poly IgG and IgA in the fluids. Several stud-
ies have shown that ADPKD kidney cyst fluid contain cytokines and growth factors 
both of which contribute to cyst formation and cyst growth when imposed on kidney 
cell lines or cells from ADPKD cyst epithelium 18-22. We did not observe cytokines or 
growth factors in our samples, but we did not use specific enzyme-linked immuno-
sorbent assays in order to detect these molecules. The Gene Ontology classification 
of the proteins identified by nLC-MS/MS showed that most proteins we identified 
are involved in metabolism (73%), regulation of biological processes (41%), and de-
fense response (39%). Only 9% of proteins identified play a role in either stimulation 
or inhibition of cell proliferation. However, apart from proteins, other biological fac-
tors present in the cyst fluids, such as cAMP or lipids, may contribute to cystogenesis 
23-25.
In conclusion, the results presented here demonstrate that hepatocystin is not secret-
ed in liver cyst fluid from PRKCSH mutated PCLD patients, despite the central role 
of hepatocystin in PCLD. This suggests mutant hepatocystin is either not produced 
or degraded intracellularly. We have identified a large number of ubiquitous serum 
proteins in liver cyst fluid, even though PCLD cysts develop from the intralobular 
bile ducts. Many of the identified proteins fulfill a role in metabolism and paracrine 
or autocrine proliferation factors were not recognized. Furthermore, PCLD cyst 
fluid resembles that of ADPKD and isolated liver cyst fluid indicating a common 
pathway for cystogenesis.
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The pathogenesis of polycystic liver disease (PCLD) is not well understood. The 
putative function of the associated proteins hepatocystin and Sec63p do not 
give insight in their role in cystogenesis and their tissue wide expression does 
not fit with the liver specific phenotype of the disease. We designed this study 
with the specific aim to dissect whether pathways involved in polycystic kidney 
diseases are also implicated in polycystic liver disease. Therefore, we immuno-
histochemically stained cyst tissue specimen with antibodies directed against 
markers for apoptosis, proliferation, growth receptors, signaling, and adhesion. 
We analyzed genotyped polycystic liver disease cyst tissue (n=21) compared with 
normal liver tissue (n=13). None of the cysts showed proliferation of epithelial 
cells. In addition, anti-apoptosis marker Bcl-2 revealed slight increase in expres-
sion, with variable increase of apoptosis marker active caspase 3. Growth factor 
receptors EGFR and c-erbB-2 were overexpressed and mislocalized. We found 
EGFR staining in the nuclei of cyst epithelial cells regardless of mutational state 
of the patient. Further, in hepatocystin mutant PCLD patients, apical membra-
nous staining of c-erbB-2 and adhesion markers MUC1 and CEA was lost and 
the proteins appeared to be retained in cytoplasm of cyst epithelia. Finally, we 
found loss of adhesion molecules E-cadherin and Ep-CAM in cyst epithelium 
of all patients. Nevertheless, we observed normal β-catenin expression. In con-
clusion, our results show that PCLD cystogenesis is different from renal cysto-
genesis. PCLD involves overexpression of growth factor receptors and loss of 
adhesion. In contrast, proliferation or deregulated apoptosis do not seem to be 
implicated. Moreover, differential findings for PRKCSH- and SEC63- associated 
polycystic liver disease suggest a divergent mechanism for cystogenesis in these 
two groups. 
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IntroductIon
Patients suffering from polycystic liver disease (PCLD) develop numerous fluid 
filled cysts restricted to the liver 1. So far, two genes, PRKCSH and SEC63, have 
been linked to PCLD by genome-wide linkage analyses and extensive sequencing 2, 
3. The incriminated proteins, hepatocystin and Sec63p respectively, are predicted to 
have their function in the glycosylation and transport of glycoproteins into and out 
of the endoplasmic reticulum (ER) (reviewed in 4). Hepatocystin and Sec63p show a 
tissue wide expression, but the phenotype of PCLD is restricted to the liver 2, 5-7. This 
paradox is not well understood and suggests that additional liver specific events that 
mediate cystogenesis occur. 
Cystogenesis in other polycystic diseases such as autosomal dominant polycystic 
kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARP-
KD) is studied to a greater extent. In these disorders, cystogenesis is associated with 
deregulated apoptosis, increased proliferation and aberrant localization of growth 
factor receptors 8-14. In addition, the Wnt signaling pathway, cell-cell adhesion and 
cell-matrix adhesion have been indicated to play a role in polycystic kidney diseases 
15-21. Cell adhesion molecules do not only mediate adhesion but also contribute to 
outside-in and inside-out cell signaling, which affects cell fate, differentiation and 
morphology (reviewed in 22). To add another level of complexity, all the processes 
mentioned above are intricately intertwined and interconnected. 
In this study, we set out to investigate whether the findings of the major pathways 
involved in renal cystogenesis can be extrapolated to PCLD. We hypothesized that 
cystogenesis in PCLD follows the same route as in ADPKD. Therefore, we analyzed 
the tissue expression of marker antigens of apoptosis, proliferation, cell growth, cell 
signaling, and cell adhesion in cyst epithelium from PCLD patients. 
materIals and methods 
Tissues
Cyst tissue samples were collected from 21 PCLD patients who underwent laparo-
scopic cyst fenestration or liver transplantation due to PCLD (all female, median 
age at procedure 44 years, range 35-62 years) 23. Mutational analysis showed that 16 
patients carried a PRKCSH mutation, while 2 patients were SEC63 mutants and 3 
patients were wild-type for both PRKCSH and SEC63. All mutations were found in 
a heterozygous state consistent with the autosomal dominant inheritance pattern of 
the disorder. Non-pathological tissue samples from 13 autopsy livers (4 males, 9 fe-
males; median age at death 45 years, range 31-68 years) were used for control purpos-
es. Autopsy patients died from causes other than liver disease or cancer. The study 
was performed according to the guidelines of the code for adequate use of secondary 
tissue (Version 2002, Federation of Medical Scientific Societies, www.fmwv.nl). 
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Immunohistochemistry
We prepared consecutive 4 µm paraffin sections, which we deparaffinized, rehy-
drated and blocked for endogenous peroxidase (30 min 3% hydrogen peroxide in 
PBS). If necessary, antigen retrieval was performed by 10 min microwave exposure 
in 10 mM citrate buffer (pH 6.0) after which the slides were allowed to cool down 
for at least 90 min. We used the avidin/biotin-blocking kit (Vector Laboratories, Inc., 
Burlingame, CA, USA) to block endogenous avidin and biotin and a 10 min pre-in-
cubation with 20% normal horse serum to block a-specific binding sites. Primary an-
tibodies (Table 7.1) were incubated overnight at 4 °C followed by 30 min incubation 
with biotinylated horse-anti-mouse antibody or goat-anti-rabbit antibody (both from 
Vector Laboratories, Inc., Burlingame, CA, USA). Next, we tagged antibodies with 
avidin-biotin-peroxidase complex (Vector Laboratories, Inc., Burlingame, CA, USA) 
and chromagen 3,3’-diaminobenzidene (DAB) with a hematoxylin counterstaining. 
Negative controls were produced by omitting the primary antibody. 
ta b l e   7.1   Primary antibodies used for immunohistochemistry.
Antigen Antibody Corporation Antigen retrieval Dilution
Active caspase 3 C92-605 BD Biosciences, San Jose, CA, USA M 1:500
Bcl-2 Clone 124 DakoCytomation, Glostrup, Denmark M 1:20
β-catenin Clone 14 BD Biosciences, San Jose, CA, USA M 1:1000
CEA B01-94-11M-P
BioGenex, San Ramon, CA, USA, 
monoclonal - 1:320
CEA A115
DakoCytomation, Glostrup, Denmark, 
polyclonal
- 1:2700
c-erbB-2 Clone CB11 BioGenex, San Ramon, CA, USA M 1:20
E-cadherin HECD-1 Takara Bio Inc, Otsu, Shiga, Japan M 1:50
EGFR Sc-03
Santa Cruz Biotechnology, Santa Cruz, 
CA, USA
M 1:100
Ep-CAM Ber-EP4 DakoCytomation, Glostrup, Denmark M 1:100
Ki67 MIB-1 DakoCytomation, Glostrup, Denmark M 1:100
MUC1 Clone E29 DakoCytomation, Glostrup, Denmark - 1:100
M: 10 min microwave exposure in 10 mM citrate buffer (pH 6.0), -: no antigen retrieval
Histological evaluation
Sections were examined and photographed using a Zeiss Axioskop 2 FS plus micro-
scope (Zeiss, Jena, Germany) and a ProgRes C10 plus digital camera with ProgRes 
Capture Pro 2.1 software ( JenOptik, Jena, Germany). Immunohistochemistry re-
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sults were classified as negative (-), weak positive (+/-), positive (+), strong positive 
(++), or very intense positive (+++). We distinguished clusters of moderately dilated 
bile duct structures as Von Meyenburg complexes and conspicuously expanded bile 
ducts as cysts. However, most cyst tissue samples consisted of sections through cyst 
wall and lining cells were considered cyst epithelium. The proliferation index was 
defined as the percentage of Ki67/MIB-1 positive (+/-, +, ++, or +++) cells in the 
cyst epithelium.
results
Proliferation and apoptosis in PCLD
Increased proliferation and deregulated apoptosis are involved in ADPKD and 
ARPKD cystogenesis 10, 11, 24. Therefore, we first examined proliferation markers in 
PCLD cyst tissue. Immunohistochemical staining of Ki67 revealed that in none of 
our patient’s cyst epithelia, proliferation was increased compared to control liver bile 
ducts. In all patients, the proliferation index was less than 1%, with only occasionally 
a positive cell in the cyst epithelium (Figure 7.1b). Lymphocytes present in the tissue 
samples showed positive staining and were regarded as an internal staining control.
Next, we studied apoptosis by assessing the expression of Bcl-2 (anti-apoptosis) and 
active caspase 3 (pro-apoptosis). Compared to normal liver bile ducts, we found that 
Bcl-2 staining was slightly elevated in cyst epithelia. In addition, some but not all 
bile ducts in cystic tissue had increased staining (Figure 7.1d). Finally, active caspase 
3 expression was slightly elevated in cyst epithelia of some but not all PCLD tissue 
specimens regardless of genotype. Furthermore, active caspase 3 expression showed 
marked heterogeneity between different cysts in a single sample (Figure 7.1g-f). In 
controls, expression of Bcl-2 as well as active caspase 3 was absent. 
Growth factor receptors are expressed in cyst epithelia
We have determined the expression of two growth factor receptors in PCLD cyst 
epithelia; epidermal growth factor receptor (EGFR, c-erbB-1) and c-erbB-2 (Her2/
neu). EGFR was strongly expressed in cyst epithelia and also hepatocytes were oc-
casionally positive. Staining was seen often in the nucleus, but also in the cytoplasm 
of positive cells. Hepatocytes in control livers weakly expressed EGFR in the cyto-
plasm only. EGFR staining was negative in bile ducts in both cyst tissue and control 
liver. 
C-erbB-2 expression showed divergent staining in patients with different mutations. 
Cyst epithelium of PRKCSH mutation carriers showed strong staining of c-erbB-2 
in the cytoplasm of cyst epithelia. Patients wild-type for both genes or carrying a 
SEC63 mutation showed expression of c-erbB-2 in some but not all cyst epithelia, 
and moreover, staining intensity was less explicit and mainly located on the apical 
surface. This staining resembled the normal bile duct staining in these patients. In 
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contrast to the apical staining seen on all bile ducts in patient samples, only the large 
bile ducts in control liver samples showed positive apical staining for c-erbB-2. The 
smaller bile ducts were negative as were the hepatocytes. Representative images of 
the stainings are depicted in figure 7.2. 
F i g u r e   7.1   Expression of proliferation and apoptosis markers in control and PCLD 
liver.
a-b| Immunohistochemical staining showed no increase in expression of proliferation marker Ki67 in 
PCLD liver compared to control liver. C-d| Expression of Bcl-2, an anti-apoptosis protein, is slightly 
elevated in cyst epithelia and bile ducts (insert) from PCLD patients. e-g| Finally, active caspase 3, a pro-
apoptosis marker, showed variable expression intensities within samples. We found no mutation dependent 
expression variation. Arrowheads indicate bile ducts and scale bars correspond to 50µm. 
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F i g u r e   7.2   Expression of growth factor receptors EGFR and c-erbB-2 in control and 
PCLD liver.
a-C| We observed increased EGFR expression in the nucleus and cytoplasm of PCLD cyst epithelial cells, 
regardless of mutational status. d-F| Patients carrying a PRKCSH mutation showed a distinct cytoplasmic 
overexpression of c-erbB-2. This is in contrast to a more variable c-erbB-2 expression in wild-type and 
SEC63 mutated patients. Arrowheads indicate bile ducts and scale bars correspond to 50µm. 
Cell signaling and cell adhesion
MUC1 is a glycoprotein active on the crossroads of many signaling pathways, from 
growth factor signaling to Wnt signaling, cell adhesion and morphogenesis. We 
found MUC1 over expression in the cytoplasm of the majority of cyst epithelia from 
patients with a PRKCSH mutation. The staining pattern matched exactly that of 
c-erbB-2 in these patients. In cyst epithelia from SEC63 mutation carriers and wild-
type patients, we also observed over expression of MUC1. However, in most cyst 
epithelia, staining showed a more apical concentration with weaker staining in the 
cytoplasm. This pattern resembled the apically centered expression in bile ducts seen 
in control liver (Figure 7.3a-c). 
Next, we assayed the expression of CEA, a representative of the IgG like adhesion 
molecules, using two different antibodies. As CEA is strongly glycosylated (28 po-
tentially N-glycosylation sites), the epitope of the antibody raised against the protein 
backbone might be masked. In our study, both antibodies displayed the same stain-
ing pattern, yet the staining of the antibody raised against the fully glycosylated 
protein was more pronounced. CEA was strongly expressed on the bile canaliculi 
in normal liver and in patient cyst tissue. In contrast to negative staining of bile 
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ducts, cyst epithelia showed strong cytoplasmic staining of CEA. In patients carry-
ing a PRKCSH mutation, this staining pattern matched the patterns for MUC1 and 
c-erbB2. In these patients, cysts negative for MUC1 and c-erbB-2 were also negative 
for CEA. In SEC63 mutated patients or wild-type patients both positive cytoplasmic 
staining and negative staining was seen. Here, no correlation could be found to other 
markers (Figure 7.3d-f).
Further, we assayed the expression of E-cadherin as a representative of the cadherin 
family of adhesion molecules. We observed E-cadherin expression in hepatocytes 
and bile ducts of normal liver and in addition, in cyst epithelia of patient cyst tissue. 
Occasionally, minor focal loss of E-cadherin expression was seen in cyst epithelia 
of all patients without correlation to mutational state (Figure 7.3g-i). An absence of 
E-cadherin can cause disruption of the Wnt signaling pathway. To evaluate Wnt sig-
naling involvement, we assessed β-catenin expression in cyst epithelia. We found that 
β-catenin staining was strong positive on membranes of all cyst epithelia, bile ducts 
and hepatocytes in normal liver and patient tissue. No translocation of β-catenin to 
the nucleus or cytoplasm was observed (Figure 7.3j-l). This implicates that in con-
trast to ADPKD cystogenesis, a disruption of Wnt signaling does not seem to be 
involved in PCLD cystogenesis. 
Finally, the adhesion molecule Ep-CAM was stained because of its negative regula-
tory effect on adhesions mediated by the classic cadherins (including E-Cadherin)25. 
In concordance, we hypothesized that Ep-CAM would be (over)expressed in cyst 
epithelia that showed loss of E-cadherin. Surprisingly, Ep-CAM showed a more ex-
tensive loss than E-cadherin in cyst epithelia of all patients. Ep-CAM was expressed 
on the membrane of bile ducts in control liver and patient tissue (Figure 7.3m-o). 
Table 7.2 summarizes the results of the immunohistochemical stainings of cyst epi-
thelia compared to normal liver bile ducts. Most antibodies showed results similar 
for all patients regardless of mutational status. However, c-erbB-2, MUC1 and CEA 
revealed differential expression in patients with a PRKCSH mutation.
dIscussIon
Here, we report that PCLD cyst tissue shows (1) normal proliferation, (2) slight in-
crease in expression of anti- and pro-apoptosis factors, (3) increased growth factor 
receptor expression, (4) loss of adhesion molecule expression, and (5) mislocalization 
of c-erbB-2, MUC1 and CEA in PRKCSH mutated cyst epithelia. The current results 
indicate that, similar to ADPKD, PCLD cystogenesis involves EGFR and c-erbB-2 
over expression. However, in contrast to the findings in ADPKD, PCLD cystogen-
esis does not seem to involve increased proliferation or (anti-)apoptosis.
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F i g u r e   7.3   Immunohistochemical staining of adhesion molecules in control and PCLD 
liver.
a-C| Staining of MUC1 revealed a slight increase in staining intensity in wild-type and SEC63 mutant 
patients. Staining was apically centered. In contrast, patients carrying a PRKCSH mutation showed strongly 
increased cytoplasmic expression in cyst epithelia. Bile ducts in all patients showed MUC1 staining on the 
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apical membrane (inserts). d-F| We observed an increased expression of CEA in cyst epithelia. In addition, 
PRKCSH mutant patients showed similar cytoplasmic overexpression as was seen in MUC1 and c-erbB-2 
stainings. g-i| E-cadherin expression was focally lost in cyst epithelia regardless of mutational state. j-l| 
However, β-catenin expression was not lost and was solely found in membrane association. m-o| Finally, 
staining of Ep-CAM revealed extensive loss in all PCLD cyst epithelia. Arrowheads indicate bile ducts and 
scale bars correspond to 50µm. 
ta b l e   7.2   An overview of the results found in this study separated by genotype.
Antibody
Mutation
PRKCSH SEC63 WT
Ki67 N N N
Bcl-2 +/- +/- +/-
Active caspase 3 N/+ N/+ N/+
EGFR + + +
C-erbB-2 +++* N/+ N/+
MUC1 +++* + +
CEA +++* N/++ N/++
E-cadherin F- F- F-
β-catenin N N N
Ep-CAM F-- F-- F--
WT: wild-type; N: normal expression; +/-: slight increase of expression; +: increased expression; +++ 
strong increase of expression; F-: focal loss; F--: more extensive focal loss; N/+: normal expression in 
some cysts, increase of expression in other cysts; N/++: normal expression in some cysts, strong increase 
of expression in other cysts; * corresponding pattern. 
Proliferation and apoptosis
It has been suggested that deregulated proliferation and apoptosis play an important 
role in polycystic kidney diseases (PKDs). Tissue sample proliferation indexes are 
increased and several studies have shown that diverse factors, such as calcium, c-myc, 
laminin 5 and cAMP, increase proliferation in PKD cells 8, 11, 26-31. Recently, Alvaro 
and coworkers found that in ADPKD liver cyst epithelia, proliferating cell nuclear 
antigen is highly expressed and that cyst fluid stimulates proliferation of cells derived 
from ADPKD liver cyst epithelia 8. In this study, we used the MIB-1 antibody di-
rected against Ki67 to determine the proliferation index in PCLD cyst tissue. This 
antibody stains cells in all phases but the G0 (or rest) phase, in contrast to the com-
monly used staining for PCNA which is only expressed late in cell cycle phase G1 and 
S phase 32, 33. Consequently, MIB-1 gives a more valid impression of proliferation. 
Our results show that proliferation is not increased in PCLD cyst epithelium com-
pared to control liver bile ducts. The proliferation index was smaller than 1% in all 
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patients studied. In addition, we found that all cysts (both large and small) were 
completely lined with cubic or flattened epithelium and we did not find any denuded 
basement membranes. Accordingly, as cyst size ranges from a few mm to several cm 
it can be argued that cyst epithelium has to proliferate to keep covering the entire 
cyst.  Most cysts that were part of our sample were large and were located on the 
surface of the dorsal liver. The results suggest that these cysts expanded (passively) 
by fluid retention instead of actively proliferating to a large diameter. Finally, it can 
be argued that that cysts grow either very slowly or by a non-linear fashion, e.g. in 
growth spurts. In summary, although some proliferation is needed to sustain the cyst 
coverage, (excessive) proliferation does not seem to be the main cause of cystogen-
esis in PCLD.
The role of apoptosis is ambivalent in PKDs. Both increased apoptosis and increased 
inhibition of apoptosis have been implicated in renal cystogenesis. In human AD-
PKD, increased Bcl-2 expression with normal levels of Bax seems to tip the balance 
to anti-apoptosis 10. However, the same study detected increased apoptosis. Woo and 
coworkers found concordant results and reported that increased apoptosis causes 
loss of renal tissue and leads to renal dysfunction in ADPKD 24. Furthermore, the 
absence of the anti-apoptotic protein Bcl-2 in bcl-2 –/– mice leads to severe polycys-
tic kidney disease in animals as young as 10 days 13. In addition, down regulation of 
Bcl-2 in the end stage of kidney development due to knockout of transcription fac-
tor AP-2β in AP-2β –/– mice also leads to massive apoptosis, polycystic kidneys and 
postnatal death 34. 
In this study, we found weak expression of Bcl-2 together with expression of active 
caspase 3 in some but not all cysts. It seems therefore that in some PCLD cysts the 
balance tips to anti-apoptosis (higher Bcl-2 and low active caspase 3), but in other 
cysts the balance seems to be in equilibrium (higher Bcl-2 together with high active 
caspase 3). This indicates that PCLD is a dynamic disease. The scored cysts are in 
different stages of growth and development, with some cysts degenerating and oth-
ers developing. 
Further, we found large numbers of bile ducts in cystic tissue with increased Bcl-2 
staining (Figure 7.1d). Increased expression of Bcl-2 is found in reactive bile ducts in 
various cholestatic liver diseases 35, 36. Reactive bile ducts develop from proliferation 
of pre-existing bile ductules and differ from normal bile ducts in their protein ex-
pression pattern. The existence of reactive bile ducts in cystic tissue would be a plau-
sible explanation for the abundance of bile ducts found in some patient’s tissues.
Growth factors
Paradoxically, the overexpression of growth factor receptors EGFR and c-erbB-2 in 
PCLD cyst epithelia argues for presence of active proliferation. We found a nuclear 
staining pattern for EGFR in PCLD. This is reminiscent of highly proliferative or 
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neoplastic tissues such as breast carcinomas. In the nucleus, EGFR can act as a tran-
scription factor of cyclin D, iNOS and c-myb, expression of which contributes to 
increased proliferation 37-39. Interestingly, translocation of EGFR is EGF-dependant 
and mediated by the Sec61p translocon 40. This raises the question whether PCLD 
protein Sec63p, which is part of the Sec61p translocon, could also have a role in 
EGFR translocation.
In PKD cyst epithelia, both EGFR and c-erbB-2 are overexpressed and mislocalized 
to the apical surface, instead of normal basolateral expression on collecting tubules 
in the kidney 9, 14, 41. Subsequently, overexpressed EGF accounts for an autocrine pro-
liferative response 9. In accordance, non-functional EGFR leads to less severe PKD 
in double mutant orpk;wa2 mice 12 and selective inhibition of c-erbB-2 decreases cyst 
growth and results in improvement of kidney function in PKD1 null mice 14. 
Mislocalization
In our study, three proteins, c-erbB-2, MUC1 and CEA, showed over expression 
and mislocalization restricted to or more pronounced in PRKCSH mutated patients. 
Their staining pattern mirrored the staining pattern for hepatocystin 42. Cysts devoid 
of hepatocystin expression showed the cytoplasmic staining pattern for c-erbB-2, 
MUC1 and CEA. The common denominator for these proteins is that they are all 
extensively N-glycosylated, a process mediated by hepatocystin. Defective glycosyla-
tion leads to misfolded glycoproteins resulting in retention in the ER or transloca-
tion out of the ER followed by degradation by the proteasome (reviewed in 43). De-
struction of the proteins mentioned above seems not to be the case in our study as 
intense staining represents presence of protein. Additionally, N-glycosylation is not 
only important in protein folding but also in protein trafficking. For example, differ-
ences in glycan composition are found in secreted and membrane-bound MUC1 44. 
MUC1 is a versatile protein interacting with e.g. EGFR, β-catenin, p53 and estrogen 
receptor α (ERα), but also inhibiting proliferation and influencing cell-cell adhesion 
through its extraordinary length 45-49. Intriguing is the fact that MUC1 stabilizes and 
stimulates ERα 47. This is significant, as hepatic cyst growth is promoted by estrogen 
supplementation and pregnancies 1, 50, 51. Nevertheless, we did not find overexpres-
sion of ERα in PCLD tissues (data not shown). This suggests that the MUC1/ERα 
pathway is not responsible for increased cystogenesis in female PCLD patients.
The discrepancy between the results in PRKCSH-mutated patients and SEC63-mu-
tated or wild-type patients indicate that PCLD cystogenesis might evolve through 
divergent pathways. A defect in hepatocystin seems to have effect on highly glycosy-
lated proteins in addition to the general effects also seen in Sec63p mutants. 
Adhesion
Finally, we turned our attention to the expression of adhesion molecules E-cadherin 
and Ep-CAM. The loss of both Ep-CAM and E-cadherin expression from PCLD 
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cyst epithelia was surprising, as expression of Ep-CAM is known to discard E-cad-
herin mediated cell-cell adhesions 25, 52. Our results indicate that loss of E-cadherin 
in PCLD cyst epithelia is not induced by Ep-CAM and that multiple adhesion pro-
cesses are involved in PCLD cystogenesis. 
Crucial for the normal functioning of E-cadherin is β-catenin 53. However, β-catenin 
expression in PCLD cyst epithelia was unaltered compared to normal bile ducts. 
More specifically, we found no accumulation of β-catenin in the cytoplasm or nuclei. 
This suggests that the canonical Wnt signaling pathway is not active in PCLD cyst 
epithelia. This is in contrast with the findings in ADPKD and nephronophthisis, 
where cystic kidneys develop respectively due to the activation or the failure of inhi-
bition of the canonical (β-catenin mediated) Wnt signaling pathway 18, 19, 54. However, 
further research using more sensitive methods are warranted to confirm and specify 
our results. 
Another arm of the Wnt signaling pathway, the non-canonical pathway or the planar 
cell polarity pathway, is also associated with ADPKD 55. This pathway mediates 
cytoskeletal organization and cell polarity. Lengthening of tubules, a major compo-
nent of kidney and liver development, involves lengthwise oriented cell proliferation. 
Loss of cell polarity undermines cell orientation and leads to cell division in planes 
other than the tubule axis, which can give rise to cystic structures. Our results can-
not exclude involvement of this pathway in PCLD cystogenesis.
In summary, our results show that PCLD cystogenesis is different from cystic kidney 
diseases. PCLD cystogenesis involves overexpression of growth factor receptors and 
loss of adhesion, but no decrease or increase in apoptosis or proliferation. Moreover, 
differential findings for PRKCSH- and SEC63-associated PCLD suggest a divergent 
mechanism for cystogenesis in these two groups. 
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Polycystic liver disease (PCLD) is an inherited disorder caused by mutations 
in either PRKCSH (hepatocystin) or SEC63 (Sec63p). However, expression pat-
terns of the implicated proteins in diseased and normal liver are unknown. We 
analyzed subcellular and cellular localization of hepatocystin and Sec63p using 
cell fractionation, immunofluorescence, and immunohistochemical methods. 
Expression patterns were assessed in fetal liver, normal adult liver and PCLD 
liver. We found hepatocystin and Sec63p expression predominantly in the en-
doplasmic reticulum. In fetal tissue, there was intense expression of hepatocys-
tin in ductal plate, bile ducts, and hepatocytes. However, Sec63p staining was 
prominent in early hepatocytes only and weak in bile ducts throughout develop-
ment. In PCLD tissue, hepatocystin was expressed in hepatocytes, bile ducts, 
and in cyst epithelium of PRKCSH mutation negative patients. In contrast, the 
majority of cysts from PRKCSH mutation carriers did not express hepatocystin. 
Sec63p expression was observed in all cyst epithelia regardless of mutational 
state. We conclude that hepatocystin is probably required for development of bile 
ducts and does not interact with Sec63p. The results support the hypothesis that 
cyst formation in PCLD results from a cellular recessive mechanism involving 
loss of hepatocystin. Cystogenesis in SEC63-associated PCLD occurs via a dif-
ferent mechanism. 
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IntroductIon
Polycystic liver disease (PCLD) is a rare autosomal dominant inherited disorder that 
is estimated to be present in 0.05-0.13% of the population 1, 2. The pathology dictates 
the presence of multiple fluid-filled cysts scattered throughout the liver parenchyma. 
Hepatic cysts are thought to develop from embryonic ductal plate malformations on 
the level of the intralobular bile ductules 3. During life, these malformations, or Von 
Meyenburg complexes, evolve through overgrowth and subsequent dilatation into 
cysts that have lost their continuity with the biliary tree 4, 5. The number and size of 
the cysts increase with age and the disease typically becomes apparent at the fourth 
decade of life. In women, the disease manifests earlier and is found with a clinically 
more severe phenotype. Furthermore, the number of pregnancies correlates with 
a more severe phenotype 5. Symptoms, such as abdominal pain and shortness of 
breath, arise from the mass effect of the enlarged liver 6. 
To date, two proteins are implicated in the pathogenesis of PCLD. The first protein, 
hepatocystin, is thought to be the non-catalytic β-subunit of glucosidase IIα, which is 
involved in folding and quality control of glycoproteins 7. There are some issues with 
respect to the localization of hepatocystin. As it contains an endoplasmic reticulum 
(ER) retention signal, much credential has been given to the ER as the primary site 
of hepatocystin 8, 9. On the other hand, studies have localized hepatocystin on the 
surface of human arterial tissue, mouse kidney mesangial and tubular cells, and hu-
man glial cells 10. Hepatocystin was found in the membrane fraction of the human 
kidney cell line HEK293 when co-expressed with the ion channel TRPV5, and he-
patocystin translocates to the nucleus when MCF-7 cells are treated with fibroblast 
growth factor 1 11, 12. Furthermore, in pig liver, hepatocystin’s partner glucosidase IIα 
is localized in both rough and smooth ER 13, but in pig kidney it is also localized in 
the Golgi apparatus 14. Consequently, there is little consensus on the cellular localiza-
tion of hepatocystin and it is unclear in which cellular compartment of human liver 
cells hepatocystin executes its function. 
The second protein, Sec63p, was linked to PCLD on the basis of a genome-wide 
linkage study 15. Sec63p is an integral ER membrane protein that contains three 
trans-membrane spanning domains and a DnaJ-like domain 16. In mammals, the 
83 kD protein forms a complex together with Sec62 and BiP, and is thought to be 
involved in the protein translocation machinery of the ER 17. Sec63p is also impli-
cated in the ER associated degradation (ERAD) pathway. This system translocates 
misfolded or unassembled proteins out of the ER to be degraded by the ubiquitin-
proteasome system 18, 19.
Despite the involvement of hepatocystin and Sec63p in PCLD, no clear pathways 
for the cystogenesis in this disease are known and, above all, the presumed biologi-
cal roles of hepatocystin and Sec63p do not afford immediate insight as to why they 
participate in this neocystogenic disorder. 
Autosomal dominant polycystic kidney disease (ADPKD) is a disorder with predom-
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inant presence of renal cysts. Several groups have shown that cystogenesis in ger-
mline carriers is driven by inactivation of the somatic allele of one of the ADPKD 
genes. Although this is an attractive hypothesis, it is not known whether the same is 
true for PCLD. Hence, it can be speculated that cysts in PCLD arise through a mo-
lecular recessive mechanism for the genes that encode hepatocystin (PRKCSH) and/
or Sec63p (SEC63). If so, this would lead to absence of either protein in the PCLD 
tissues. Therefore we designed this study with two goals in mind: (1) to establish the 
localization of hepatocystin and Sec63p, on the subcellular as well as on the tissue 
level, and (2) to assess whether the two hit model is applicable in the pathogenesis of 
PCLD by determining the expression patterns in PCLD and control livers.
materIals and methods
Immunofluorescence confocal laser scanning microscopy (CLSM)
SK-ChA-1 cholangiocytes and HeLa cells (grown in DMEM/10% FCS) were cul-
tured on coverslips and fixed with freshly prepared 2% paraformaldehyde/0.1 M 
PHEM (pH= 7.3) for 30 min 20. The cells were permeabilized for 30 min with 0.15% 
Triton X-100 in PBS containing 20 mM glycine, 5% normal swine serum, and 0.1% 
cold water fish skin gelatin. Immunofluorescent double staining was achieved by co-
incubating the primary antibodies for hepatocystin and Sec63p with markers for ER, 
cis-Golgi, Golgi and lysosomes. Mitochondria were visualized with Mito Tracker 
(Invitrogen, Breda, the Netherlands) according to the manufacturers’ protocol. Anti-
bodies used in this study are listed in Supplementary Table T8.1. Primary antibodies 
were incubated over-night at 4°C or 2 h at 37°C and were detected using appropriate 
secondary antibodies conjugated with Alexa 488 or Alexa 567, respectively (Invitro-
gen, Breda, the Netherlands). Finally, the cells were embedded in mowiol (Hoechst, 
Frankfurt, Germany), and analyzed on a confocal laser-scanning microscope (MRC 
1024, Biorad, Hemel Hempsteadt, UK) equipped with an argon/crypton laser. All 
images were taken using a Nikon PlanApo lens (60×, N.A. 1.40).
Cell Fractionation 
Liver samples for cell fractionation purposes came from organ transplant donors 
between 1 and 2 h after death, and were snap frozen in liquid nitrogen and stored 
at -80°C until use 21. Cell fractionation was adapted from Fleischer and Kervina 22. 
Briefly, liver tissue was homogenized and (ultra)centrifuged in sucrose gradients re-
sulting in fractions enriched in nucleus, mitochondria, plasma membrane, lysosomes, 
peroxisomes, Golgi, rough microsomes, smooth microsomes, and cell cytoplasm. 
Western blot analysis
Cell fractionation samples were analyzed using Western blot analysis. Briefly, sam-
ples with equal protein concentration were separated on a 10% SDS polyacrylamide 
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gel and transferred onto a Protran nitrocellulose membrane (Schleicher & Schuell 
BioScience Inc., Keene, NH, USA). Membranes were blocked with 5% low-fat milk 
for 30 min, incubated overnight with primary antibodies (Supplementary Table T8.2) 
and subsequently for 1 h with appropriate peroxidase-labeled secondary antibod-
ies. Antibodies were visualized using ECL Western blotting detection reagents (GE 
Healthcare Limited, Buckinghamshire, UK) and Hyperfilm MP (Amersham Biosci-
ences UK Ltd, Buckinghamshire, UK).
 
Tissues
To study the expression profile of hepatocystin and Sec63p during liver development, 
we collected human fetal liver tissue (gestational age ranging from 11 to 40 weeks) 
and neonatal liver tissue (age ranging from 0 to 15 months after birth) from autop-
sies (n=17). In addition, we collected non-pathological tissue samples from 13 adult 
autopsy livers (4 males, 9 females; mean age at death 46 years, range 31-68 years). 
PCLD cyst tissue samples were collected from patients who underwent laparoscopic 
cyst fenestration or liver transplantation due to PCLD. Tissue samples were collected 
in phosphate buffered formalin, dehydrated, and embedded in paraffin. A total of 21 
female patients were included in our study (mean age at procedure 45 years, range 
35-62 years). Gall bladder tissue from four PCLD patients was also studied (1 male, 
3 females, mean age at procedure 44 years, range 32-56 years). Three healthy gall 
bladders without changes on routine histopathological examination (3 females, mean 
age at procedure 44 years, range 20-66 years) were used as controls. Autopsy patients 
died from causes other than liver disease or cancer. The study was performed ac-
cording to the guidelines of the code for adequate use of secondary tissue.
Genotyping
Genomic DNA from PCLD patients was extracted from peripheral blood leuko-
cytes according to standard protocols (Gentra Systems, Minneapolis, USA) and 
genotyping for PRKCSH and SEC63 was performed according to earlier established 
methods 23. 
Immunohistochemistry
Consecutive paraffin sections of 4 µm thickness were deparaffinized in xylol, re-
hydrated, and incubated with 3% hydrogen peroxide in PBS to block endogenous 
peroxidase. Antigen retrieval was performed either by 10 min pronase incubation at 
37°C or by 10 min microwave exposure in 10 mM citrate buffer (pH 6.0) after which 
the slides were allowed to cool down for at least 90 min. Subsequently, endogenous 
avidin and biotin were blocked using an avidin/biotin blocking kit (Vector Labora-
tories Inc., Burlingame, CA, USA).  After pre-incubation with 20% normal horse 
serum for the monoclonal antibodies and 20% normal goat serum for the poly-
clonal antibodies, sections were incubated over-night with primary antibodies at 4°C. 
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Supplementary Table T8.3 lists the antibodies used in this study. Primary antibodies 
were detected using appropriate biotinylated secondary antibodies and avidin-biotin-
peroxidase complex (Vector Laboratories Inc., Burlingame, CA, USA). Finally, 3,3’-
diaminobenzidene was used as chromogen and sections were counterstained with 
hematoxylin. Negative controls were constructed by omitting the primary antibody. 
Hepatocystin was detected using two antibodies with different antigen recognition 
sites to avoid false positive results. Antibodies were adapted to paraffin protocol 
after extensive testing on Western blot and snap frozen non-fixed liver tissue (data 
not shown). 
Histological evaluation
The general characteristics of tissue samples were determined by a pathologist using 
hematoxylin and eosin (HE) staining. Cysts were defined as conspicuously dilated 
bile ducts, although most samples consisted of sections through the cyst wall in 
which the lining epithelium was considered as cyst epithelium. Von Meyenburg com-
plexes were defined as a cluster of moderately dilated bile duct structures. Immuno-
histochemistry results were classified as negative (-), weak positive (+/-), positive (+), 
strong positive (++), very intense positive (+++). Developing biliary structures in 
fetal tissue were categorized according to Libbrecht et al. and Fabris et al. 24, 25.
results
Subcellular localization 
Immunofluorescence CLSM 
First, we studied the endogenous subcellular expression of hepatocystin and Sec63p 
in SK-ChA-1 cholangiocytes and HeLa cells by confocal immunofluorescent mi-
croscopy. Double staining with markers for ER, cis-Golgi, Golgi, mitochondria, 
and lysosomes revealed that both hepatocystin and Sec63p were almost exclusively 
expressed in the ER (Figure 8.1). We could not detect staining for hepatocystin 
and Sec63p in the Golgi apparatus, cis-Golgi system, lysosomes or mitochondria 
(Supplementary Figures F8.1 and F8.2). 
Cell fractionation 
Next, we verified the subcellular expression of hepatocystin and Sec63p in human 
liver. Cell fractioned liver was subjected to Western blot analysis and probed with 
appropriate antibodies. Both hepatocystin and Sec63p were localized in the ER-en-
riched fraction and a small fraction of Sec63p was localized to the nucleus-enriched 
fraction (Figure 8.1g).
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F i g u r e   8 .1   Subcellular distribution of hepatocystin and Sec63p. 
a-F| Immunofluorescence double staining of hepatocystin (a) and Sec63p (d) in conjunction with ER mark-
er PDI (b and e) in cholangiocytes. C and f show overlays. (Scale bars correspond to 10µm) g| Western blot 
analysis of cell fractionation fractions. For each lane, 50µg protein was loaded and numbers indicating 
the lanes correspond to fraction numbers. Blots were incubated over-night at 4°C with antibodies against 
hepatocystin, Sec63p, ER marker PDI, or nucleus marker Histon 3.1, and subsequently for 1 h at room 
temperature with appropriate secondary antibodies. Antibodies were visualized using ECL detection. Both 
hepatocystin and Sec63p are concentrated in the ER-enriched fraction indicated by PDI. A small fraction 
of Sec63p localizes to the nucleus-enriched fraction.
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Tissue level expression
PCLD arises from ductal plate malformations that are established early in fetal life. 
We hypothesized that hepatocystin and/or Sec63p are involved in the ductal plate 
formation. Therefore, we studied the expression pattern of hepatocystin and Sec63p 
during fetal development and healthy adult livers. 
Expression in developing liver
Immunohistochemistry on fetal liver tissue obtained at 11 weeks after gestation re-
vealed prominent hepatocystin expression in both bile ducts and hepatocytes. Hepa-
tocystin was expressed throughout differentiation of cholangiocytes from the early 
ductal plate to mature bile ducts. The staining intensity of the bile ducts and hepa-
tocytes decreased after 26 weeks of gestation to a level of intensity seen in adult liver 
(Figure 8.2). Sec63p was weakly expressed in ductal plate and bile ducts; however 
it was highly expressed in hepatocytes until 17 weeks after gestation. Interestingly, 
hepatocystin was also present in endothelium and arteriolar muscle bundles, but 
staining intensity of the muscle bundles diminished in the first months after birth. 
Sec63p expression was present in endothelium, but was absent in the arteriolar mus-
cle bundles. Figure 8.2 shows representative examples of hepatocystin and Sec63p 
tissue expression during liver development. All negative controls were devoid of any 
staining (Figure 8.2c).
Expression in adult liver tissue 
Prominent hepatocystin immunoreactivity was detected in bile ducts from control 
livers regardless of their size, whereas Sec63p expression was weak in small bile ducts 
and more intense in large ducts (Figure 8.2). Both proteins were present in hepato-
cytes and, in addition, demonstrated weak staining of the endothelium. There were 
no differences in expression between males and females and a correlation between 
staining intensity and age was absent.
Pathological tissue
We studied expression of PCLD proteins in cyst tissue samples from PCLD patients 
and included gall bladder tissue as control. Even though the gall bladder is part of 
the biliary tree and is lined with cholangiocytes, PCLD patients do not develop cysts 
in the gall bladder. PCLD is confined to the liver. We hypothesized that if hepato-
cystin and/or Sec63p expression is altered in liver cysts, this altered expression would 
not be present in cyst free gall bladder. In order to assess the contribution of the 
mutant germline allele to the expression of the PCLD proteins, we genotyped our 
PCLD cohort for PRKCSH and SEC63 mutations. 
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F i g u r e   8 .2   Hepatocystin and Sec63p expression from fetal to adult liver.
a|  Representative images of hepatocystin and Sec63p immunohistochemical staining on normal fetal and 
infant liver (age ranging from 11 weeks after gestation to 15 months after birth), and adult liver. Hepato-
cystin displayed intense expression in ductal plate, bile ducts, and hepatocytes. In contrast, Sec63p staining 
was weak in bile ducts throughout development but prominent in early hepatocytes. Arrowheads indicate 
bile ducts and ductal plate and scale bars correspond to 100µm. b| Schematic overview of hepatocystin 
and Sec63p staining intensity in hepatocytes and cholangiocytes of fetal and infant (age ranging from 11 
weeks after gestation to 15 months after birth), and adult liver. Staining intensity was classified as negative 
(0), weak positive (0.5), positive (1), strong positive (2), highly positive (3). C| Negative controls for the 
hepatocystin and Sec63p stainings. Negative controls were constructed by omitting the primary antibody. 
Notice the absence of staining. Arrowheads indicate bile ducts and scale bars correspond to 100µm.
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Genotyping 
The cohort consisted of 24 singleton PCLD patients. Mutational analysis showed 
that 4 patients were wild-type for both PRKCSH and SEC63. A total of 18 patients 
carried a PRKCSH mutation, while two patients were SEC63 mutants (Table 8.1). All 
mutations were found in a heterozygous state consistent with the autosomal domi-
nant inheritance pattern of the disorder. 
ta b l e   8 .1   Genotype of PCLD patients.
Mutation Cyst tissue samples Gall bladder samples
PRKCSH c.1338-2A>G 10 -
PRKCSH c.292+1G>C 4 1
PRKCSH c.374_375delAG 1 -
PRKCSH c.416G>A 1 -
PRKCSH c.464A>G - 1
SEC63 c.1702_1704delGAA 2 -
Wild-type 3 2
Total 21 4
Histology
Normal gall bladders displayed no significant anomalies with no atypical epithelia, 
no inflammation, and no sign of malignancy. Incidentally a superficial Rokitansky-
Aschoff sinus could be seen. All PCLD gall bladders showed mild chronic chole-
cystitis, yet exhibited multiple and exceptionally large Rokitansky-Aschoff sinuses 
(Figure 8.3b). The sinuses penetrated through the smooth muscle and some sinuses 
were lined with atypical epithelium. All patient’s cyst tissue samples contained mul-
tiple cystic lesions and the cyst wall consisted of dense fibrous connective tissue cov-
ered with a single layer of mainly flat but occasionally cubic epithelium. Pre-existent 
liver parenchyma with hepatocytes and (normal) bile ducts was present focally in the 
cyst wall. Von Meyenburg complexes were also seen and in some patients there was 
abundant proliferation of bile ducts. All cyst epithelia strongly expressed CK18 and 
CK19 consistent with bile duct origin (Figure 8.4i-p).
Hepatocystin and Sec63p expression in gall bladder. 
Both hepatocystin and Sec63p were expressed in all gall bladder epithelia. Hepa-
tocystin showed a distinct heterogenous staining pattern with negative and highly 
positive cells side by side. There were no differences in staining between patients and 
controls (Figure 8.3c-f). 
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F i g u r e   8 .3   Morphology and expression of hepatocystin and Sec63p in gall bladder.
a-b| Rokitansky-Aschoff sinuses were observed in control (a) and more severely in PCLD gall bladder (b) 
(arrowheads, hematoxylin eosin (HE) staining). C-F| Hepatocystin was expressed heterogeneously in both 
control (C) and PCLD gall bladder (d), in contrast to consistent Sec63p expression in control (e) and PCLD 
gall bladder (f). Scale bars correspond to 500µm (a and b) and 100 µm (C-f).
Loss of hepatocystin expression in cyst tissue
In PCLD tissues, both bile ducts and hepatocytes expressed hepatocystin and Sec63p. 
Cyst tissue from patients with wild-type or mutant SEC63 showed normal expres-
sion of hepatocystin in the cyst epithelia (++). In contrast, hepatocystin expression 
was lost in cyst wall from PRKCSH mutation carriers. Patients carrying the c.1338-2-
A>G mutation or the c.374_375delAG mutation showed loss of hepatocystin expres-
sion in the majority (90%) of cysts and in Von Meyenburg complexes. In addition, 
hepatocystin expression was either lost completely or present in all cuboid cells lin-
ing the cyst. This indicates that hepatocystin is lost at an early stage of cystogenesis, 
when the cyst consists of a minimal number of cells. In case of loss at a later stage, 
we would expect that a significant number of cells lining the cyst still retains hepa-
tocystin expression. We were able to confirm these results using two different anti-
hepatocystin antibodies, both recognizing different epitopes of the protein. Patients 
carrying the PRKCSH c.292+1G>C mutation showed weak cytoplasmic staining for 
hepatocystin in the majority of cysts. These results indicate that residual wild-type 
expression, although drastically reduced, is present in cyst epithelia of these patients. 
Representative images are depicted in figure 8.4. In our study, we included cyst tissue 
from one patient with a point mutation in PRKCSH (c.416G>A). We failed to ob-
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serve down regulation of hepatocystin expression in cyst epithelia from this patient. 
It is possible that this missense mutation does not result in absence of hepatocystin, 
but rather renders the protein non-functional. Our approach does not allow distin-
guishing between these two possibilities.  
Intense Sec63p expression in cyst tissue
Remarkably, the majority of cysts in all patients showed intense staining for Sec63p 
in cyst epithelia compared to weak or positive staining in bile ducts and hepatocytes 
respectively, from the same specimen (Figure 8.4). In addition, focal loss of Sec63p 
in cyst epithelia was occasionally seen in patients regardless of their mutational state. 
Von Meyenburg complexes, when present, stained weakly positive, similar to control 
bile ducts. This suggests that these complexes have not yet fully acquired the cyst 
phenotype. Table 8.2 recapitulates localization and staining intensity subdivided by 
mutational state.
ta b l e   8 .2   Hepatocystin and Sec63p expression in PCLD liver cyst tissue.
Mutation
Cyst epithelia Bile ducts Hepatocytes
HC Sec63p HC Sec63p HC Sec63p
PRKCSH c.1338-2A>G - ++ ++ + ++ +
PRKCSH c.374_375delAG - ++ ++ + ++ +
PRKCSH c.292+1G>C +/- ++ ++ + ++ +
PRKCSH c.416G>A ++ ++ ++ + ++ +
SEC63 c.1702_1704delGAA ++ ++ ++ + ++ +
Wild-type ++ ++ ++ + ++ +
HC: hepatocystin; - negative; +/- weak positive; + positive; ++ strong positive
dIscussIon
In the present investigation, we assessed the cellular and subcellular localization of 
hepatocystin and Sec63p, two proteins implicated in the cystogenesis of PCLD. Our 
results show that: (1) both hepatocystin and Sec63p are localized in the ER frac-
tion of human liver; (2) during embryonic liver development, both hepatocystin and 
Sec63p are expressed in several cell types in a time-regulated fashion; (3) a truncat-
ing mutation in PRKCSH leads to absence of hepatocystin in PCLD cyst epithelium; 
(4) Sec63p is highly expressed in all cyst epithelia regardless of mutational state; and 
(5) hepatocystin and Sec63p are expressed in epithelium of gall bladders of PCLD 
patients. Taken together, these data suggest a complex role for both hepatocystin and 
Sec63p in the cystogenesis in PCLD, possibly by various mechanisms. 
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F i g u r e   8 .4   Immunohistochemical staining for hepatocystin and Sec63p in PCLD cyst 
tissue.
Representative images of staining for hepatocystin and Sec63p are shown. a-d| Hepatocystin is absent in 
cyst lining of the majority of cysts in patients carrying a PRKCSH c.1338-2A>G mutation (a), drastically 
reduced in patients carrying a PRKCSH c.292+1G>C mutation (b), and present in all cysts of patients car-
rying a SEC63 c.1702_1704delGAA mutation or wild-type for both genes (C and d). e-h| Sec63p staining, 
on the other hand, is positive in cyst epithelia regardless of mutational state. i-p| All cyst epithelia strongly 
expressed CK18 and CK19 consistent with bile duct origin (i-l and m-p respectively). Scale bars correspond 
to 100 µm. Scale bars in a, e, m and i correspond to 500µm, with scale bar in inserts 100µm. 
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Previous studies showed several cellular localizations of hepatocystin expression in 
different cell lines and tissues 8-10, 12-14. Proteins could fulfill different functions when 
expressed in different cellular compartments and as only the liver is affected in PCLD, 
it is important to ascertain the subcellular localization in liver tissue. To investigate 
whether the proteins exert their functions in the ER of liver cells, we performed 
liver cell fractionation. Our results are compatible with ER localization in human 
liver and the cholangiocyte cell line SK-ChA-1 (Figure 8.1). This is a relevant finding 
because we can now establish that the perturbed hepatocystin and Sec63p function 
in PCLD is most likely related to the putative ER associated action of both proteins. 
The roles for hepatocystin encompass folding and quality control of glycoproteins 
through mannose tree trimming, while Sec63p is involved in transport of proteins 
into (co- or post-translational) or out of (ERAD pathway) the ER 7, 17, 19. One possible 
reason for the conflicting data with respect to localization is that there is recycling 
of hepatocystin. On the other hand, this seems unlikely as subcellular fractionation 
data suggest that the large majority of hepatocystin is retained in the ER. 
Hepatocystin is expressed very early in fetal bile duct development. This implicates 
a role for hepatocystin in the induction of the normal ductal plate and bile duct for-
mation. In contrast, Sec63p is weakly expressed in fetal bile ducts. These results of 
developmental expression suggest that hepatocystin and Sec63p do not interact and 
suggest that they are not part of the same complex or pathway. This is different form 
the situation in ADPKD where polycystin-1 and polycystin-2 are known to interact 
26, 27. 
A two hit model for cystogenesis, analogous to the classic model for carcinogenesis, 
is proposed in ADPKD and data is accumulating to support this theory (reviewed 
by Pei in 2001 28) This model assumes that the healthy allele of a gene is inactivated 
by a somatic mutation (second hit) or by loss of heterozygosity. This results in a local 
molecular recessive situation without expression of the functional protein. 
We present evidence that this model might also be true in PCLD. We used two an-
tibodies with different antigen recognition sites (C-terminal and mid-protein), that 
both failed to detect hepatocystin in cystic epithelia. Therefore, it seems fit to assume 
that neither wild-type nor mutant protein is expressed in the majority of cyst epithe-
lia from patients carrying the PRKCSH c.1338-2A>G or c.374_375delAG mutation 
(Figure 8.4). The consistently high number of hepatocystin-negative cysts among 
PRKCSH germline carriers limits the possibility that the nature of the somatic muta-
tion is a chance event. In contrast, for Sec63p the two hit model does not seem appli-
cable. Our results show that this protein is highly expressed in cyst epithelia regard-
less of mutational state. Furthermore, we failed to observe absence of hepatocystin 
in cyst lining derived from SEC63 mutant carriers (Figure 8.4). This implicates that 
a trans-heterozygous event does not occur here. It is important to underline that the 
SEC63 mutation found in our patients is an in-frame deletion of a single amino acid. 
This might not have a profound structural effect but rather functional effects; hence, 
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detection by the antibody might not be lost. Therefore, these results indicate that cyst 
initiation can occur by a dosage effect without loss of the normal protein. In patients 
carrying the PRKCSH c.292+1G>C mutation, we found a severely decreased expres-
sion of hepatocystin, also indicating that reduction of expression is sufficient for 
cyst initiation. These results are in line with recent dosage effect studies in ADPKD. 
Both increase and decrease in expression of the associated proteins lead to ADPKD 
in mice 29, 30. Alternatively, cyst initiation in PCLD might also be due to somatic 
changes at other loci that are yet to be identified.
In ADPKD, only a minority of PKD2 cystic tissues fails to stain for polycystin-2, 
and a similar pattern is present in PKD1 where the majority of cysts stain with 
polycystin-1 antibodies 26. In PCLD, this appears to be different as we found that the 
large majority of cysts from PRKCSH mutants fail to stain for hepatocystin. Previous 
studies in ADPKD revealed that there is a marked up-regulation of angiogenic fac-
tors in biliary epithelium. Studies have shown that cholangiocyte derived angiogenic 
factors drive the vascular supply to the growing cysts and stimulate the proliferation 
of the biliary epithelium in an autocrine fashion 24, 31. This might well be a general 
mechanism that dictates cyst growth but fails to explain why the various mutations, 
unique to ADPKD and PCLD, cause cysts in the first place. 
Hepatocystin is probably required for normal bile duct formation and our results 
show that absence of hepatocystin leads to cyst formation. On the other hand, loss of 
hepatocystin is not required for cyst formation in SEC63-related PCLD. Apart from 
these early events, probably other factors such as the second messenger cAMP may 
also account for epithelial cell proliferation and fluid secretion. Indeed, an elegant 
study showed that cAMP is increased in bile ducts of an animal model for polycystic 
liver disease 32. All in all, in PRKCSH-mutated PCLD, a cellular recessive (two-hit) 
model appears to be present. Whether a second hit is established by somatic muta-
tions, promoter methylation, or loss of heterozygosity remains to be determined. 
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Su p p l e m e n ta ry  F i g u r e   F8 .1   Subcellular expression of hepatocystin and Sec63p 
in cholangiocytes.
Immunofluorescence double staining of hepatocystin (a, C-e) and Sec63p (b, f-h) in green in conjunction 
with ER marker PDI (a and b), cis-Golgi apparatus marker ERGIC-53 (C and f), Golgi apparatus marker 
Giantin (d and G), and Lysosome marker LAMP1 (e and h) in red. Scale bars correspond to 10µm. 
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Su p p l e m e n ta ry  F i g u r e   F8 .2   Subcellular expression of hepatocystin and Sec63p 
in HeLa cells.
Immunofluorescence double staining of hepatocystin (a, C-f) and Sec63p (b,G-j) in green together with 
ER marker PDI (a and b), cis-Golgi apparatus marker ERGIC-53 (C and G), Golgi apparatus marker Giantin 
(d and h), Lysosome marker LAMP1 (e and i) and mitochondrial marker Mito Tracker (f and j) in red. Scale 
bars correspond to 10µm.
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Su p p l e m e n ta ry  ta b l e   t8 .1   Primary antibodies used for immunofluorescence 
microscopy.
Organelle Antigen Antibody Corporation Dilution Source
Hepatocystin Sc10774 Santa Cruz Biotechnology, 
Santa Cruz, CA, USA
1:400 Rabbit
Sec63p Kind gift from Prof  Hart-
mann, Berlin 17
1:1000 Rabbit
ER PDI Clone 1D3 Stressgen Bioreagents, Ann 
Arbor, MI, USA
1:500 Mouse
Golgi Giantin Clone G1/133 Kindly provided by Prof  
Hauri, Basel 33
1:1500 Mouse
Lysosomes LAMP1 CD107a BD Transduction Laborato-
ries, San Jose, CA, USA
1:1000 Mouse
Cis-Golgi ERGIC-53 Clone G1/93 Kindly provided by Prof  
Hauri, Basel 34
1:100 Mouse
Su p p l e m e n ta ry  ta b l e   t8 .2   Primary antibodies used for Western blot analysis.
Organelle Antigen Antibody Corporation Dilution Source
Hepatocystin Clone 2 BD Transduction Labora-
tories, San Jose, CA, USA
1:1250 Mouse
Sec63p Kind gift from Prof  Hart-
mann, Berlin 17
1:1000 Rabbit
ER PDI Clone 1D3 Stressgen Bioreagents, 
Ann Arbor, MI, USA
1:500 Mouse
Nucleus Histon 3.1 Kind gift from Dr Van 
der Vlag, Nijmegen
1:1000 Mouse
Cell membrane Vinculin HVIN-1 Sigma, Saint Louis, MI, 
USA
1:4000 Mouse
Cytoplasm GST α Clone 1A11 Kindly provided by Dr 
Peters, Nijmegen 35
1:6000 Mouse
Mitochondria 39kD Complex I 20C11 Invitrogen, Breda, the 
Netherlands
1:1000 Mouse
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Su p p l e m e n ta ry  ta b l e   t8 .3   Primary antibodies used for immunohistochemistry.
Antigen Antibody Corporation Dilution Source
Hepatocystin Clone 2 BD Transduction Laboratories, San Jose, 
CA, USA
1:200 Mouse
Hepatocystin Sc10774 Santa Cruz Biotechnology, Santa Cruz, 
CA, USA
1:200 Rabbit
Sec63p Kind gift from Prof  Hartmann, Berlin 17 1:1000 Rabbit
CK18 Clone DC10 BioGenex, San Ramon, CA, USA 1:20 Mouse
CK19 Clone RCK108 BioGenex, San Ramon, CA, USA 1:200 Mouse
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Polycystic liver disease (PCLD), characterized by development of numerous he-
patic cysts, is a disease of which the pathogenesis is still not understood com-
pletely. Recently, we showed that cyst epithelia were devoid of hepatocystin ex-
pression despite the fact that the disease is inherited in a dominant manner. We 
hypothesized that the absence of hepatocystin expression was a result of a cel-
lular recessive mechanism through a two-hit model. Using laser microdissection, 
we dissected cyst epithelial cells and bile duct cells from snap frozen PCLD cyst 
tissue of 5 patients carrying a truncating PRKCSH mutation. We isolated DNA 
and we analyzed it for the germline mutation, loss of heterozygosity, and somatic 
mutations using PCR and direct sequencing. In 6 out of 10 cysts, we found that 
the heterozygous germline mutation had changed into a homozygous state. SNP 
analysis showed that this was caused by a loss of heterozygosity reaching up to 
82 kb surrounding the PRKCSH gene. Further, we found 3 somatic mutations in 
the remaining 4 cysts, which brings the total mutation frequency to 90%. In con-
clusion, this study provides the first proof for a two-hit model in PCLD patho-
genesis. We show that hepatocystin expression is absent in cyst epithelial cells 
due to loss of heterozygosity and somatic mutations. 
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IntroductIon
Autosomal dominant polycystic liver disease (PCLD) is a Mendelian disease with 
devastating consequences. Patients suffering from PCLD present with grossly en-
larged livers due to multiple cysts, which lead to symptoms like nausea, anorexia and 
shortness of breath 1. Multiple loci are involved in PCLD. It can be caused by muta-
tions in PRKCSH encoding hepatocystin, or SEC63 encoding Sec63p, and possibly 
a third locus 2-4. 
Hepatocystin is the β-subunit of glucosidase IIα, a glucose-trimming enzyme in-
volved in protein maturation and quality control in the ER 5. We found that the 
common c.1338-2A>G PRKCSH mutation leads to premature termination of trans-
lation and a truncated hepatocystin protein 2. Moreover, the mutated protein fails 
to assemble with glucosidase IIα and is not retained in the endoplasmic reticulum 
6. In addition, we have shown that under experimental conditions, truncated hepa-
tocystin can be secreted from the cell. However, in human PCLD, matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry and nanoscale liquid 
chromatography tandem mass spectrometry failed to reconstitute hepatocystin from 
PCLD cyst fluid 7. We next investigated whether the mutated and wild type protein 
were produced at the level of cyst epithelia. Using immunohistochemical staining of 
human PCLD cyst tissues, we found that hepatocystin expression is completely lost 
in cyst epithelia of germline PRKCSH mutants 8. This suggests that hepatocystin is 
either not produced in cyst epithelia or is prematurely degraded. 
Taking all these results into account, we hypothesize that PCLD is caused by a cel-
lular recessive two-hit mechanism and that loss of heterozygosity and somatic muta-
tions are the major causes of somatic inactivation of PRKCSH. According to this 
hypothesis, each cyst represents a benign, fluid-filled tumor. Inactivation of both 
copies of a PCLD disease gene by germline and somatic mutations within an epi-
thelial cell provides growth advantages for it to proliferate clonally into a cyst. We 
designed this study to identify the cellular mechanism underlying the absence of 
hepatocystin in cyst epithelia from PRKCSH mutant patients. 
materIals and methods
Tissues
We collected liver cyst tissue samples from 4 patients with a heterozygous c.1338-2-
A>G PRKCSH mutation and one patient with a heterozygous c.292+1G>C PRKCSH 
mutation, who underwent laparoscopic cyst fenestration due to PCLD (all female, 
median age at procedure 42 years, range 35-54 years) 9. All tissue specimens were 
snap frozen at -80°C immediately after excision. The study was performed accord-
ing to the guidelines of the code for adequate use of secondary tissue (Version 2002, 
Federation of Medical Scientific Societies, www.fmwv.nl).
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Laser microdissection and DNA isolation
Snap frozen tissue was cut into 10 µm sections and mounted on PEN-membrane-
covered slides (MicroDissect GmbH, Herborn, Germany). Slides were stained with 
hematoxylin and eosin for 2 min, and washed in water. After drying over-night at 
37°C, cyst epithelial cells and bile duct cells were isolated using the laser microdissec-
tion system Leica LMD6000 (Leica Microsystems, Wetzlar, Germany). The micro-
dissected tissue was captured in 15 µl ATL buffer (QIAamp DNA Micro kit, Qiagen 
Benelux B.V., Venlo, the Netherlands) and DNA was isolated using the QIAamp 
DNA micro kit. Briefly, samples were treated with Proteinase K at 56°C for 3 h. Sub-
sequently, DNA was precipitated and purified using the QIAamp MinElute Column. 
Finally, the DNA was resolved in water. We isolated DNA from cyst epithelia from 
two different cysts per patient. For control purposes, we also isolated genomic DNA 
from laser-dissected bile ducts and from peripheral blood (Gentra Systems, Minne-
apolis, USA) from each patient.
Germline mutation analysis
Isolated DNA was amplified using the GenomePlex Complete Whole Genome Am-
plification kit (Sigma, Saint Louis, MO, USA). All samples were analyzed for their 
germline mutation using PCR and RFLP. Briefly, DNA was amplified by PCR as 
described preciously 4. Subsequently, the PCR products were digested using BanI 
(c.1338-2A>G) or DdeI (c.292+1G>C) at 37°C (New England Biolabs, Ipswich, MA, 
USA). The digests were separated on a 3% agarose gel and stained with ethidium 
bromide. In addition, the PCR products were purified (QIAquick Gel Extraction 
Kit, Qiagen, Hilden, Germany) and sequenced using the BigDye terminator kit and 
an ABI3730 capillary sequencer (Perkin Elmer Applied Biosystems, Boston, MA, 
USA).
Loss of heterozygosity analysis
To study loss of heterozygosity (LOH) of the PRKCSH gene region we analyzed 
single nucleotide polymorphisms (SNPs). SNPs were selected on the basis of the 
heterozygosity rates and their proximity to the PRKCSH locus. We analyzed 5 SNPs; 
rs167479, rs34095, rs313624, rs311786, and rs311805, in the genes RGL3, MGC20983, 
PRKCSH, ELAVL3, ZNF653 respectively. The SNPs cover a genetic distance of 
82 kb and share a high degree of heterozygosity in the European population (>0.3). 
We used PCR and direct sequencing for analysis. The PCR reaction mix (25 µl) con-
sisted of 1 µl DNA, 0.25 mmol of each dNTP, 5.0 U Taq DNA polymerase, 200 nM 
of each primer, 10 mmol Tris-HCl (pH 9.0), 50 mmol KCl, 0.1% TRITON and 1.5 
mM MgCl2. The PCR program started with 5 minutes preheating at 95°C, followed 
by 35 cycles of 30 seconds at 95°C, 30 seconds at 55 and 64°C and 1 minute at 72°C. 
The program terminated with 5 minutes elongation at 72°C. Amplicons were puri-
fied (QIAquick Gel Extraction Kit, Qiagen, Hilden, Germany) and subsequently 
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sequenced using the BigDye terminator kit and an ABI3730 capillary sequencer (Per-
kin Elmer Applied Biosystems, Boston, MA, USA).
Somatic mutation analysis
Somatic mutations were analyzed using PCR and sequencing (primers available upon 
request). The PCR reaction mix and program were used as described above with an 
1.75 mM MgCl2 concentration and annealing temperatures of 55-65°C. Amplicons 
were purified (QIAquick Gel Extraction Kit, Qiagen, Hilden, Germany) and se-
quenced (ABI3730, Perkin Elmer Applied Biosystems, Boston, MA, USA).
results
To study whether absence of hepatocystin in cyst epithelia is due to down regulation 
at the transcriptional level, PRKCSH mutation analysis was performed using DNA 
isolated from cyst epithelia. We isolated DNA from epithelial cells of 10 cyst and 5 
bile duct samples using laser guided microdissection (Figure 9.1).
F i g u r e   9.1   Laser microdissection of PCLD cyst epithelia.
Epithelial cells and bile duct cells were isolated from 10 samples of 5 patients using laser microdissection. 
a| Immunohistochemical staining for hepatocystin. Adapted from 8. Note that hepatocystin is not ex-
pressed in cyst epithelia. b| Marking of epithelial cells using Leica LMD6000 software. C| Circumcision 
of the area of interest. d| View of the isolated cells in the collection tube. Scale bars represent 50 µm (a-C) 
and 200 µm (d).
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Germline mutation
The presence of the germline PRKCSH mutations was verified using direct sequenc-
ing and RFLP. We found that in 6 cysts, the wild type allele was lost leaving only the 
mutant allele to be present. In contrast, in DNA isolated from blood lymphocytes 
and bile duct cells from these patients, we found the germline PRKCSH mutations in 
the heterozygous state (Figure 9.2, Table 9.1). In the remaining 4 cysts the wild type 
allele was not lost from the epithelium. 
F i g u r e   9.2   Germline mutation analysis. 
a| Verification of the germline c.1338-2A>G PRKCSH mutation. Ethidium bromide stained agarose gel of 
PCR products digested with BanI. Products of 111 and 49 bp represent the wild type allele and products 
of 66, 49 and 45 bp represent the mutant allele. Product source is indicated above the lanes and numbers 
specify the base pairs of the 100 base pair-spaced molecular-size marker. Note that cysts 1, 3 and 4 are 
homozygous mutant for the c.1338-2A>G allele. Bile duct samples from both patients are heterozygous. b|  
Sequence electropherograms showing the c.1338-2A>G mutation heterozygously in DNA isolated from 
white blood cells (top panel) and homozygously in DNA isolated from a cyst (lower panel) from the same 
patient. 
Loss of heterozygosity
In order to estimate the extent of the loss of heterozygosity in cyst epithelia, we 
tested 5 SNPs surrounding the PRKCSH gene (Figure 9.3). We analyzed the 6 cysts 
in which we found loss of heterozygosity, and found that all cysts were homozygous 
for the SNPs analyzed (Table 9.1). This indicates that the loss of heterozygosity is at 
least 82 kb and involves multiple genes.
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F i g u r e   9.3   Schematic overview of the SNP locations surrounding PRKCSH. 
SNPs are depicted by blue triangles. The two germline mutations in PRKCSH c.292+1G>C and c.1338-2-
A>G are represented by red crosses.
Somatic mutations 
Direct sequencing of the entire PRKCSH open reading frame of the cysts not af-
fected by loss of heterozygosity, demonstrated additional somatic mutations in 3 
cysts (Table 9.1). We found a deletion of thymidine at position 1204 (c.1204delT) in 
cyst 2 and a deletion of cytosine at position 77 (c.77delC) in cyst 7, both causing a 
frameshift and premature termination of translation. In cyst 6, we found a mutation 
in intron 16 of the wild type allele (c.1440+24del67ins32), which disturbs the accep-
tor splice site. We analyzed this mutation using the splice site prediction by neural 
network (SSPNN; http://www.fruitfly.org/seq_tools/splice.html). Even though the 
mutation abrogated the original acceptor splice site (score 0.87), a new in frame 
splice site is created with a score of 0.51. When this splice site is used, the mutation 
results in the substitution of valine for leucine at position 481 of the protein. How-
ever, further studies are required to determine the exact effect of this mutation on 
the protein structure. 
dIscussIon
We conducted this study to examine the relationship between PRKCSH mutations 
and various genetic and epigenetic alterations in polycystic liver disease. We identi-
fied a loss of heterozygosity in 6 out of 10 cysts (60%) and we found 3 somatic muta-
tions in the remaining cysts (30%). This provides the first proof for a two-hit model 
in PCLD pathogenesis. 
However, we have to keep several limitations in mind. First, although the laser mi-
crodissection technique is very precise, we cannot exclude contamination of the 
samples with non-epithelial cells like leukocytes. These cells can cause false nega-
tive results in loss of heterozygosity analyses. Second, we found somatic mutations 
in 3 cysts, but in only 1 cyst, we were able to confirm that the wild type allele had 
acquired the somatic mutation. Third, we used PCR with primers in the flanking 
introns followed by direct sequencing for mutation detection system. This method
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ta b l e   9.1   Results from the mutation analyses on laser microdissected DNA.
Cell type Germline mutation
Loss of  heterozygosity Somatic 
mutationrs167479 rs34095 rs313624 rs311786 rs311805
Patient 1 c.1338-2A>G
Blood +/– +/– +/– +/– +/– +/– -
Bile duct 1 +/– +/– +/– +/– +/– +/– -
Cyst 1 –/– –/– –/– –/– –/– –/– -
Cyst 2 +/– +/– +/– +/– +/– +/– c.1204delT
Patient 2 c.1338-2A>G
Blood +/– –/– –/– –/– +/– +/– -
Bile duct 2 +/– - - - +/– +/– -
Cyst 3 –/– - - - –/– –/– -
Cyst 4 –/– - - - –/– –/– -
Patient 3 c.1338-2A>G
Blood +/– –/– +/– +/– +/– +/– -
Bile duct 3 +/– - +/– +/– +/– +/– -
Cyst 5 –/– - –/– –/– –/– –/– -
Cyst 6 +/– - +/– +/– +/– +/–
c.1440+24
in/del
Patient 4 c.1338-2A>G
Blood +/– +/– –/– –/– +/– +/– -
Bile duct 4 +/– +/– - - –/– +/– -
Cyst 7 +/– +/– - - +/– +/– c.77delC
Cyst 8 +/– +/– - - +/– +/– -
Patient 5 c.292+1G>C
Blood +/– +/– +/– +/– –/– –/– -
Bile duct 5 +/– +/– +/– - - - -
Cyst 9 –/– –/– –/– - - - -
Cyst 10 –/– –/– –/– - - - -
 –/– homozygous mutant; +/– heterozygous; - no data
might miss mutations located in the intronic sequences or in the promoter region 
of the gene. Moreover, the technique is unable to identify deletions of entire exons. 
Fourth, in this study, we examined DNA isolated from cyst epithelial cells on the 
presence of somatic mutations and loss of heterozygosity only. In addition, genetic 
inactivation can be accomplished by loss of (allele-specific) transcription or promoter 
methylation. Furthermore, although it is likely that the two-hit model involves two 
of the same PCLD genes, it also remains a possibility that the second hit is located in 
 137 
two-hit model in pCld
SEC63 or an alternative, yet unidentified PCLD gene. Despite these limitations, we 
found a mutation frequency of 90%.
Much research has been performed on the similar disorder autosomal dominant 
polycystic kidney disease (ADPKD), in which cysts predominate in the kidneys. Sev-
eral groups have shown that cystogenesis in germline carriers is driven by inactiva-
tion of the somatic allele of the ADPKD genes PKD1 or PKD2 10-19. Taken together, 
they found loss of heterozygosity, somatic mutations, and transheterozygous events 
in PKD1 or PKD2 in only 23.2% of the cysts studied. This is significantly lower than 
the mutation rate found in our study (90%). However, the ADPKD genes are much 
larger and more complex, which complicates mutation detection. Then again, ac-
cording to immunohistochemistry analyses, the encoded proteins are still expressed 
in a large quantity of ADPKD cyst epithelia. This might indicate that the second-hit 
hypothesis does not apply in each cyst and other mechanisms are also associated 
with cystogenesis in ADPKD. On the other hand, in frame or missense mutations 
can result in non-functional proteins, which are nevertheless recognized by the anti-
bodies used in immunohistochemistry analyses. Moreover, transheterozygous events 
do not imply absence of protein expression. Further, mutations may lead to loss of 
negative feedback or loss of protein degradation leading to high protein levels. 
In contrast to the findings in ADPKD, the immunohistochemistry experiments in 
PCLD are more unambiguous. We found loss of hepatocystin expression in the large 
majority of the cysts of patients harboring a truncating germline PRKCSH mutation 
8. Also, germline mutations in PRKCSH are more often truncating mutations. 
Even though the total number of cysts analyzed in this study is relatively low, we 
found second hit mutations in all 5 patients studied. This indicates that the occur-
rence of second hits is not a chance event limited to a single patient. On the other 
hand, all patients in this study possessed a germline mutation in PRKCSH. Further 
research should evaluate whether the two-hit model is also applicable for SEC63-
associated PCLD. 
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This thesis describes research conducted in order to gain insight in the molecular 
mechanisms underlying the pathogenesis of polycystic liver disease (PCLD). PCLD 
is an inherited disease, associated with mutations in PRKCSH or SEC63, encoding 
hepatocystin and Sec63p respectively. Mutations in one of these genes lead to nu-
merous cysts scattered throughout the liver parenchyma and massive enlargement 
of the liver. In order to develop effective treatment for PCLD patients, an in-depth 
knowledge of the pathogenesis of the disease is required. Therefore, the main aim of 
this thesis was to gain insight in the PCLD pathogenesis. 
The experiments described in this thesis approach the problem from different per-
spectives. First, in chapter 2, we present an overview of the literature on PCLD and 
the genes involved. We describe the role of hepatocystin and Sec63p in glycosylation 
and transport of glycoproteins. Based on these facts, we propose PCLD as a new 
type I congenital disorder of glycosylation (CDG) and we focus on similarities and 
differences between PCLD and other glycosylation disorders. 
Next, we studied mutations in the genomic DNA of patients. In order to gain insight 
in the distribution of mutations, we conducted a genotype-phenotype correlation 
study described in chapter 3. We screened a large cohort of unrelated patients, di-
vided into three groups by the number of hepatic cysts, for mutations in both genes. 
We found a total mutation frequency of 16%. The severe disease group (>20 cysts) 
displayed the highest mutation frequency (25%) and showed the more severe (protein 
truncating) mutations. However, we also found that patients with as few as 8 cysts 
harbored mutations in both PRKCSH and SEC63. This finding argues for adjust-
ment of the diagnostic criterion of PCLD, which is currently set at the presence of 
more than 20 cysts in the liver without involvement of the kidneys. In chapter 4, we 
give an update of the newly identified mutations in PRKCSH and SEC63 and we ana-
lyze all mutations known to date for effects on protein structure and function. With 
14 novel PRKCSH and 11 novel SEC63 mutations, the total of known PLCD muta-
tions comes to 47. In silico analyses showed that all mutations located at the splice 
sites influenced splicing. Other mutations were located at CpG dinucleotides, which 
may influence gene transcription regulation, or secondary protein structure. Further, 
we performed homology modeling on two domains of Sec63p and we showed severe 
effects of the mutations on the tertiary domain structures. Finally, we found two hot 
spots and the majority of truncating mutations in PRKCSH. 
Subsequently, we studied the value of a well-known serum tumor marker in poly-
cystic liver patients (chapter 5). The carbohydrate antigen CA19-9 is widely used to 
differentiate between benign and malignant gastrointestinal disorders. After finding 
alarmingly high serum and cyst fluid CA19-9 levels in a first polycystic liver patient, 
we set out to examine the value of CA19-9 measurement in polycystic liver patients. 
We found that hepatic cyst fluid levels were extremely elevated in both polycystic 
liver patients and in patients with a few hepatic cysts (<5). In contrast, serum CA19-9 
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levels were significantly higher in polycystic liver patients. Further, we found that se-
rum CA19-9 levels correlated well with liver volume or the size of the largest cyst and 
we found high expression of CA19-9 using immunohistochemistry on cyst epithelia. 
Finally, evacuation of cyst fluid led to decrease of serum CA19-9 levels. From these 
results, we concluded that CA19-9 is produced by the cyst epithelia and secreted into 
the cyst fluid, where it leaks into the circulation. Importantly, we found no evidence 
for malignancy in the patients. As treatment of the cysts led to a decrease of serum 
CA19-9 levels, we propose CA19-9 as a novel biomarker to monitor disease progres-
sion and intervention efficiency.
Previous studies indicated that mutated hepatocystin is not retained in the endopas-
mic reticulum (ER) when overexpressed in HeLa cells. In chapter 6, we first showed 
that hepatocystin is secreted from both the basolateral and the apical side of trans-
fected MDCK cells. This confirmed that hepatocystin could indeed be secreted into 
the cyst fluid. Second, we analyzed 60 hepatic cyst fluid samples using Western blot, 
MALDI-TOF MS and nLC-MS/MS and we identified 163 conventional serum pro-
teins. However, we failed to identify hepatocystin or a PCLD specific protein pattern 
in the fluids. From this we concluded that mutant hepatocystin is not secreted in cyst 
fluid but is either not produced or degraded intracellularly. 
From genomic DNA, serum and cyst fluid, we turned our focus on cyst tissue. In 
chapter 7 we first study the molecular pathways involved in PCLD. We analyzed 
the tissue expression of markers for apoptosis, proliferation, growth factor recep-
tors, signaling and adhesion. The markers were all previously studied in relation 
with polycystic kidney diseases (PKDs). In contrast to PKDs, we found that PCLD 
does not involve excessive proliferation and apoptosis. We did find overexpression 
of growth factor receptors and a loss of adhesion in the cyst epithelia. Moreover, we 
found mislocalization of MUC1, CEA and c-erbB-2 in hepatocystin mutated tis-
sues only. These results suggest a divergent pathogenesis for PRKCSH- and SEC63-
associated PCLD.
In the literature, many putative subcellular localizations are described for hepato-
cystin. As protein functions can differ with the localization, we analyzed the subcel-
lular localization of both hepatocystin and Sec63p in human liver cells in chapter 
8. We found that both proteins were predominantly expressed in the ER, indicating 
that the putative ER functions of the proteins might be involved in PCLD cysto-
genesis. These putative functions comprise glycoprotein processing and folding for 
hepatocystin and translocation of glycoproteins into and out of the ER for Sec63p. 
Subsequently, we analyzed protein expression in fetal, neonatal and adult liver tissue. 
We found that hepatocystin and Sec63p both show a different time- and cell type-
dependent expression pattern during liver development. In addition, hepatocystin 
was absent from cyst epithelia of patients with a truncating mutation in PRKCSH, in 
contrast to Sec63p, which was expressed in cyst epithelia of all patients. The results 
in this chapter support the hypothesis that cysts in PCLD develop from a cellular 
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recessive mechanism. 
In the last chapter, chapter 9, we set out to identify the cellular mechanism under-
lying the absence of hepatocystin in cyst epithelia from PRKCSH mutant patients. 
Using laser micro dissection we collected cyst epithelial cells and isolated their DNA. 
We show that 6 out of 10 cysts from 5 patients lost heterozygosity of the germline 
mutation in PRKCSH. SNP analyses showed that the loss of heterozygosity reached 
up to 82 kb. In addition, we found somatic mutations in another 3 cysts. These re-
sults confirm the two-hit hypothesis for the pathogenesis of PRKCSH-associated 
PCLD. 
Future perspectives
This thesis describes first insights in the molecular pathogenesis of PCLD. Never-
theless, as we find more answers, we uncover even more questions.   
Several findings in this thesis indicate a divergent pathway of pathogenesis for 
SEC63-associated PCLD. However, only a few samples were available from SEC63 
mutated patients. Therefore, in future studies, special care should be taken to include 
tissue samples from patients with more different types of SEC63 mutations. Then, 
we can conclude with more certainty whether the two-hit model is also applicable in 
SEC63-associated PCLD and whether the common pathways involved in PRKCSH-
associated disease are also involved in SEC63-associated disease.
Another interesting field of research would be to study the effects of hepatocystin 
knockout in cell lines. What processes will be influenced? Can we shed light on the 
causes of the aberrant localization of MUC1, CEA and c-erbB-2 in hepatocystin 
negative cyst epithelia and evaluate their effects on cell signaling? Does hepatocys-
tin knockout have different consequences in cholangiocytes compared to other cell 
types? Does hepatocystin process liver specific splice variants of PKD associated 
proteins polycystin 1, polycystin 2 or fibrocystin? Answers to these questions would 
give even further insight in the pathogenesis of PCLD. 
Finally, we only found a total mutation frequency of 25% in PRKCSH and SEC63 of 
patients diagnosed with PCLD. Despite the fact that the promoter region of neither 
gene has been studied, the results strongly indicate that a third or even a fourth gene 
is involved in PCLD pathogenesis. It would be fruitful therefore to direct future 
research into identifying these new genes. New genes with new functions might give 
new perspectives in the pathogenesis research. 
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Dit proefschrift beschrijft onderzoek naar de moleculaire mechanismen van de pa-
thogenese van polycysteuze leverziekte (PCLD). PCLD is een erfelijke aandoening 
die geassocieerd is met mutaties in de genen PRKCSH en SEC63, coderend voor de 
eiwitten hepatocystine en Sec63p. Mutaties in één van deze genen leiden tot multi-
pele cysten in het gehele lever parenchym en ernstige vergroting van de lever. Een 
diepgaand begrip van de pathogenese is nodig, teneinde een effectieve behandeling 
voor PCLD te ontwikkelen. Het voornaamste doel van dit proefschrift was dan ook 
het inzicht krijgen in de PCLD-pathogenese. 
De experimenten beschreven in dit proefschrift, benaderen het probleem vanuit ver-
schillende perspectieven. Als eerste geven we in hoofdstuk 2 een overzicht van de 
literatuur over PCLD, de betrokken genen en we beschrijven de rol van hepatocys-
tine en Sec63p in de glycosylering en transport van glycoproteïne. Hierop gebaseerd 
stellen we PCLD voor als een nieuw aangeboren glycosylerings defect en we focus-
sen op de overeenkomsten en verschillen tussen PCLD en andere glycosylerings 
aandoeningen. 
Vervolgens, hebben we ons gericht op de mutaties in het genomisch DNA van PCLD 
patiënten. Om meer inzicht te krijgen in de verdeling van de mutaties hebben we de 
genotype-fenotype studie, die beschreven is in hoofdstuk 3, uitgevoerd. We hebben 
een grote groep niet-verwante patiënten onderzocht op het voorkomen van mutaties. 
De groep was op basis van het aantal levercysten onderverdeeld in drie groepen. We 
vonden een totale mutatiefrequentie van 16% en de groep met ernstige ziekte (>20 
cysten) toonde de hoogste mutatiefrequentie (25%) en bevatte de meer ernstige (eiwit 
afkappende of truncerende) mutaties. Echter, we vonden ook dat patiënten met maar 
8 cysten mutaties hebben in zowel PRKCSH als SEC63. Deze bevinding betwist de 
diagnostische standaard voor PCLD (meer dan 20 levercysten in afwezigheid van 
niercysten). In hoofdstuk 4 beschrijven we de nieuwste mutaties in PRKCSH en 
SEC63 en analyseren we alle bekende mutaties op effecten op de structuur en func-
tie van het eiwit. Met 14 nieuwe PRKCSH-mutaties en 11 nieuwe mutaties in SEC63 
komt het totaal van beschreven PCLD-mutaties op 47. In silico analyses laten zien 
dat alle splice site mutaties de herkenning van de splice sites beïnvloeden. De andere 
mutaties waren gelokaliseerd op CpG dinucleotides, die de gentranscriptie kunnen 
beïnvloeden, of hadden een effect op de secundaire eiwitstructuur. Verder hebben 
we de tertiaire structuur van twee domeinen van Sec63p gemodelleerd op basis van 
homologie met andere eiwitten. Hieruit bleek dat de mutaties in deze domeinen al-
len effect hadden op de tertiaire structuur. Tot slot vonden we twee zogenaamde 
hotspots van mutaties in PRKCSH en vonden we dat de meeste eiwit afkappende 
mutaties in dit gen voor kwamen. 
In het volgende hoofdstuk hebben we de waarde van een bekende serum tumormar-
ker bepaald in patiënten met een polycysteuze lever (hoofdstuk 5). Het carcinogeen 
antigeen, CA19-9, wordt veel gebruikt voor de differentiatie tussen goed- en kwaad-
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aardige gastrointestinale aandoeningen. Nadat we bij een polycysteuze leverpatiënt 
extreem hoge waardes voor CA19-9 in het serum en cystevocht hadden gevonden, 
besloten we de waarde van CA19-9 als biomarker in polycysteuze leverpatiënten te 
onderzoeken. We vonden een sterke verhoging van CA19-9 waardes in cystevloeistof 
van zowel polycysteuze leverpatiënten als patiënten met een enkele levercyste (<5 in 
aantal). Echter, de serum CA19-9 waardes waren significant hoger in polycysteuze 
leverpatiënten. Verder vonden we dat de serumwaardes correleerden met het lever-
volume of de grootte van de grootste cyste en vonden we met immunohistochemi-
sche kleuringen een hoge expressie van CA19-9 in het cyste-epitheel. Tot slot zagen 
we dat evacuatie van de cystevloeistof leidde tot een afname van de serum CA19-9 
waarde. Uit deze resultaten hebben wij geconcludeerd, dat CA19-9 door het cyste-
epitheel wordt geproduceerd en uitgescheiden in de cystevloeistof, vanuit waar het 
in de bloedcirculatie lekt. Belangrijk was ook dat we geen bewijs voor maligne aan-
doeningen vonden bij deze patiënten. Aangezien behandeling van levercysten leidt 
tot een afname van CA19-9 waardes, kan CA19-9 gebruikt worden als biomarker om 
ziekteprogressie en interventie-effectiviteit te beoordelen.
Hierna hebben we in hoofdstuk 6 de bestanddelen van cystevloeistof bestudeerd. 
Uit voorgaand onderzoek was gebleken, dat gemuteerd hepatocystine niet in het en-
doplasmatisch reticulum (ER) blijft, maar uitgescheiden wordt door de cel. In deze 
studie hebben we eerst aangetoond, dat hepatocystine zowel aan de basolaterale als 
aan de apicale zijde van de cel kan worden uitgescheiden en dus inderdaad in de 
cystevloeistof terecht kan komen. Vervolgens hebben we 60 levercystevloeistoffen 
geanalyseerd met Western blot, MALDI-TOF MS en nLC-MS/MS. We hebben 163 
normale serumeiwitten geïdentificeerd, maar we hebben geen hepatocystine in de 
cystevloeistof gevonden. Bovendien konden we geen PCLD specifiek eiwitpatroon 
in de cystevloeistof aantonen. Hieruit hebben we geconcludeerd, dat hepatocystine 
niet door de cyste-epitheelcellen wordt uitgescheiden, maar dat het eiwit ofwel niet 
geproduceerd ofwel intracellulair afgebroken wordt.
Van genomisch DNA, serum en cystevloeistof hebben we ons vervolgens gericht op 
het cysteweefsel. In hoofdstuk 7 hebben we eerst de moleculaire processen bestu-
deerd, die betrokken zijn bij PCLD. We hebben gekeken naar de expressie van mar-
kers voor apoptose, proliferatie, groeifactorreceptoren, celsignalering en celadhesie. 
De markers waren eerder beschreven in relatie met polycysteuze nierziekten (PKDs). 
In tegenstelling tot de situatie in deze PKDs, vonden wij dat PCLD niet veroorzaakt 
wordt door verhoogde proliferatie of apoptose. We vonden wel overexpressie van 
groeifactorreceptoren en een verlies van celadhesie in de cyste-epitheelcellen. Bo-
vendien zagen we een bijzondere cellulaire lokalisatie van MUC1, CEA en c-erbB-2 
in hepatocystine gemuteerd, maar niet Sec63p gemuteerd cyste-epitheel. Deze resul-
taten duiden op een uiteenlopende pathogenese voor PRKCSH- en SEC63-geasso-
cieerde PCLD. 
In de literatuur zijn veel verschillende subcellulaire lokalisaties beschreven voor 
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hepatocystine. Omdat eiwit functies kunnen verschillen per locatie, hebben we in 
hoofdstuk 8 de subcellulaire locatie van zowel hepatocystine als Sec63p bestudeerd 
in humane levercellen. We vonden beide eiwitten voornamelijk in het ER. Dit wijst 
erop, dat de ER gerelateerde functies van de eiwitten een rol spelen in het ontstaan 
van PCLD. Deze functies omvatten voor hepatocystine de verwerking en vouwing 
van glycoproteïnen en voor Sec63p de translocatie van glycoproteïnen het ER in en 
uit. Vervolgens hebben we de expressie van beide eiwitten bepaald in foetaal, neona-
taal en volwassen leverweefsel. We vonden een tijd- en celtype-afhankelijke expres-
sie van hepatocystine en Sec63p gedurende de lever ontwikkeling. Bovendien was 
hepatocystine-expressie afwezig in cyste-epitheel van patiënten met een truncerende 
hepatocystine mutatie. Dit in tegenstelling tot Sec63p, dat tot expressie kwam in elk 
cyste-epitheel onafhankelijk van de onderliggende PCLD mutatie. De resultaten in 
dit hoofdstuk bevestigen de hypothese, dat cysten in PCLD ontstaan vanuit een cel-
lulair recessief mechanisme. 
In het laatste hoofdstuk, hoofdstuk 9, hebben we ons gericht op de identificatie van 
het cellulaire mechanisme, dat leidt tot de afwezigheid van hepatocystine in cyste-
epitheel van patiënten met een PRKCSH-mutatie. Met lasermicrodissectie hebben we 
cyste-epitheelcellen uit de weefsels verzameld en het DNA geïsoleerd. Met mutatie-
analyse vonden we dat 6 van de 10 cysten een verlies van heterozygositeit lieten zien 
voor de kiembaanmutatie in PRKCSH. SNP-analyses lieten vervolgens zien, dat dit 
verlies van heterozygositeit een gebied van meer dan 82 kb omvatte. Verder vonden 
we somatische mutaties in 3 andere cysten. In het totaal identificeerden we bij 90% 
van de cysten een tweede mutatie.  Deze resultaten bevestigen het two-hit model 
voor de pathogenese van PRKCSH-geassocieerde PCLD.
Toekomstig onderzoek
Dit proefschrift beschrijft eerste inzichten in de moleculaire pathogenese van PCLD. 
Echter, hoe meer antwoorden we vinden hoe meer vragen er ontstaan.
Het proefschrift bevat verschillende aanwijzingen dat de pathogenese anders ver-
loopt in PRKCSH-geassocieerde dan in SEC63-geassocieerde ziekte. We hebben ech-
ter maar een beperkt aantal monsters van patiënten met een SEC63-mutatie kunnen 
onderzoeken. In de toekomst zal het daarom belangrijk zijn om weefselmonsters 
te verzamelen van meer patiënten met verschillende SEC63-mutaties. Alleen dan 
kunnen we met meer zekerheid concluderen of het two-hit model ook voor SEC63-
geassocieerde PCLD geldt en of de moleculaire processen die betrokken zijn bij 
PRKCSH-geassocieerde ziekte ook betrokken zijn bij SEC63-geassocieerde PCLD.
Een andere interessante richting voor toekomstig onderzoek is het bestuderen van 
de effecten van de afwezigheid van hepatocystine in cellijnen. Welke processen zul-
len zijn aangedaan? Wat is de reden van de mislokalisatie van MUC1, CEA en C-
erbB-2 in voor hepatocystine negatief cyste-epitheel en wat voor een effect heeft dit 
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op de cel signalering? Geeft de afwezigheid van hepatocystine andere effecten in 
cholangiocyten in vergelijking met andere celtypes? Verwerkt hepatocystine in het 
ER misschien leverspecifieke splice varianten van de PKD geassocieerde eiwitten 
polycystine-1, polycystine-2, of fibrocystine? Antwoorden op deze vragen zullen het 
inzicht in de pathogenese van PCLD sterk vergroten.
Tot slot vinden we een mutatie frequentie van 25% in PRKCSH en SEC63 van pati-
ënten gediagnosticeerd met PCLD. Los van het feit dat de promotorregio nog van 
geen van beide genen onderzocht is, wijzen de resultaten erop dat er nog een derde 
of vierde gen betrokken is bij het ontstaan van PCLD. Het zou daarom nuttig zijn 
om toekomstig onderzoek toe te spitsen op het identificeren van deze nieuwe genen. 
Nieuwe genen met nieuwe functies zullen nieuwe perspectieven bieden op de patho-
genese van PCLD. 
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Misschien wel het moeilijkst te schrijven hoofdstuk van een proefschrift is het dank-
woord. Niet alleen omdat je voor het eerst sinds tijden weer een stuk tekst in het 
Nederlands schrijft, maar ook omdat het het enige hoofdstuk is, waarvan je zeker 
weet dat het door iedereen gelezen zal worden. Dit in tegenstelling tot de weten-
schappelijke hoofdstukken, die door niet ingewijden meestal worden geïnterpreteerd 
als abracadabra. De druk is dan ook hoog om voor het dankwoord een origineel 
stukje tekst te schrijven. Nu dacht ik laatst: “Wat zou het heerlijk zijn om er alleen het 
woord BEDANKT neer te zetten.” Wel in hoofdletters natuurlijk, want ik ben heel 
wat dank verschuldigd. Heel origineel, al zeg ik het zelf. Maar dan zou ik me er toch 
wel heel makkelijk vanaf maken. Bovendien doe ik geen eer aan al de mensen, die me 
geholpen hebben mijn proefschrift tot dit mooie boekje te maken. Want zoals bij veel 
andere proefschriften geldt ook hier een veel geciteerde uitspraak van Michelangelo 
(1475-1564): “If you knew how much work went into it you wouldn’t call it genius.” 
Als eerste wil ik mijn promotor Prof. dr. Drenth bedanken. Beste Joost, bedankt dat 
je deur altijd voor me open stond, ondanks dat je vaak niet fysiek in de buurt kon 
zijn. De sneltreinvaart waarmee je mijn manuscripten nakeek en mijn mails beant-
woordde, hebben me vaak versteld doen staan. 
Een onmisbare steun tijdens mijn promotie was René te Morsche. Beste René, wat 
zou er van dit proefschrift geworden zijn zonder jouw hulp en technische kennis? 
Bedankt! 
Ook de andere (ex)leden van het ‘lab gastro’, Wilbert, Hennie, Annie, Marloes, Mi-
chelle, Loes, Daan, Hilbert, Wim, Saskia, Albert, buurvrouw Alma en de vele stu-
denten wil ik bedanken voor hun steun, goede raad, gezelligheid, de ontelbare potjes 
Rikken en de geweldige werksfeer. Hierbij wil ik nog in het bijzonder mijn kamerge-
notes Loes, Michelle, Marloes, en Carolien noemen. Altijd in voor een goed gesprek 
over interessante (heeft een mandarijn significant vaker een even dan oneven aantal 
partjes?) en minder interessante onderwerpen (welke statistische methode gebruik je 
om dit te testen?). Meiden bedankt voor de heerlijke tijd op +1! Loes en Michelle, ik 
vind het erg fijn dat jullie naast mij staan op de laatste dag van mijn promotietraject. 
Ik zal jullie missen, maar we zien elkaar als we gaan kappoesjinoen! 
Martijn, gelukkig hebben we jou voor onder andere die statistische vragen. Bedankt 
dat je altijd tijd wilde vrijmaken en bedankt voor je goede en significante raad. Se-
rena, bedankt voor de gezelligheid en de vele praatjes in het voorbijgaan. 
Een erg leuke ervaring was het begeleiden van twee studenten tijdens hun stage. 
Anke Lameris en Oğuzhan (Ozan) Özdemir bedankt voor jullie enthousiasme en 
inzet. Ik heb ook veel van jullie geleerd. 
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Buiten de MDL heb ik op twee afdelingen van het Radboud erg veel tijd doorge-
bracht. Bij de afdeling Celbiologie in het NCMLS ben ik dank verschuldigd aan Jack 
Fransen en Huib Croes in het bijzonder. Beste Huib, bedankt dat je mij netjes binnen 
de lijntjes hebt leren kleuren en voor de vele uurtjes samen in een donker hok dag-
dromend over Nobelprijzen en Covers van Cell. 
Veel dank gaat ook uit naar de afdeling Pathologie. Ten eerste Prof. dr. Van Krieken, 
beste Han, bedankt voor je enthousiasme, voor het meedenken over het onderzoek 
en voor de mogelijkheid om zoveel experimenten te doen bij de pathologie. 
Ik heb mijn vervolgopleiding kleuren gevolgd bij Cathy Maass. Cathy bedankt voor 
jouw bijna onuitputtelijke bron van kennis en gezelligheid. Ook de mensen van het 
immunolab, Anneke, An, Gursah, en nog vele anderen bedankt voor de leuke werk-
sfeer. William, Kiek en Henry, dankzij jullie heb ik weer een aantal technieken op 
mijn lijstje bij kunnen schrijven. 
Tot slot wil ik graag twee bijzondere dames bedanken voor hun enorme inzet om 
monsters te bemachtigen uit andere ziekenhuizen. José Aldeweireldt en Els Dries-
sen-Schut bedankt voor alle hulp in voor jullie erg drukke tijden. 
Ik heb het voorrecht gehad om met veel mensen van veel afdelingen samen te wer-
ken. Ik wil alle medewerkers van deze afdelingen bedanken voor hun gastvrijheid en 
gezelligheid. Een goede werksfeer is toch een van de belangrijkste ingrediënten voor 
een succesvol proefschrift. Velen hebben ook een directe bijdrage aan de voltooiing 
van dit proefschrift geleverd. Bedankt allemaal! 
Ook buiten de professionele setting zijn een heel aantal mensen belangrijk voor mij 
geweest. 
Als eerste wil ik noemen de leden van de AP (Anonieme Promovendi). Jullie weten 
wie jullie zijn. Bedankt voor jullie steun! 
Rianne & Frank, Thijs & Marieke, Carola & Ivo, Esther G & Frank, Jiske & Stijn, 
Izaak, Jan-Willem, Gero, en alle (ex)leden van Popkoor Popolo: bedankt voor jullie 
vriendschap, de gezelligheid, de afleiding en de luisterende oren en steun in moeilijke 
tijden. Vanaf nu zal ik meer tijd voor jullie maken!
Eva, bedankt voor je altijd weer relativerende opmerkingen en het vertrouwen in 
mijn kunnen. 
To my English speaking friends Bryony, Noa, Michelle, Ernest and JT: Thank you 
for awesome times in Canada and England. I have learnt a lot about me and who I 
want to be. Thank you for being such good examples. 
Verder wil ik de volledige families Waanders en Alferdinck bedanken voor de warm-
te en geborgenheid. Ik besef dat het bijzonder is dat we zulke hechte familiebanden 
hebben en ik ben er trots op. Bedankt voor jullie belangstelling en steun.
  160 
Tot slot de belangrijkste mensen in mijn leven. 
Lieve Nick, ondanks dat je ver weg woont, beteken je niet minder voor me. Je bent 
en blijft mijn grote broer. Bij jou kan ik altijd terecht voor raad en advies; ook op de 
gekste tijden van de dag. Dat is dan weer een voordeel van ver weg wonen. Ik ben 
heel erg blij dat jij en Julie erbij kunnen zijn in december.
Lieve pap en mam, bedankt voor jullie vertrouwen, liefde en onvoorwaardelijke 
steun. Bedankt voor alle mogelijkheden die jullie mij hebben gegeven en bovenal 
bedankt dat jullie altijd voor mij klaar staan. Woorden schieten tekort. Ik houd van 
jullie.
Esmé
Nijmegen 
20 oktober 2008
Stellingen behorende bij het proefschrift:
InsIghts In the molecular pathology of 
polycystIc lIver dIsease
A view from different perspectives
De diagnose PCLD zou al bij 8 levercysten gesteld moeten worden (1. dit proefschrift).
Hoewel PCLD een sterk variabel phenotype vertoont, geven ernstige mutaties, die 2. 
resulteren in een frameshift, een ernstiger ziektebeeld (dit proefschrift). 
De mutatie frequenties van 3. PRKCSH en SEC63 wijzen erop dat een derde locus betrok-
ken is bij de PCLD pathogenese (dit proefschrift). 
Cyste-epitheel produceert en secreteert CA19-9, waardoor sterk verhoogde CA19-9 4. 
waarden worden gemeten in cystevloeistof en serum van patiënten met een polycys-
teuze lever (dit proefschrift). 
Cystevloeistof bestaat voor het grootste deel uit serum (5. dit proefschrift).
Getrunceerd hepatocystine komt niet tot expressie in het cyste-epitheel en wordt 6. in vivo 
niet uitgescheiden in de cystevloeistof (dit proefschrift). 
Verhoogde apoptose en proliferatie spelen geen rol in de PCLD cystogenese (7. dit proef-
schrift).
Bij patiënten met een truncerende 8. PRKCSH mutatie ontstaan levercysten door een cel-
lulair recessief mechanisme waarbij onder andere loss of heterozygosity en somatische 
mutaties betrokken zijn (dit proefschrift).
De kat komt niet uit de boom door er naar te kijken. 9. 
“Every mammal on this planet instinctively develops a natural equilibrium with its sur-10. 
rounding environment, but humans do not. Humans move to an area and multiply and 
multiply until every natural recourse is consumed. The only way humans survive is 
to spread to another area. The one organism that follows the same pattern is a virus.” 
Agent Smith (The Matrix).
Piekeren is misbruik maken van je fantasie.11. 
Een promotie traject is een 4-jarige assertiviteitstraining.12. 
At nich kan zoat mut, mut mer zoat kan.13. 
Esmé Waanders, 17 december 2008

